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Abstract 
 
The balance between signals delivered by positive and negative costimulatory 
molecules is crucial to the ultimate fate of cellular immune responses. Manipulation 
of T cell costimulatory pathways may offer a novel approach for reinvigorating 
exhausted T cell responses, especially in the context of chronic infections. T cells also 
display profound exhaustion in old age and this thesis investigates the hypothesis that 
T cell inhibitory receptor upregulation may define a reversible defect in age onset 
immune decline. 
 
Data presented here illustrate how T cells utilise different inhibitory receptors as they 
differentiate and that KLRG1 signalling is causative of dysfunctions in highly 
differentiated CD8+ T cells. The inhibitory receptors KLRG1 and CTLA-4 are 
revealed to undergo age-associated upregulations on CD8+ T cells but their blockade 
does not reverse the characteristic hypo-responsiveness of CD8+ T cells amongst old 
donors. 
 
The dysregulated immune response to lifelong chronic cytomegalovirus (CMV) 
infection is thought to play a major role in driving age related immune dysfunctions. 
We found that CMV accelerates age-associated telomere attrition amongst CD8+ and 
CD4+ T cells. CMV infection is also shown to drive CTLA-4, PD-1 and KLRG1 
upregulation on both CD4+ and CD8+ T cells. Moreover, the PD-1/Ligand (L) 
inhibitory pathway defines a reversible proliferative dysfunction in the responses of 
CMV specific CD8+ T cells. Specifically, the CD45RA re-expressing memory subset 
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exhibits a proliferative deficiency, relative to their central and effector memory 
counterparts, that is reversible upon PD-L blockade. However, this augmented 
proliferative response was not accompanied by increased telomerase function, 
suggesting this does not result in true reversal of exhaustion.  
 
In summary, the dysfunctions of highly differentiated and CMV specific CD8+ T cells 
can be at least partially reversed by perturbation of inhibitory receptor pathways, 
whose further manipulation may provide a therapeutic modality to combat age-
associated immune decline. 
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1 Introduction 
 
The dramatic expansion of life expectancy in developed countries over the twentieth 
century, increasing at the rate of several hours per day (Kirkwood, 2008), ranks as one 
of humanity’s great triumphs. However, this achievement, combined with declining 
birth rates, now form one of society’s greatest challenges: the rapid ageing of the 
world’s population. Indeed, by 2031 over a quarter of people worldwide will be over 
65 (Khaw, 1999; O'Connell and Ostaszkiewicz, 2005; Rajan et al., 2003; Goldacre, 
2009) and the declining health status, economic productivity and cost of care of the 
aged (McNamee et al., 2001; Robertson and Tracy, 1998) make understanding the 
mechanisms governing physiological ageing one of the most pertinent challenges 
facing scientists today. 
 
1.1   How and why we age 
 
1.1.1  How we age 
The ageing process is driven by the lifelong accumulation of a wide variety of cellular 
and molecular damage that leads to age related frailty, disease and ultimately 
mortality (Kirkwood, 2005). The Mitochondrial Free Radical Theory of Ageing 
(Harman, 1956) proposes a single physiological cause as the root source of this 
damage, but is being increasingly refuted (Bonawitz and Shadel, 2007; Buffenstein et 
al., 2008; Gems and Doonan, 2009; de Magalhaes and Church, 2006; Blagosklonny, 
2008; Fukui and Moraes, 2008; Lapointe and Hekimi, 2010). Indeed, ageing is 
increasingly being recognised as a process with no single cause but being driven by a 
multitude of factors, including oxidative stress, translation errors, nutritional 
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components and telomere attrition (Rattan, 2006; Kirkwood, 2008; Hayflick, 2007; 
Holliday, 2006).   
 
1.1.2  Why we age 
Fundamentally, age related changes can occur either as a consequence of a genetically 
driven program or the stochastic accumulation of damage with age. Programmed 
death theories proposed that ageing was advantageous to the species by removing 
aged members from the population (Weismann, 1889). However, traditional 
Darwinian mechanics exclude the possibility of evolving and retaining a design that 
produces a net reduction in individual benefit. Moreover, due to high extrinsic 
mortality in the wild, virtually all animals die before they reach old age, which lead to 
the formulation of the Theory of Mutation Accumulation, which hypothesised that 
there is little selection pressure against late acting deleterious traits that cause ageing 
(Medawar, 1952). This was further developed into the antagonistic pleiotropy 
hypothesis that proposed natural selection selects genes that are beneficial at early 
ages but become harmful with advancing age (Williams, 1957). Nevertheless, 
programmed death theories have enjoyed a resurgence of popularity following the 
discovery of ageing genes (Ghazi et al., 2007; Francia et al., 2004) and the arisal of 
alternative ideas of evolutionary mechanics, particularly group selection (Mitteldorf 
and Pepper, 2007) and evolvability theories (Goldsmith, 2008). 
 
1.2   Immunosenescence 
 
1.2.1  Introduction 
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1.2.1.1  The significance of age related immune changes 
Ageing is accompanied by a progressive, multidimensional, physiological 
degeneration, with immune system alterations playing a key role regulating these age-
related declines (Gorczynski and Terzioglu, 2008). 
 
1.2.1.2 The immune system 
Humans are continually exposed to pathogens that attempt to invade and colonise the 
host. Primary resistance is based on physical barriers but when these are breached the 
infectious agent encounters a secondary highly organised system of defence called the 
immune system. Indeed, such pathogenic microorganisms that breach host barriers 
only occasionally cause disease. The majority are eliminated rapidly, within hours or 
even minutes, by the mechanisms of innate immunity. If an infectious organism 
breaches the innate lines of defence then an adaptive immune response ensues. Unlike 
innate responses, adaptive immunity requires several days for optimal generation but 
is specific and results in long lived protective immunity. This generation of 
immunological memory is considered a hallmark of the adaptive immune system and 
enables rapid and efficient resolution of infection upon pathogen re-encounter 
(Zinkernagel et al., 1996).  
 
1.2.1.3  The ubiquitous nature of immunosenescence 
This age-associated immune deterioration, termed immunosenescence, is ubiquitous 
and has been documented in a wide range of captive and free-living species including 
primates (Jayashankar et al., 2003) cats and dogs (Day, 2010), horses (Horohov et al., 
2010), birds (Lavoie et al., 2007; Holmes and Austad, 2004; Cichon et al., 2003; 
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Palacios et al., 2007) and even invertebrates, which lack an adaptive immune system 
(Adamo et al., 2001; Kurtz, 2002). Amongst such different species, 
immunosenescence appears as a function of their age relative to their life expectancy 
rather than chronological time (Ginaldi et al., 2001) and is considered a major 
contributory factor towards the increase in morbidity and mortality associated with 
advanced age.  
 
1.2.1.4  Consequences of this age related immune decline 
The age related decline in immune function is reflected in infectious diseases being an 
increasingly important cause of morbidity and mortality amongst the aged, who 
experience greater infection frequency, duration and severity (High, 2004). This age 
related immune deficit is particularly noticeable against novel antigenic challenges 
from previously unencountered pathogens. This is most clearly illustrated by the 
example of seasonal influenza, which is considered a relatively innocuous disease 
amongst the young but constitutes a major cause of death amongst the aged (Minino 
et al., 2002; Simonsen et al., 2007). Furthermore, newly emerging pathogens cause 
disproportionate amounts of disease and death amongst the aged. Indeed, SARS 
(Severe Acute Respiratory Syndrome) was rarely fatal in the young but infected 
elderly experienced mortality rates of over 50% (Donnelly et al., 2003). Additionally, 
West Nile Virus is mostly asymptomatic amongst immunocompetent hosts but can 
cause a life threatening neuroinvasive disease that is 40-50 times more common 
amongst the over 70s compared with those under 40 (Brien et al., 2009). Moreover, 
many vaccines exhibit reduced efficacy in aged individuals, limiting preventative 
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prophylaxis (Grubeck-Loebenstein, 2010), being only 17-53% efficacious amongst 
the aged compared with rates of 70-90% in the young (Goodwin et al., 2006).  
 
Although memory generated from aged individuals functions poorly, memory 
responses generated towards pathogens encountered before the onset of 
immunosenescence are well-maintained into old age (Haynes et al., 2003). Indeed, 
neutralising antibody was recently identified from aged survivors of the 1918 
influenza epidemic and in those infected or vaccinated with smallpox as children, 
despite not being re-exposed to antigen for up to 90 years (Yu et al., 2008; Taub et al., 
2008).  
 
1.2.2  How individual immune system components are affected by ageing 
 
Age-associated deleterious changes have been best characterised amongst the 
adaptive immune system, particularly amongst T cells, which exhibit profound age-
associated alterations. Indeed, the diminution of the naïve CD8+ T cell pool with the 
corresponding reduction in T cell receptor (TCR) diversity and increase in memory 
cells are seen as hallmarks of immune system ageing (Pawelec et al., 2010c). 
Although B cell age-associated alterations have been documented, these may largely 
be a consequence of dysfunctional CD4+ T cell help (Maue and Haynes, 2009). With 
regard to innate immunity, some reviewers state that its functionality amongst the 
aged is largely preserved or even enhanced (Franceschi et al., 2000a). Nevertheless, it 
should be noted that non-immune age related changes also contribute towards 
immunosenescence, for example the decreased function of epithelial barriers of the 
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skin, lungs and gastro-intestinal tract amongst the aged permit increased invasion of 
mucosal tissues by pathogenic organisms (Weiskopf et al., 2009; Bodineau et al., 
2009).  
 
1.2.3  T cells 
   
1.2.3.1  Introduction 
 
1.2.3.1.1 Activation of Naïve T cells 
T cell progenitors are produced in the bone marrow and mature in the thymus into 
CD4+ or CD8+ T cells, (further described in section 1.3.1.1). T cells exiting the 
thymus migrate throughout the body and gather in secondary lymphoid organs. Here 
they are considered immunologically naïve until they have encountered their specific 
antigen, which they recognise through their T cell receptor (TCR). TCRs are 
transmembrane heterodimers consisting of 2 polypeptide chains - predominantly αβ 
(though a minority of T cells ~5% express a γδ TCR). TCRs possess a conserved 
segment that participates in the signalling function and a highly variable region 
responsible for antigen recognition. These variable regions are generated by the 
stochastic rearrangement of the relevant genes producing a diverse TCR repertoire 
that can recognise an enormous range of peptides. TCRs recognise antigen in the 
context of major histocompatibility complex (MHC) molecules that are expressed on 
the surface of target cells (Zinkernagel and Doherty, 1997). This also requires the 
binding of a CD4 or CD8 coreceptor that associates with the TCR and binds a 
conserved region on a MHC class II or class I molecule, respectively. However, a 
primary immune response can only develop if naïve T cells receive coordinated 
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stimulation by 3 signals: (1) a specific peptide-MHC complex with high affinity (2) 
appropriate costimulation (further discussed in section 1.5.1) and (3) inflammatory 
cytokine signals (Mescher et al., 2006), which result in rapid T cell proliferation 
accompanied by extensive cellular changes, as T cells acquire effector functions, 
change their cytokine and chemokine expression and move towards peripheral 
infection sites as activated effector T cells. 
 
1.2.3.1.2 Effector T cell functions 
Naïve CD8+ T cells differentiate into cytotoxic effectors that play critical roles in 
cellular immune responses directed against intracellular pathogens whereas CD4+ T 
cells are robust producers of effector cytokines that functionally organise the immune 
response and provide help to B cell and CD8+ T cell responses (Zhang et al., 2009). 
Indeed, functionally distinct CD4+ T cell effector subsets exist, whose differentiation 
decision is determined primarily by the cytokine milieu in the microenvironment 
(signal 3) (Zhou et al., 2009). T helper type (Th) 1 cells play a key role in cellular 
immunity, Th2 are required for humoural immunity against extracellular pathogens, 
Th17 are important in the clearance of extracellular bacteria and fungi particularly at 
mucosal surfaces, whereas T follicular helpers (Tfh) regulate the maturation of B cell 
responses (Zhou et al., 2009). Regulatory CD4+ T cell (Tregs) subsets also exist: the 
thymically derived naturally occurring Tregs (nTregs) and peripherally produced 
inducible Tregs (iTregs) who dampen effector responses and play critical roles in 
maintaining peripheral tolerance (Curotto de Lafaille and Lafaille, 2009; Josefowicz 
and Rudensky, 2009).  
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1.2.3.1.3 Memory formation 
Following successful elimination of the pathogen, a rapid T cell contraction phase 
ensues resulting in the death of most (90-95%) effector cells with the remaining cells 
representing memory precursors. This not only increases the number of antigen 
specific cells in the peripheral T cell pool, as in addition, memory cells differ in 
function from naïve cells, having a higher antigen affinity, lower activation threshold, 
being less dependent on costimulation, being able to more rapidly expand and induce 
effector functions and having altered chemokine and adhesion receptor profiles that 
enables memory cells to scan peripheral tissues (Rogers et al., 2000). A key feature of 
memory cells that distinguishes them from effector cells is their ability to persist long 
term in an antigen independent manner (Surh and Sprent, 2008). Nevertheless, the 
memory responses to chronic infections differ from the model presented above 
(further discussed in section 1.4.3). 
 
1.2.3.1.4 Central and effector memory 
Memory lymphocytes confer immediate protective immunity in the periphery and can 
mount proliferative recall responses in secondary lymphoid organs. Amongst B 
lymphocytes, distinct cell types mediate these functions, with plasma cells secreting 
antibodies that confer immediate protective immunity and memory B cells mediating 
reactive memory by proliferating and differentiating to plasma cells in response to 
antigenic challenge (Lanzavecchia and Sallusto, 2009). Similarly, amongst T cells, 
protective memory has been suggested to be mediated by effector memory T cells 
(TEM) that circulate in the periphery and execute immediate effector functions but 
exhibit limited proliferative responses, whereas central memory cells (TCM) confer 
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reactive memory, expressing lymphoid homing receptors, exhibiting vigorous 
proliferation but little immediate effector functions upon secondary antigenic 
challenge and efficiently differentiating into effector cells (Sallusto et al., 2004).  
 
1.2.3.1.5 CD45RA-revertant memory T cells 
An age-associated accumulation of T cells with a terminally differentiated phenotype 
has also been described. These cells share phenotypic features with effector memory 
cells being CD69-CD25-CD62LlowCD127lowCCR7lowCD27lowCD28low, but they re-
express CD45RA (normally restricted to naïve T cells) and thus have been termed T 
effector memory cells, re-expressing CD45RA (TEMRA) or CD45RA-revertant 
memory T cells (TREV) (Nikolich-Zugich, 2008). These cells were originally described 
as exhausted, quiescent cells near the end of their replicative lifespan that could 
execute immediate effector functions but exhibited severely dysfunctional 
proliferative responses (Champagne et al., 2001; Geginat et al., 2003). They were 
thought to allow maintenance of specific immune responses without proliferation that 
could otherwise drive their terminal exhaustion (Dunne et al., 2005). However, more 
recent data using a specific peptide stimulus in the presence of exogenous interleukin-
2 (IL-2), rather than an anti-CD3 one, suggest that TREVS maintain a high proliferative 
capacity (van Leeuwen et al., 2002; Wills et al., 2002), which has been supported by 
in vivo observations (Gamadia et al., 2004). Differential costimulation requirements 
have been shown to be key in explaining these distinct TREV proliferative responses, 
with TREVs lacking CD28 and the Tumour Necrosis Factor (TNF) Receptor family 
member CD137L (41-BBL, see section 1.5.1.3) being a critical costimulatory ligand 
for induction of their proliferation (Waller et al., 2007). Moreover, TREVs have 
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relatively long telomere lengths, at least in young donors (Plunkett et al., 2005). 
Furthermore, their functional importance is highlighted by the association of both the 
proportion and absolute numbers of Human Immunodeficiency Virus (HIV) 
(Northfield et al., 2007) and Cytomegalovirus (CMV) (Lilleri et al., 2008) specific 
CD8+ TREVs with improved viral control, despite the absence of such a consistent link 
with the overall magnitude of the HIV specific CD8+ response (Northfield et al., 
2007). In summary, these data argue that rather than being a dysfunctional end stage 
population, TREVs can mediate strong antiviral responses in vivo. Nevertheless, this 
scenario may not be applicable in aged populations whose TREVs possess very short 
telomeres and may thus be dysfunctional and close to replicative senescence (Akbar 
and Fletcher, 2005). 
 
1.2.3.1.6 Effector and memory subpopulation differentiation pathways 
The differentiation pathways and factors driving lineage decisions between these 
effector and memory T cell subpopulations remain incompletely understood. Initial 
models proposed a fixed linear differentiation pathway whereby memory cells arise as 
direct descendants of effector cells (Figure 1.01A) (Wherry et al., 2003). Alternatively, 
more recent divergent models predict that memory and effector cells arise as separate 
lineages (Figure 1.01B) possibly dependent on antigen signal strength (Lanzavecchia 
and Sallusto, 2002) or as a result of asymmetric division of naïve cells (Chang et al., 
2007). Evidence to support both linear and divergent differentiation models currently 
exist, as reviewed in (Kalia et al., 2010). The re-expression of CD45RA on memory 
cells appears to be a consequence of homeostatic proliferation in the absence of 
antigen (Geginat et al., 2003; Dunne et al., 2005; Lilleri et al., 2008; Carrasco et al., 
 32 
 
 
2006; Sallusto et al., 2004). However, the origins of these CD45RA-revertant memory 
T cells are also unclear with both central (Geginat et al., 2003; Dunne et al., 2005) and 
effector memory (Lilleri et al., 2008)  populations being proposed as their source. 
 
A. Linear Differentiation Model 
 
 
 
 
B. Divergent Differentiation Model 
 
Fig 1.01 Models of Memory T cell Differentiation 
 
1.2.3.1.7 Identification of T cell subpopulations 
 
TN TCM 
TEM 
TEFF 
TN TEFF TEM TCM 
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These distinct T cell subsets are characterised by functional and phenotypic 
differences that can be defined on the basis of their heterogeneity in antigen 
expression, as illustrated in Table 1.02. Naïve T cells express the CD45 high 
molecular weight isoform CD45RA; their differentiation to memory cells coincides 
with a loss of CD45RA expression, which is replaced by its low molecular weight 
isoform CD45RO (Sallusto et al., 2004; Schiott et al., 2004). Naïve T cells also 
express lymph node homing receptors, such as CCR7 and CD62L, which are 
expressed on central memory cells but lost on the peripherally residing effector 
memory cells. Although the complexity of CD62L expression limits its usefulness as 
a phenotypic marker (Sallusto et al., 2004; Lefrancois, 2006; Fierro et al., 2008; 
Schiott et al., 2004), the loss of CCR7 has been widely used to distinguish central and 
effector memory populations, so that naïve cells are defined as CCR7+CD45RA+, 
central memory cells as CCR7+CD45RA- and effector memory cells as CCR7-
CD45RA- (Lanzavecchia and Sallusto, 2000; Sallusto et al., 1999). Revertant memory 
T cells re-express CD45RA and lack lymphoid homing markers and therefore can be 
identified as a CCR7-CD45RA+ population. The pattern of CD27 expression is largely 
superimposable to that of CCR7 (Fierro et al., 2008) however CD27 staining better 
delineates the positive and negative populations. Thus CD27, alongside CD45RA, has 
been suggested as the most useful antigen combination to identify the four main T cell 
subsets: CD27+CD45RA+ (naïve, TN), CD27+CD45RA- (central memory, TCM), 
CD27-CD45RA- (effector memory, TEM) and CD27-CD45RA+ (revertant memory, 
TREV) (Fierro et al., 2008). 
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 Naïve Central Memory Effector Memory Revertants 
CD27 Hi Hi Lo Lo 
CCR7 Hi Hi Lo Lo 
CD62L Hi Hi Lo Lo 
CD45RA Hi Lo Lo Hi 
CD45RO Lo Hi Hi Lo 
CD28 Hi Inter Lo Lo 
Telomere length Hi Inter Lo Inter/Lo 
 
Table 1.01 Phenotypic comparison of CD8+ T cell subpopulations 
 
1.2.3.2  Effects of advancing age on the T cell compartment 
 
1.2.3.2.1 Overview 
Although peripheral T cell numbers do not diminish with age (Pawelec et al., 2009a) 
the peripheral T cell pool undergoes a striking age-associated remodelling, with a 
diminution in naïve T cells and TCR diversity accompanied by an age-associated 
accumulation of more differentiated memory cells, which accumulate oligoclonal 
expansions (Pawelec et al., 2010c). Furthermore, these memory T cells display 
phenotypic changes such as CD28 loss which has been reported to be a key predictor 
of immune incompetence in the aged (Vallejo, 2005). These age-associated changes 
are much more strikingly observed amongst the CD8+ T cell compartment than the 
CD4+s, experiencing clonal expansions and CD28 loss at a far lower frequency 
(Naylor et al., 2005; Goronzy et al., 2007; Naylor et al., 2005; Effros et al., 1994). 
TN TCM TEM TREV 
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Age-associated defects are not just limited to αβ T cells, as γδ T cells, which 
recognise antigen in a non-classical manner, also exhibit age related deficits, being 
reduced in number with attenuated proliferative responses and increased apoptotic 
sensitivity amongst old donors (Colonna-Romano et al., 2002). 
 
1.2.3.2.2 CD28 Loss 
Indeed, although the number or structure of TCRs (signal 1) do not change with age 
(Fulop, Jr. et al., 1999), diminution of CD28 expression, (signal 2) is one of the most 
profound and consistent age-associated human immune alterations. At birth virtually 
all human T cells express CD28 but by the age of 80, 10-15% of peripheral blood 
CD4+ and over half of CD8+ T cells lack CD28 expression (Weng et al., 2009). 
Following normal antigenic stimulation, CD28 expression drops but rapidly returns to 
the same level as before stimulation, but repeated or sustained stimulation can drive 
CD28 expression loss, along with homeostatic proliferation (Chiu et al., 2006) and 
inflammation (Bryl et al., 2001). In comparison with CD28+ cells, CD28- T cells 
exhibit reduced TCR diversity, shorter telomeres, defective telomerase and 
proliferative responses and are pro-inflammatory and highly cytotoxic (Weng et al., 
2009). Their functional significance is highlighted by their accumulation being 
associated with impaired immune responses (Goronzy et al., 2001; Saurwein-Teissl et 
al., 2002). This deficiency is further exacerbated by the impaired induction of its 
ligands B7.1 and B7.2 amongst the aged (Pawelec et al., 2010c), so that even cells 
that still express CD28 may exhibit diminished responses. However, the idea that 
CD28 loss is a critical factor in the dysfunction of CD28-CD8+ T cells has been 
challenged by the finding that restoration of CD28 signalling could not reverse their 
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low telomerase activity (whose significance is explored below) (Plunkett et al., 2007), 
though this finding itself has recently been disputed (Effros, 2010). 
 
1.2.3.2.3 Cellular senescence 
 
Naïve T cell loss and CD28 diminution has only been demonstrated to partially 
explain the inability to adequately activate T cells from old donors, which also reflects 
age-associated deleterious alterations on a per cell basis (Maue et al., 2009; Eaton et 
al., 2004; Pfister et al., 2006). Indeed, this may be a consequence of cellular 
senescence, defined as the irreversible loss of the replicative potential of somatic cells, 
which can be induced in a telomere dependent or telomere independent manner 
 
1.2.3.2.3.1 Telomeres 
 
The complete replication of linear chromosomes is problematic for the eukaryotic 
DNA replication machinery as it requires a 5’ primer for the initiation of DNA 
synthesis. This ‘end replication problem’ (Osterhage and Friedman, 2009) prevents 
complete replication of the 3’ end of chromosomes, producing a single DNA strand 
that is unstable, resulting in the loss of 50-200 base pairs of DNA with each cell 
division (Kaszubowska, 2008). To overcome this problem, linear chromosome ends 
are composed of non-coding double stranded repeat sequences, known as telomeric 
DNA, that protect DNA ends from erosion. This DNA is associated with a protein 
complex to form capped structures known as telomeres (Andrews et al., 2009). These 
prevent chromosome ends undergoing illegitimate recombination, fusion events and 
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the possibility of being recognised by cellular repair systems as double stranded DNA 
breaks. 
 
Telomeres erode with each somatic cell division and cells can only undergo a finite 
number of cell divisions (the Hayflick number (Hayflick and Moorhead, 1961)) 
before their telomeres reach a critically short length and uncap (Verdun and Karlseder, 
2007). This results in a DNA damage response (DDR) signal being transmitted that 
temporarily arrests cell growth whilst the lesion is repaired (Campisi and d'Adda di, 
2007; d'Adda di et al., 2003). If the damage is irreparable, prolonged DDR signalling 
ensues that triggers either apoptosis or an irreversible state of growth arrest termed 
replicative senescence, dependent upon the cell type (Blackburn, 2005; Verdun and 
Karlseder, 2007). Independently of telomere erosion, damage anywhere in the 
genome, oncogene expression and cellular stress can all induce a DDR that results in 
senescence (Campisi and d'Adda di, 2007). The presence of critically short sentinel 
telomeres rather than the mean cellular telomere length is critically important to 
initiate this process (Hemann et al., 2001). In vivo, cellular senescence prevents 
incipient cancer cells proliferating, thereby forming a critical means of inhibiting 
tumourigenesis (Campisi, 2005). However, amongst aged tissues, the accumulation of 
senescent cells can perturb normal tissue homeostasis, compromise regenerative 
capacity and promote ageing (Tyner et al., 2002; Hornsby, 2002; Kim and Sharpless, 
2006). 
 
1.2.3.2.3.2 Telomerase 
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Germ cell telomeres, in contrast to somatic cells, do not undergo attrition with every 
cell division because they are maintained by the reverse transcriptase activity of the 
enzyme telomerase (Hiyama et al., 1995). However, lymphocytes are unique amongst 
somatic cells in that they can upregulate telomerase during entry into the cell cycle 
that can initially compensate for replication associated telomere loss (Hiyama et al., 
1995; Igarashi and Sakaguchi, 1997). Nevertheless, the ability of T cells to upregulate 
telomerase progressively diminishes following repeated activation (Valenzuela and 
Effros, 2002; Roth et al., 2003) 
 
Telomerase induction in lymphocytes is primarily regulated through PI3K/Akt, which 
directly phosphorylates and activates hTERT, the catalytic unit of telomerase 
(Akiyama et al., 2004). Furthermore, Akt, alongside PKC, activates NF-κB, which 
mediates the nuclear translocation and indirect activation of hTERT (Sheng et al., 
2006; Akiyama et al., 2004). PI3K/Akt pathway is a key downstream mediator of 
CD28 costimulatory signals (further discussed in section 1.5.1.1) and following 
repetitive stimulation, T cells lose CD28 expression (as described in section 1.2.3.2.2), 
which mirrors their loss of telomerase induction. However, restoration of CD28 
signalling in CD28-CD27-CD8+ T cells could not reverse their telomerase impairment 
(Plunkett et al., 2007). This, instead, was associated with defective phosphorylation of 
the key signalling kinase Akt at Ser473 (Plunkett et al., 2007), which is one of two 
phosphorylation sites that control its activation (Jacinto et al., 2006; Alessi et al., 
1996). Nevertheless, blocking E-cadherin significantly reversed their defective Akt 
phosphorylation, but these cells remained refractory to telomerase induction (Henson 
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et al., 2009), indicating that other, Akt independent, mechanisms are involved in their 
telomerase downregulation. 
 
1.2.3.2.3.3 Significance of cellular senescence in immune system ageing 
 
The adaptive immune system is particularly sensitive to the effects of replication 
associated telomere loss, as its competence is critically dependent upon lymphocytes 
undergoing massive clonal expansion upon encountering cognate antigen (Akbar et al., 
2004; Kaszubowska, 2008; Andrews et al., 2009). Their age related loss of telomerase 
induction results in lymphocytes exhibiting progressive telomere attrition (Plunkett et 
al., 2001; Hodes et al., 2002; Rufer et al., 1999; Son et al., 2000), whose significance 
is highlighted by their shortened telomeres being predictive of earlier mortality 
(Cawthon et al., 2003) and associated with a variety of age-associated pathologies 
(Calado and Young, 2009).  
 
As well as irreversible growth arrest, most senescent cells acquire apoptotic resistance 
(Campisi and d'Adda di, 2007), which may account for their age-associated 
accumulation (Passos et al., 2010). By contrast, lymphocytes from old, as compared 
with young, humans exhibit an increased propensity to undergo apoptosis following a 
wide variety of mitogenic stimuli (Herndon et al., 1997; Potestio et al., 1998). 
Nevertheless, this may largely reflect the apoptotic process involved in deletion of 
effector cells following infection resolution, by a process termed activation induced 
cell death (AICD). AICD is mediated through Fas/FasL interactions and, indeed, 
lymphocytes from aged humans are more sensitive to apoptosis induced by the Fas 
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and TNFα death receptor pathways than their young counterparts (Aggarwal and 
Gupta, 1998; Aggarwal et al., 1999; Salvioli et al., 2003). However, these extrinsic 
apoptotic mechanisms likely differ from the intrinsic pathway, which is induced 
following a wide variety of stimuli that include oxidative stress and DNA damage 
(Monti et al., 2000). Indeed, human EBV specific CD8+ T cells repeatedly stimulated 
to divide in culture develop growth arrest and become resistant to apoptosis in 
response to a variety of stimuli that strongly induced apoptosis in their less 
differentiated counterparts (Spaulding et al., 1999). Moreover, human TEM and TREV 
CD8+ T cells, whose numbers increase with age (as described earlier), are more 
resistant to oxidative stress, calcium and TNFα induced apoptosis than their TN and 
TCM counterparts (Gupta and Gollapudi, 2006; Gupta, 2005) and lymphocytes from 
human donors of advanced age are more resistant to apoptosis under conditions of 
oxidative stress compared with the young (Monti et al., 2000). Furthermore, the age 
related accumulation of oligoclonal CMV specific CD8+ T cell expansions (detailed in 
section 1.4.3.3.2) results from their extended lifespan (Wallace et al., 2010), 
suggesting such cells become senescent, acquiring apoptosis resistance. Nevertheless, 
unlike fibroblasts and epithelial cells, following a DDR lymphocytes preferentially 
undergo apoptosis (Campisi and d'Adda di, 2007). However, lymphocytes can still 
become senescent (Schmitt et al., 2004; Vallejo et al., 2004; Montes et al., 2008; 
Aoshiba and Nagai, 2009; Simpson et al., 2010; Plunkett et al., 2005) and even if this 
only reflects a small proportion of lymphocytes undergoing a DDR, their rapid 
turnover (Hellerstein et al., 1999) would manifest itself as an age related accumulation. 
Senescent lymphocytes also remain metabolically active, exhibiting widespread 
changes to gene expression unrelated to proliferation, most notably up-regulating pro-
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inflammatory secretory genes (Fumagalli and d'Adda di, 2009), which may underlie 
the development of the age related subclinical pro-inflammatory state termed 
‘inflammaging.’  
 
1.2.3.2.4  Inflammaging 
Multiple studies have also demonstrated that the age relate decline in immune cell 
activity is at least in part mediated by the accumulation of factors in the serum of old 
animals, likely including cytokines alongside, for example, hormones (Gomez et al., 
2006; Bagnara et al., 2000; De et al., 2004). In particular, the in vitro addition of 
exogenous IL-2 can rejuvenate many lymphocyte functions of the aged including 
proliferation, differentiation and cytotoxicity defects (Haynes et al., 2000; Haynes and 
Eaton, 2005).  
 
Indeed, the complex immune system remodelling observed during ageing includes a 
well characterised profound modification of the cytokine network. A key feature of 
this phenomenon is an increase in pro-inflammatory molecules alongside a decrease 
in tropic agents (e.g. IL-2). Murine studies generally support an age related shift from 
a Th1 like (IL-2, IFNγ) to a predominantly Th2 like (IL-4, IL-6, IL-10) cytokine 
response (Shearer, 1997; Segal et al., 1997). However, a meta-analysis of over 60 
human studies revealed no such consistent change (Gardner and Murasko, 2002).  
 
Ageing is associated with an increase in plasma levels and the capability of 
leukocytes to produce inflammatory components including TNFα (Bruunsgaard et al., 
1999; Paolisso et al., 1998), IL-6 (Cohen et al., 1997) and acute phase proteins such as 
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CRP (Ballou et al., 1996). These circulating inflammatory parameters can be 
positively correlated, suggesting a generalised activation of the entire inflammatory 
network (Bruunsgaard et al., 1999). However, the observed 2-4 fold increase in 
circulating inflammatory parameters is far from levels attained in acute infection 
(Bruunsgaard et al., 2001). Therefore, ageing is said to be associated with a low grade 
chronic pro-inflammatory condition termed ‘inflammaging’ (Franceschi et al., 2000b).  
 
Inflammaging may be driven by the chronic exposure of macrophages, the central 
source of these pro-inflammator molecules, to a variety of stressors such as reactive 
oxygen species (ROS) from endogenous metabolic pathways or antigens, leading to 
their systemic activation (Franceschi, 2007; Franceschi et al., 2000b). Alternatively, 
the age-related increase in other pro-inflammatory cells such as T cells lacking CD28 
expression may underpin inflammaging (Weiskopf et al., 2009). Indeed, these cells 
are augmented amongst CMV seropositive donors and, as the dominant chronic 
stressor, CMV antigens may mediate systematic macrophage activation and 
exacerbate inflammaging. Indeed, CMV seropositivity is associated with an 
upregulation of a variety of pro-inflammatory agents (Mogensen and Paludan, 2001; 
Varani et al., 2009; Tong et al., 2001). Additionally, ageing is correlated with 
increased adiposity and adipiocytes can secrete large quantities of pro-inflammatory 
adipokines and cytokines (Tchkonia et al., 2010), which recruit and activate 
macrophages to a classically activated phenotype that further propagates the 
inflammatory response (Maury and Brichard, 2010). 
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Although inflammation is a process critical for dealing with infections and tissue 
damage, inflammaging appears to be physiologically deleterious and is predictive of 
all-cause mortality in multiple elderly cohorts (Krabbe et al., 2004). Moreover, 
inflammation is a characteristic part of the pathological processes of many of the most 
prevalent and severe age related pathologies, including cardiovascular diseases, 
rheumatoid arthritis and Alzheimer’s, whose development are further associated with 
inflammaging (reviewed in Macaulay et al, manuscript submitted). 
 
1.2.3.2.5 Other age-associated T cell alterations 
Aged humans also exhibit a compromised ability to effectively form immunological 
synapses (Tomoiu et al., 2007). These result from a dynamic lipid raft reorganisation 
at the TC-APC interaction site that segregates positive and negative activators of T 
cell activation, generating an environment for the amplification of signalling 
transduction cascades. Impairment in their generation diminishes the signalling 
intensity, and thus impairs the ability of T cells to activate, expand and differentiate 
(Garcia and Miller, 2002). A major factor underlying this defect is the increased 
cholesterol content of cell membranes of the aged, increasing membrane rigidity and 
impairing membrane raft functionality (Tomoiu et al., 2007), which may in part 
explain the multiple deleterious alterations in TCR signalling cascades observed in 
aged T cells. Indeed, increasing the membrane cholesterol content of young T cells to 
that of old donors rendered them functionally aged and conversely decreasing 
cholesterol of aged T cells improved their IL-2 production and proliferation (Tomoiu 
et al., 2007).  
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1.3   What causes these age related T cell changes? 
 
These T cell changes are considered biomarkers of human immune system ageing and 
are precipitated by two key events: 1) decline in lymphocyte generation resulting from 
thymic involution and 2) continuous attrition caused by lifelong chronic antigen 
burden. 
 
1.3.1  Thymic Involution 
 
1.3.1.1  Introduction 
The thymus plays a crucial role in T cell development, providing a specialised 
microenvironment in which hematopoietic bone marrow derived precursors are able 
to replicate, mature and undergo strict selection procedures to shape a T cell repertoire 
that is sufficiently diverse and sensitive towards the vast array of foreign antigens but 
is also non-reactive to self (Sebzda et al., 1999). 
 
The gene rearrangement process that generates TCRs is random. It may thus result in 
ineffective T cells which bind too weakly to MHC to recognise antigenic peptide or 
autoreactive T cells that bind strongly to self-MHC peptide complexes and such cells 
are eliminated in the thymus by the processes of positive and negative selection, 
respectively (Klein et al., 2009). Only interactions with intermediate affinity allow 
lineage commitment and export into the periphery, resulting in the deletion of the vast 
majority (∼97%) of thymocytes (Klein et al., 2009). Surviving cells are exported into 
the periphery as recent thymic emigrants, which mature post thymically to form naïve 
T cells (Houston, Jr. et al., 2008).  
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1.3.1.2  Age-associated thymic changes 
The human thymus regresses (or involutes) progressively throughout life with its 
functional tissue becoming gradually replaced with adipocytes, to the extent that this 
organ becomes barely identifiable in adults. This constitutes one of the most 
ubiquitous, dramatic and recognisable changes during ageing (Steinmann et al., 1985).  
 
1.3.1.3  Homeostatic peripheral expansion 
Nevertheless, considering 1% of the total T cell pool has been estimated to be 
replenished each day, equating to 3 × 109 T cells (Goronzy et al., 2007) and 
thymopoiesis is the exclusive mechanism by which novel T cells may be generated, 
the total size of the T cell pool changes remarkably little with advancing age (Pawelec 
et al., 2009a). However, T cells can also be replenished extra-thymically, by a process 
termed homeostatic proliferation, that is independent of antigen, which already 
significantly contributes towards building the T cell repertoire in neonates, with over 
half of all foetal T cells being generated homeostatically (Schonland et al., 2003). 
Moreover, thymectomised infants appear to build a normal T cell compartment with 
no reported increased frequencies of major infections (Goronzy et al., 2007). However, 
such individuals also exhibit signs of a prematurely aged immune system (Sauce et al., 
2009), suggesting that although homeostatic proliferation is the major mechanism of 
T cell production in adults, thymic export still makes a significant contribution. 
Nevertheless, homeostatic proliferation may itself have physiological limitations. 
Indeed, this peripheral expansion depends on self-recognition and may be subject to 
selection pressures that compromise TCR diversity over time (Goronzy and Weyand, 
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2005). Furthermore, homeostatic proliferation can induce the differentiation of naïve 
to memory T cells (Ge et al., 2002), which would drive attrition of the naïve T cell 
pool and loss of TCR repertoire diversity.  
 
1.3.1.4  TCR Repertoire Diversity 
The receptor diversity of the naïve T cell compartment is critical to the ability to 
mount a T cell response to novel antigenic challenges such as those provided by 
newly emerging viruses, such as SARS, and by antigenic drift of existing viruses, 
such as influenza, both of which disproportionately affected the elderly in terms of 
incidence and severity (Naylor et al., 2005).  
 
The enormous TCR repertoire diversity reflects the highly polymorphic nature of the 
TCR. The TCR is a heterodimeric protein that consists of two polypeptide chains (α 
and β) each containing one variable, V and one constant, C domain. The CDR3 (third 
complementary-determining region) loops of the α and β chain V domains is largely 
responsible for the peptide specificity of the TCR (Robins et al., 2009). These CDR3 
loops are formed by recombination between multiple V, D and J gene segments in the 
β chain locus and between analogous V and J segments in the α locus, which allow a 
large number of distinct CDR3 sequences to be encoded and the diversity is further 
increased by addition and deletion of nucleotides at the recombination junctions 
during TCR gene rearrangement (Robins et al., 2009). 
 
A theoretical estimate of TCR diversity generated by this system is of the order of 
1015 but intrathymic selection processes limit the generated repertoire to around 1013 
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(Nikolich-Zugich et al., 2004). However, the human T cell system is estimated to 
consist of approximately 3x1011 cells with a naïve T cell diversity of 107-108 different 
TCRs, with each T cell specificity being represented by a clone of at least 1000 cells 
(Robins et al., 2009). By comparison, the T cell repertoire of the memory pool is 
contracted by an estimated factor of 100 (Nikolich-Zugich et al., 2004).  
 
Maintenance of the TCR repertoire is seen as critical to ensure responses to a wide 
range of antigenic challenges. Indeed, a twofold reduction in murine TCR diversity is 
sufficient to generate holes in the repertoire to various antigens (Woodland et al., 
1990) and the human TCR repertoire can be closely correlated with remaining 
lifespan amongst the very old (Hadrup et al., 2006). Moreover, through interclonal 
competition, clonal diversity limits inappropriate T cell expansions and its loss may 
promote autoimmunity (Goronzy and Weyand, 2003). 
 
1.3.2 Lifelong antigenic burden 
 
It has been shown that immune alterations typically associated with advanced age are 
observed amongst young individuals who have been subjected to a high antigenic 
burden. This is demonstrated in healthy African populations who are known to live in 
an environment in which the immune system is continuously challenged (van Baarle 
et al., 2005; Miles et al., 2007; Ben-Smith et al., 2008), as well as HIV infected 
individuals (Naeger et al., 2010; Desai and Landay, 2010; Appay et al., 2007; van 
Baarle et al., 2005), patients with X-linked proliferative syndrome (XLP) (Plunkett et 
al., 2005) (who undergo uncontrolled lymphocyte expansion in response to primary 
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Epstein-Barr virus (EBV) infection (Nelson and Terhorst, 2000)) and subjects 
affected by the long term persistent antigen stimulation provided by cancer (Pawelec 
et al., 2006) or autoimmune diseases (Thewissen et al., 2005; Thewissen et al., 2007). 
These data suggest that lifelong antigen burden rather than ageing per se may be the 
primary factor driving extreme differentiation of the T cell pool.  
 
1.3.2.1  Persistent poorly controlled antigenic challenges 
Very large antigenic loads are incurred by the host immune system in response to 
persistent viral infections, such as HIV and Hepatitis C virus (HCV). In such 
infections, the virus continually replicates in the face of an ongoing immune response, 
continuously and systematically stimulating and exhausting the virus specific T cells, 
such that they typically cause pathology resulting in chronic diseases with poor 
prognoses. Therefore, although such diseases incur a high antigenic load in the host, 
they are far from ubiquitous, affecting only a small minority of the old and causing 
premature mortality in the affected young. Thus they are not considered to be 
contributory towards the typical ageing process and such infections will not be further 
discussed, except to draw parallels between the functional consequences of such 
infections and those that result from T cell ageing. 
 
1.3.2.2  Latent infections 
More likely candidates that could contribute towards age-associated immune decline 
are latent infections. In contrast to persistent viral infections, these are systemically 
controlled after initial infection but instead of being cleared from the host, as in acute 
viral infections, the virus finds a niche where it can establish a quiescent latency. 
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Latency is a unique transcriptional and translational viral state whereby the productive 
replicative cycle and hence the expression of most or all antigens is silent but their 
genome persists. Such viruses must intermittently enter the lytic part of their life cycle 
and reactivate to spread both within and between hosts. Thus, by virtue of their 
repeated lifelong reactivation without causing overt disease, latent viruses may 
repetitively stimulate the immune system and play a role in driving age-associated 
immune changes 
 
The best studied latent viruses in this context are the herpesviridae. Of these, CMV in 
particular appears to act as the dominant chronic stressor, being highly ubiquitous and 
associated with many of the same phenotypic and functional alterations to T cell 
immunity, collectively known as the Immune Risk Phenotype (IRP), that have been 
suggested as biomarkers of immune system ageing (Wikby et al., 2002; Olsson et al., 
2000) (further discussed in section 1.4.2). The significance of CMV infection in 
health outcomes of elderly individuals is further highlighted by its association with 
deleterious responses to influenza vaccination (Trzonkowski et al., 2003), 
heterologous infection (Griffiths, 2006; Khan et al., 2004) and cancer (Pawelec et al., 
2010b). Moreover, the immune response towards CMV is very large in magnitude and 
progressively expands with age such that the T cell pool of old donors is frequently 
dominated by large, usually CMV specific, dysfunctional T cell clones, (further 
discussed in section 1.4.3.3.2). This ‘memory inflation’ is also a feature of persistent 
HIV and HCV infections but not EBV or Varicella Zoster Virus (VZV) (Brunner et 
al., 2010). 
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1.3.2.3  Other chronic pathogens 
However, not everyone is CMV positive even at advanced age but still exhibit 
characteristics of immunosenescence. Indeed, each human individual harbours an 
estimated 8-12 chronic infections (Virgin et al., 2009), which may also play roles in 
driving age-associated immune decline. A good candidate amongst CMV negative old 
individuals is EBV, which infects 99.9% of people and whose T cell responses 
expand with age only in the absence of CMV infection (Khan et al., 2004). Additional 
contributions may be made by the polyomavirus family, which consist of five viruses 
that share many features with herpesviruses that are pertinent to T cell ageing, 
including benign primary infection at an early age, high prevalence that only causes 
pathological consequences when there is concomitant immuno-suppression and 
reactivation with increasing frequency amongst the aged (Zhong et al., 2007; Kean et 
al., 2009; Nguyen et al., 2009; Sharp et al., 2009). Furthermore, in other environments, 
intestinal parasites, which can produce millions of eggs and copious 
excretory/secretory products that persistently stimulate the host immune system 
(Kassu et al., 2003), may play a similar role in driving age-associated immuno-
dysfunction. Indeed, infected subjects displayed substantial alterations to immune 
parameters similar to those described as CMV or age-associated, which were largely 
reversible upon parasite treatment (Kalinkovich et al., 1998). Other candidates include 
anelloviruses, the adeno-associated virus (AAV) (Virgin et al., 2009) and human 
herpes viruses 6 (HHV-6) and HHV-7 (Moss, 2010). Nevertheless, many of the 
aforementioned pathogens’ impact on the ageing process remain poorly explored and 
CMV remains the only pathogen to be associated with the immune risk profile. 
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1.4   CMV 
 
1.4.1  Introduction 
 
1.4.1.1  Background 
CMV is a member of the β-subfamily of the herpesviridae, which are ancient 
organisms that have evolved alongside eukaryotic cells for millions of years and 
possess the ability to remain latent in their hosts after initial infection. Indeed, CMV is 
frequently cited as one of the most successful human pathogens, being highly 
ubiquitous (McDonald et al., 2004) with its primary infection widely considered 
asymptomatic and persisting causing minimal impairment in immuno-competent hosts, 
enabling them to remain active and maximise the opportunity of encountering other 
successful contacts. Nevertheless, amongst immnocompromised patients, CMV is one 
of the most common and severe opportunistic pathogens (Freeman, Jr., 2009; 
Steininger et al., 2006) and primary infection during pregnancy carries a significant 
risk of developmental defects and mental retardation in newborns (Tsutsui, 2009). 
 
1.4.1.2 CMV infection routes and dissemination 
CMV is able to infect by a number of routes including trans-placentally, intra-
uterinally, peri-natally, and post-natally via infected sweat saliva, semen, urine and 
breast milk; blood transfusion and organ transplantation (Drago et al., 2000). Once in 
vivo, CMV can infect an exceptionally wide range of host cell types, including 
multiple haematopoietic cell types and the parenchymal and connective tissue cells of 
virtually any organ (Sinzger et al., 2008). In particular, monocytes and endothelial 
cells, which recruit and transfer virus to the migrating monocytes, play key roles in 
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the body wide dissemination of CMV during acute infection (Bentz et al., 2006). 
CMV pathogenesis results from the direct cytopathic effects of CMV on infected host 
organs (Bissinger et al., 2002). Additionally, the host immune response may also 
contribute to tissue damage, through CD8+ T cell mediated lysis of infected cells and 
the inflammatory nature of effector responses (Moss, 2010). 
 
1.4.1.3 Latency 
Monocytes are nevertheless not productive for viral replication, being abortively 
infected instead. However, since the genome is maintained they are considered to be 
reservoirs of latent CMV and vehicles for viral dissemination. In contrast, permissive 
viral infection occurs in macrophages, their differentiated counterparts (Smith et al., 
2004). Indeed, CMV infection of monocytes drives cellular activation, motility, 
endothelial migration and macrophage differentiation (Smith et al., 2004).  
 
1.4.1.4 Reactivation 
Monocytes are stimulated to differentiate to permissive macrophages by several 
cytokines, including the central inflammatory mediators TNFα and Interferon gamma 
(IFNγ), which also activate the CMV immediate early (IE) promoter region, thereby 
facilitating active CMV replication (Freeman, Jr., 2009). This enables spreading to 
other hosts by allowing virus to be shed in secretions associated with the 
inflammatory response. Moreover, numerous epidemiological studies associate CMV 
infection with multiple chronic inflammatory disorders, being specifically detected at 
sites of chronic inflammation, that is thought to reflect inflammation inducing CMV 
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reactivation, which further exacerbates the inflammatory response (Freeman, Jr., 
2009). 
 
1.4.1.5 Mechanisms of Immune Evasion 
CMV has the largest DNA genome of any human virus, around 240 kilobase (kB) 
pairs long, and is capable of encoding more than 200 proteins, but approximately 
three quarters of these are dispensable for viral replicative functions (Dunn et al., 
2003). Indeed, many CMV proteins possess immuno-modulatory functions, producing 
both pro-inflammatory and wide ranging immuno-suppressive effects (Freeman, Jr., 
2009). Examples of immune evasion include directly infecting the initiators of 
adaptive immunity, the DCs, inducing a so-called ‘paralysed’ phenotype, 
characterised by downregulation of MHC and costimulatory molecules and altering 
their cytokine profile so that they retain the ability to prime naïve T cells but tolerise 
or delete them rather than activate them (Rolle and Olweus, 2009). However, despite 
the presence of multi-layered viral evasion mechanisms, an immune response of 
considerable magnitude is generated against CMV and infection is well controlled in 
humans, even at an advanced age (Weiskopf et al., 2009). Nevertheless, cross 
presentation of viral antigens by uninfected DCs can bypass viral escape mechanisms 
and ensure efficient T cell priming (Benedict et al., 2008). Additionally, most of the 
studies characterising CMV ‘paralysing’ DCs (Rolle and Olweus, 2009) were 
performed on monocyte derived DCs, whereas CD11c+ myeloid DCs do not exhibit a 
paralysed phenotype and plasmacytoid DCs are resistant to CMV infection (Kvale et 
al., 2006). These constitute the two major populations of peripheral blood DC subsets 
and may thus represent the key initiators of anti-CMV immunity. 
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1.4.2 The Immune Risk Phenotype (IRP) 
 
A longitudinal study of ageing amongst healthy Swedish octogenarians (OCTO 
immune study) (Olsson et al., 2000) and further refined using a nonagenarian 
population not selected for good health (NONA study) (Wikby et al., 2002), revealed 
a cluster of immune parameters associated with poor immune function and predictive 
of earlier mortality, termed the IRP. The IRP is characterised by an inverted 
CD4:CD8 ratio, poor T cell mitogen responses, increased levels of CD28-CD8+ T 
cells and low B cell counts. Moreover, CMV infection is associated with, and is 
suggested to be a major contributor towards, the IRP (Pawelec et al., 2004; 
Derhovanessian et al., 2009).  
 
1.4.2.1  CMV is associated with the IRP 
Although all individuals with an IRP were CMV+, only a small fraction of CMV+ 
individuals possessed an IRP, and no simple direct correlation between CMV and 
mortality has been observed (Pawelec et al., 2010c). The association of CMV with the 
IRP is not thought to be linked to the presence of CMV infection alone but reflects the 
manner in which an individual’s immune system deals with the virus (Strandberg et 
al., 2009; Derhovanessian et al., 2010; Wang et al., 2010). This could be influenced 
by the duration of infection, whereby a certain time period of infection is required for 
transition from a non-IRP into the IRP category (Pawelec et al., 2005), the frequency 
of reactivation, which may increase with age (Stowe et al., 2007) and/or the host 
inflammatory genetic profile (Derhovanessian et al., 2010).  
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1.4.2.2  IRP applicability 
Whether the IRP can be identified and be predictive of mortality among younger 
individuals is a crucial question pertaining to its relevance. Indeed, individuals under 
40 years of age, have been identified in the IRP but associations with mortality only 
become apparent above the age of 60 (Wikby et al., 2008), though this may reflect  
the relative scarcity of mortality and IRP amongst younger cohorts. Moreover, the 
concept of the IRP emerged from studying relatively small numbers of people who 
live in a single Swedish municipality, unusual for having a high prevalence of long 
lived individuals. However, data has emerged from the UK (Huppert et al., 2003) and 
Brazil (Peres et al., 2003) showing that an inverted CD4:CD8 ratio, the best marker 
for the IRP, is correlated with reduced survival rates. Nevertheless, the IRP has been 
applied to younger populations undergoing autoimmune disorders, cancer and HIV, 
when it is unclear whether it is predictive of mortality under these different 
circumstances (Pawelec et al., 2010c). 
 
1.4.3  T cell immune response against latent and persistent pathogens 
 
1.4.3.1 Comparing antiviral responses against cleared and persistent antigens 
There is a large body of evidence that suggests that the success of antiviral immunity 
is critically determined by the effectiveness of CD8+ T cell response, particularly in 
the long term control of persisting and latent viruses (Bangham, 2009). During the 
acute phase of viral infection the effector T cells generated in response to latent or 
persistent viruses appear largely similar to those produced in response to acute viral 
challenge, being activated, proliferating, cytotoxic, peripherally migrating, apoptotic 
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prone and expressing the phenotypic markers CD27, CD28 and CD45RO (van Lier et 
al., 2003; Virgin et al., 2009; Appay et al., 2002). However, during an acute virus 
specific response, the pathogen is typically cleared within 1-2 weeks, after which the 
majority (around 90%) of these expanded effector cells die by apoptosis, generating 
functional memory cells persisting independently of antigen and exhibiting slow 
homeostatic proliferation (as described in section 1.3.1.3). In contrast, during a 
chronic viral infection, specific CD8+ memory T cells arise which are completely 
dependent on antigen (alongside IL-2) for their maintenance, undergo extensive 
antigen driven proliferation and display multiple dysfunctions, including defective 
cytokine production, cytolysis and proliferative responses (Wiesel et al., 2009). These 
differences between acute and chronic virus specific cells are thought to be a 
consequence of antigen persistence versus antigen clearance (Sabbaj et al., 2007; Shin 
and Wherry, 2007; Mueller and Ahmed, 2009; Bucks et al., 2009). Indeed, exhausted 
CD8+ T cell responses have also been observed in response to the persistent antigenic 
stimulation provided by tumours (Kim and Ahmed, 2010) and parasite infections 
(Joshi et al., 2009; Hernandez-Ruiz et al., 2010). It should also be noted that 
exhaustion has also been observed amongst CD4+ T cell (Brooks et al., 2005) and B 
cell responses (Moir et al., 2008). Nevertheless, exhaustion and senescence (as 
described in section 1.2.3.2.3) are separate physiological phenomena and a table 
comparing their similarities and differences is depicted below: -  
 
 Senescence Exhaustion 
Definition 
Growth arrest resulting from cellular 
turnover or stress 
Persistence of virus specific T cells 
lacking effector functions 
Induction Progressive telomere shortening with Antigen persistence following acute 
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each cell division (telomere dependent) 
DNA damage/cellular stress (telomere 
independent) 
infection giving rise to ‘antigen addicted’ 
T cells 
Cellular 
Effects 
Proliferative inability 
Apoptosis resistance 
Loss CD28 
Decreased IFNγ 
Increased pro-inflammatory cytokines  
Exhaustion comprises spectrum of 
dysfunction whereby functional 
responses are lost in a hierarchical 
manner with  
Cytotoxicity and IL-2 compromised early 
TNFα lost at an intermediate stage and 
IFNγ being the most resistant  
Proliferative impairment being 
increasingly pronounced across the 
exhaustion gradient  
Physiological 
Function 
Inhibit tumourigenesis Prevent auto-immunity 
Signalling p38MAPK→p53→p21  PD-1→ inhibits PI3K/Akt  
Irreversible? No, p38 inhibition can restore function 
No, blocking PD-1/PD-L interactions 
restores function 
 
Table 1.02  Comparison of T cell exhaustion and senescence 
Senescence results from a DNA damage response (DDR) that activates the checkpoint proteins p53 and 
p21 through the MAPK signalling molecule p38 (Passos et al., 2010; Lansdorp, 2000). Blocking these 
key signalling mediators can reverse senescence at an early stage but prolonged DDR signalling 
ultimately leads to irreversible senescence (Passos et al., 2010; d'Adda di, 2008; Rodier et al., 2009; 
Shiloh, 2003; Beausejour et al., 2003; Lansdorp, 2000; Davis et al., 2007; Brown et al., 1997). 
Exhaustion is also reversible with the interruption of PD-1/L interactions augmenting functions (further 
discussed in section 1.5.3.2.3), though highly exhausted cells co-express additional inhibitory receptors 
and may be refractory to PD-1/L blockade alone (Blackburn et al., 2008; Nakamoto et al., 2008). 
 
1.4.3.2 Exhaustion gradient 
Although functional exhaustion of virus specific CD8+ T cells has been demonstrated 
in a wide range of human persistent and latent antigenic challenges, considerable 
heterogeneity exists in the degree of dysfunction observed in these reports not only 
between different diseases but also between individuals with the same virus and also 
amongst cells specific for the same virus within a single donor (Wherry and Ahmed, 
2004). Indeed, exhaustion is not an all or nothing phenomena but instead comprises a 
spectrum of dysfunction whereby functional responses are lost in a hierarchical 
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manner with cytotoxicity and IL-2 production compromised early, TNFα lost at an 
intermediate stage and IFNγ being the most resistant to exhaustion (Shin and Wherry, 
2007). Proliferative impairment is a key feature of exhaustion, occurring when other 
functions are intact, and becomes increasingly impaired across the exhaustion 
gradient (Freeman et al., 2006). Fully exhausted cells demonstrate complete loss of all 
effector functions and in the extreme situation, exhausted T cells can undergo 
apoptotic deletion (Freeman et al., 2006; Virgin et al., 2009). Furthermore, the 
functional importance of this exhaustion hierarchy is reflected in that the level of 
exhaustion, rather than the size of the response, can be correlated with inability of the 
immune system to control the virus (Bangham, 2009). The force driving this loss of 
function is antigen load (Shin and Wherry, 2007; Mueller and Ahmed, 2009). 
However, this relationship is a complex one and also depends upon the (1) latent or 
persistent nature of the virus, (2) viral tropism, (3) epitopes presented and (4) 
presence of CD4+ T cell help (Wherry and Ahmed, 2004).  
 
CD8+ T cells can cause massive host tissue damage by virtue of their cytotoxicity and 
can proliferate at an extraordinary rate, thus functional inactivation in the presence of 
persisting antigen may represent a mechanism of peripheral tolerance (Virgin et al., 
2009). Indeed, in the hierarchy of T cell exhaustion these potentially harmful 
responses are silenced first. Most pathogenic challenges are cleared after primary 
infection, thus persisting antigen may normally be a sign of an autoimmune response. 
However, many evolutionarily ancient chronic viruses co-exist with the host without 
being significantly detrimental and thus immune responses may result in 
immunopathological damage for very little benefit (Barber et al., 2006). 
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1.4.3.3 CMV specific immune response 
 
1.4.3.3.1 Comparing CMV with other chronic viruses 
Although highly similar during primary infection, over subsequent months during the 
chronic phase of infection, CD8+ T cells specific for a particular virus tend to develop 
a predominant phenotype and level of dysfunction. Indeed, HCV and influenza 
specific CD8+ T cells tend to display an early, HIV and EBV exhibit an intermediate 
and CMV mainly a late differentiated phenotype (Appay et al., 2002). Moreover, HIV 
and HCV specific CD8+ T cells are profoundly dysfunctional whereas EBV specific 
cells retain a high degree of function (Virgin et al., 2009); CMV specific CD8+ T cells 
lie somewhere in between these two ends of this spectrum. Indeed, although CMV 
specific CD8+ T cells clearly exhibit protective capacities (Holtappels et al., 2008), 
they display highly impaired IL-2 (Almanzar et al., 2004) and IL-7R expression 
(Sauce et al., 2007b) and an age-associated impairment in IFNγ production has also 
been reported (Ouyang et al., 2003a). This suggests CMV specific CD8+ T cells 
exhibit a moderate degree of functional exhaustion which worsens with age.  
 
1.4.3.3.2 Memory inflation 
 
In direct contrast to the T cell response observed towards most other pathogens, the 
magnitude of the CMV immune response undergoes progressive long term expansion 
with age (Nikolich-Zugich, 2008; Fletcher et al., 2005) that has been estimated to 
occupy between 10% and 40% of the CD4+ T cell pool (Pourgheysari et al., 2007; 
Sylwester et al., 2005; Sester et al., 2002). Moreover, CD8+ T cell responses, directed 
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against a sole epitope of a single CMV protein, can occupy over a quarter (Khan et al., 
2002; Ouyang et al., 2003b) and up to 40% (Khan et al., 2004) of the entire CD8+ 
compartment of the elderly. Their progressive expansion is associated with an 
accumulation of increasingly dysfunctional and differentiated CMV specific CD8+ T 
cell clones (Ouyang et al., 2003a), which may out-compete other T cell populations 
for immunological space, resulting in loss of immunological memory to previously 
controlled pathogens and further constrictions in the TCR repertoire (Akbar and 
Fletcher, 2005; Khan et al., 2004; Trzonkowski et al., 2003). Indeed, their 
significance is highlighted by their association with reduced lifespan amongst aged 
individuals (Hadrup et al., 2006). Furthermore, humoural anti-CMV responses also 
significantly intensify with advancing age and their magnitude is correlated with 
functional and cognitive impairments and co-morbidity (Vescovini et al., 2010). Thus, 
the increasing weight of immune resources dedicated to the control of CMV may 
significantly impair immune responses amongst the aged.  
 
1.4.3.3.3 T cell clonal diversity 
An important feature of the immune system is the ability to generate a multi-pronged 
T cell response that can recognise a diverse repertoire of antigens presented by MHC 
molecules (epitope diversity) and also the diversity of TCRs amongst T cells that 
recognise the same peptide-MHC complexes (clonotypic diversity) (Pewe et al., 2004). 
Indeed, their functional significance is highlighted by the breadth of a CD8+ T cell 
response being correlated with the success of chronic viral control (Lauer et al., 2004; 
Day et al., 2002; Sacre et al., 2005; Messaoudi et al., 2004). A diverse T cell response 
both in terms of clonality and epitope may enable the host to select the highest avidity 
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TCR and thus produce an optimal response (Nikolich-Zugich et al., 2004). 
Additionally, it may prevent escape mutants arising in immunodominant viral 
epitopes (Price et al., 2004; Barouch et al., 2005) and avoid holes in the T cell 
repertoire that arise as a consequence of ageing or clonal exhaustion (Nikolich-Zugich 
et al., 2004). 
 
The cellular immune response directed against CMV becomes extremely focussed on 
just two proteins: UL123 (IE-1) and UL83 (pp65), as early as one week post diagnosis 
(Khan et al., 2007). An oligoclonal TCR repertoire against CMV epitopes is 
established early in primary infection by the rapid selection of high avidity public 
clonotypes (Iancu et al., 2009; Day et al., 2007). With advancing age the CMV 
specific CD8+ T cell response increases in size (as discussed earlier) and becomes 
increasingly clonally focussed (Koch et al., 2007). Indeed, lifelong persistent CMV 
reactivation may drive clonal exhaustion of the most efficient and specific T cells so 
that an increased number of suboptimal cells are required to control virus infection 
(Akbar and Fletcher, 2005). 
 
1.4.3.3.4 CMV immunosurveillance amongst the aged 
CMV immunosurveillance is widely considered to be maintained even in the very old 
(Weiskopf et al., 2009). However, CMV may subclinically reactivate with increasing 
frequency with age (Stowe et al., 2007) and intense immune responses to extracellular 
CMV in very old subjects have recently been observed, whose magnitude associated 
with comorbidity and functional decline (Vescovini et al., 2010). Thus, the increased 
frequency and magnitude of CMV reactivation in advanced age may result in direct or 
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indirect CMV related pathology, which may significantly contribute towards their 
impaired health status. It has even been suggested that undiagnosed occult CMV 
pneumonitis followed by bacterial pneumonia may constitute a common proximate 
cause of death in the elderly (Pawelec et al., 2010a). 
 
1.4.3.3.5 Effects of CMV on global T cell populations 
The effects of continuous lifelong immune surveillance against CMV, as well as the 
pro-inflammatory and immuno-modulatory effects of the virus, can be associated with 
global changes to the host’s immune profile. Such changes are particularly well 
documented in the peripheral T lymphoid pool, where CMV is said to leave a 
fingerprint of infection (van de Berg et al., 2008), being associated with lymphocyte 
phenotype alterations very similar to those published as age-associated (Weinberger et 
al., 2007). These changes are most dramatically observed amongst the CD8+ T cell 
pool, which ages faster than the CD4+ T cell compartment in every aspect studied, 
even though they principally undergo the same changes (Kovaiou et al., 2005; 
Weinberger et al., 2007; Czesnikiewicz-Guzik et al., 2008; Koch et al., 2007).  
 
Weinberger et al. observed that all the correlations they described for CMV+ people 
could be demonstrated as age-associated in the total study population without 
reference to CMV status (Weinberger et al., 2007) because of the increasing 
prevalence of CMV seropositivity with age, such that the majority of elderly donors 
are CMV-positive (Stowe et al., 2007; McVoy and Adler, 1989; Looney et al., 1999; 
Dowd et al., 2009). Some investigators have gone so far as to suggest that many of 
these age-associated changes may be a consequence of increased CMV prevalence 
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and/or increased duration of infection, rather than ageing per se (Pawelec et al., 
2004). Therefore, any age-associated correlation that we generate will be stratified by 
donor CMV status. 
 
1.5   Costimulation and inhibition 
 
1.5.1  Requirement for costimulation 
 
The loss of naïve and accumulation of memory T cells associated with ageing and 
CMV status is accompanied by concomitant loss of costimulatory molecules as T 
cells differentiate. Although TCR signalling initiates entry into cell cycle, 
costimulatory signals are necessary for upregulation of IL-2, IL-2R and increasing 
cellular metabolism to provide energy for cellular proliferation and acquisition of 
effector functions without which a tolerogenic response ensues (Fox et al., 2005) 
 
1.5.1.1 CD28 
CD28 is well characterised as the most important costimulatory molecule in the 
primary expansion of antigen specific T cells and although initial findings suggested 
that CD28 was dispensable for memory T cell responses, more recent data has 
demonstrated this molecule to be critical for the optimal generation of secondary T 
cell responses (Boesteanu and Katsikis, 2009) 
 
CD28 binds the homologous B7 family members B7.1 and B7.2 molecules that are 
both primarily expressed on professional antigen presenting cells (pAPCs). CD28 
signalling lowers the TCR activation threshold, enhances production of IL-2 and IL-
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2R, promotes cell cycle progression, increases glucose metabolism and upregulates 
anti-apoptotic proteins (Viola and Lanzavecchia, 1996; Frauwirth et al., 2002; Boise 
et al., 1995; Seder et al., 1994). The molecular basis of CD28 signalling is further 
discussed in section 1.5.4.2. 
 
1.5.1.2  ICOS 
CD28 is part of a family of five members (the CD28 family) that share structural 
homology, bind B7 family ligands and function as costimulatory (CD28, ICOS) or 
inhibitory (CTLA-4, PD-1, BTLA) receptors. ICOS, unlike CD28 is not expressed on 
naïve T cells but is induced following activation and binds B7h, which is 
constitutively expressed on B cells and macrophages and can be induced by 
inflammatory stimuli in non-lymphoid tissue and cells (Yoshinaga et al., 1999). 
Although ICOS functions overlap with CD28 in early T cell activation, ICOS 
signalling has emerged as an important player in the selective fine tuning of T cell 
effector functions (Nurieva et al., 2009). Moreover, ICOS plays a critical role in the 
generation of optimal humoural immune responses, being key in the generation of Tfh 
cells and germinal centre reactions (Bossaller et al., 2006; Dong et al., 2001). 
 
1.5.1.3  TNF/TNFR superfamily 
A second group of costimulatory molecules have been identified: the TNF 
superfamily, which are distinguishable from CD28 family members by having a more 
complex cytoplasmic tail that can recruit the TNF-R associated factor (TRAF) adaptor 
(Gruss and Dower, 1995). TNF/TNFR ligand pairings with known costimulatory 
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functions include OX-40/OX-40L, CD27/CD70, 4-1BB/41-BBL, GITR/GITR-L and 
HVEM/Light.  
 
CD27 is expressed on naïve and central memory but not effector T cells. Its signalling 
is limited predominantly by restricted expression of its ligand, CD70 to activated T 
cells, B cells and DCs (Nolte et al., 2009). Multiple studies reveal that CD27 serves as 
a potent costimulatory molecule with a non-redundant role in the formation of the 
effector pool by enhancing proliferation and survival of activated T cells (Nolte et al., 
2009) and it is further expressed on B cell and natural killer (NK) cells where it can 
play stimulatory roles.  
 
Other members of the TNFR family, including 4-1BB, CD30, OX40 and HVEM have 
been proposed to have no unique cellular functions per se but that the nature of their 
distinctive contribution relies upon their expression and that of their ligands (Croft, 
2003). Indeed, in this model proposed by Croft et al, HVEM and CD27 play critical 
roles in initiation of naïve responses alongside CD28 by virtue of their constitutive 
expression upon naïve T cells. Following naïve T cell activation, HVEM is 
downregulated whereas CD27 expression increases and OX40 and 4-1BB are induced. 
Therefore, these receptors govern the T cell response during the later stages with 
CD27-CD70 interactions driving effector cell expansion, whereas 4-1BB and OX40 
may play roles in promoting cell survival with 4-1BB playing a dominant role in 
CD8+ T cell responses and OX40 governing the CD4+ T cells. 
 
1.5.1.4  Summary 
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In recent years, an extended array of costimulatory molecules has been identified and 
characterised. Nevertheless, it is currently unclear to what degree there is functional 
overlap amongst these pathways and whether a hierarchy in the orchestration of their 
signals exist. Additional T cell costimulatory molecules are being identified, such as 
Siglecs -13, -14, -16, and -H, (Varki, 2009) and undiscovered molecules may exist 
that exhibit yet further diverse and unique functions.  
 
1.5.2  Co-inhibition 
 
1.5.2.1  Introduction 
The delivery of a second signal to activate T cells is not just dependent on the 
presence or absence of costimulatory receptors, as multiple related inhibitory 
receptors also exist and it is the balance between these inhibitory and costimulatory 
molecules that is critical to the ultimate fate of cellular responses (Kaufmann and 
Walker, 2009). The CD28 family members have been crucially implicated in 
mediating T cell inhibitory (as well as costimulatory) signalling (Chen, 2004). In 
particular, PD-1 and CTLA-4 are recognised as the primary T cell inhibitory 
molecules, having critical roles in regulating T cell activation and tolerance (Parry et 
al., 2005). A multitude of other inhibitory receptors exist, such as the NK family of 
receptors which can be expressed on effector and memory T cells (further discussed 
in section 1.5.3.3.1). 
 
1.5.2.2  Function 
These co-inhibitory molecules function to prevent inappropriate responses against self. 
A critical component of peripheral tolerance is the homeostatic migration of tissue 
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resident DCs to lymphoid organs where they present self-antigens and tolerise 
autoreactive T cells. Anergy induction is not achieved by the simple absence of 
costimulatory signals but is dependent on the engagement of CTLA-4 and PD-1 
(Abbas and Sharpe, 2005). Moreover, expression of several inhibitory receptors is 
induced by cellular activation, which limits the extent and severity of the immune 
response through negative feedback. Similarly, as they are most strongly induced on 
the most antigen reactive T cells, they prevent initial responses being dominated by a 
single highly avid clone and thus help maintain the epitope and clonal diversity of 
immune responses. Nevertheless, exploitation of these negative regulatory pathways 
represents an immune evasion strategy for several successful pathogens, particularly 
in facilitating chronic viral persistence.  
 
1.5.3  CTLA-4, PD-1 and KLRG1 
 
1.5.3.1  CTLA-4 
 
1.5.3.1.1  Structure, expression and ligands 
Cytotoxic T Lymphocyte Antigen 4 (CTLA-4), also known as CD152, is a dimeric 
transmembrane glycoprotein with a native molecular weight of 33-37kDa that is a 
member of the CD28/B7 family. Structurally it consists of an extracellular IgV like 
domain, a transmembrane domain and a cytoplasmic signalling domain, a design 
shared with other CD28 family members. 
  
CTLA-4 is specifically expressed on T cells, being constitutively expressed on 
regulatory T cells, but absent from resting naïve T cells, where it is only induced 
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following cellular activation, by de novo transcription (Sansom and Walker, 2006). 
Following activation, CTLA-4 is only transiently expressed and rapidly endocytosed 
such that only small amounts of CTLA-4 can ever be detected on the T cell surface 
(Rudd et al., 2009). Indeed, the majority of CTLA-4 molecules in resting memory T 
cells are localised in intracellular vesicles, which following cellular activation, are 
rapidly translocated to the cell surface where they are expressed in a focussed manner 
at the immunological synapse (Knieke et al., 2009). Only cell surface expressed 
CTLA-4 is functional and its level is primarily regulated by the strength of 
TCR/CD28 stimulation (Valk et al., 2008).  
 
The endogenous ligands for CTLA-4 are the homologous costimulatory molecules 
B7.1 (CD80) and B7.2 (CD86), which are primarily expressed on activated pAPCs 
and can be also found on other cells including B and T lymphocytes. CTLA-4 shares 
these ligands with its related costimulatory molecule CD28 but binds with much 
greater affinity and avidity possibly compensating for its maximal expression being 
30-50 fold less than CD28 (Rudd et al., 2009).  
 
B7.1 and B7.2, despite strong structural similarities, are distinct molecules with 
unique expression profiles (Bhatia et al., 2006). Indeed, B7.2 is constitutively 
expressed on pAPCs and is further upregulated after DC activation, peaking after 24 
hours, whereas B7.1 is absent from resting pAPCs and is induced at a slower rate, but 
is stable for a longer time period and peaks after 48-72 hours (Bhatia et al., 2006). 
Therefore, in part due to their similar expression profiles, B7.2 and B7.1 have been 
concluded as the predominant CD28 and CTLA-4 ligands, respectively (Bhatia et al., 
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2006; Sansom and Walker, 2006). Furthermore, whereas CD28 binds monovalently, 
CTLA-4 homodimers bind B7.1, though not B7.2, in a divalent manner (Teft et al., 
2006) and crystallographic data has shown CTLA-4 interacting with alternating B7.1 
homodimers to form a lattice like oligomer that could stereotypically exclude CD28 
binding and further compensate for the relative paucity in CTLA-4 expression (Teft et 
al., 2006). These lattices may also provide appropriate oligomerisation conditions for 
CTLA-4 signalling to occur, clustering CTLA-4 with TCRs in the immune synapse 
(Darlington et al., 2005). 
 
1.5.3.1.2 Function 
CTLA-4 is an immune regulatory protein whose functional significance is highlighted 
by the phenotype of CTLA-4 knockout (-/-) mice, which exhibit a polyclonal CD4+ 
dominated lympho-proliferative syndrome, characterised by multi-organ T cell 
infiltration and death within the first month of life (Waterhouse et al., 1995). The 
critical importance of CTLA-4 in the proper regulation of human immune responses is 
underlined by its polymorphisms, with only subtle functional alterations, being 
associated with cancer susceptibility and autoimmune diseases (Sun et al., 2009). 
 
CTLA-4 has two primary roles in the maintenance of T cell tolerance. It is involved in 
(a) reducing the pathogenicity of effector T cells and (b) the Treg control of immune 
responses (Sakaguchi et al., 2009; Friedline et al., 2009; Kolar et al., 2009). CTLA-4 
has a general dampening effect on T cell responses by increasing the threshold for 
effective T cell activation, the net result of which is the inhibition of cytokine 
production, particularly IL-2 and its receptor, and cell cycle arrest (Verhagen et al., 
 70 
 
 
2008). However, the precise mechanisms underpinning the functions of CTLA-4 are 
not fully understood, with several having been proposed but none accounting fully for 
its inhibitory effects. The most well regarded of these include the preferential binding 
of B7 ligands to CTLA-4, depriving T cells of critical CD28 costimulatory signals, 
and CTLA-4 delivering a negative signal via its cytoplasmic domain (Hodi, 2007). 
The cytoplasmic domain of CTLA-4 neither possesses intrinsic enzymatic activity nor 
a classic immuno-tyrosine based inhibitory motif (ITIM). However, it does possess a 
YVKM structural motif that can recruit the phosphatases: SHP-2 and PP2A (Parry et 
al., 2005), which could oppose the highly organised tyrosine phosphorylation cascade 
upon which T cell activation is critically dependent (Mustelin and Tasken, 2003). 
CTLA-4 can also reverse signal via its ligands into DCs where it induces the 
immunoregulatory enzyme Indoleamine 2,3 dioxygenase (IDO), which may underlie 
its contribution to Treg function (Onodera et al., 2009; Munn et al., 2004; Fallarino et 
al., 2003). Alternatively, CTLA-4 may inhibit TCR/CD28 mediated lipid raft 
expression, protein composition or their signalling microclusters (Rudd et al., 2009). 
CTLA-4 may also reverse the stop signal, which is transduced by the TCR after it 
encounters its specific peptide/MHC complex to generate prolonged engagement 
necessary for T cell activation (Schneider et al., 2006). Overall, it is likely that 
multiple mechanisms contribute towards CTLA-4 function, with each making distinct 
contributions in different contexts. 
 
1.5.3.1.3 Therepeutics 
Although tumour associated antigens are immunogenic, cancers induce an immuno-
regulatory environment that enable them to evade immune detection and suppress 
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immunogenic responses (de Souza and Bonorino, 2009). Recognition of the critical 
roles CTLA-4 mediates in the regulation of immune responses has prompted the 
development of cancer immunotherapies targeting this molecule. Preclinical model 
data, reviewed in (Weber, 2010) and data from clinical trials (reviewed in (Salama 
and Hodi, 2011)), support the use of 2 fully human monoclonal CTLA-4 blocking 
antibodies (temelimulab and ipilimumab) in the induction of durable anti-tumour 
immunity, best characterised against metastatic melanoma, with one recent 
randomised trial demonstrating survival benefit amongst patients with advanced 
melanoma (Hodi et al., 2010). Their use is also associated with a spectrum of immune 
related adverse events, particularly colitis/diarrhoea, dermatitis, endocrinopathologies 
and hepatitis, which are commonly mild and manageable, though rare deaths 
associated with bowel perforation have been reported (Di Giacomo et al., 2010). 
Conversely, CTLA-4 agonist drugs are also in development for the treatment of 
autoimmune conditions, with one such therapy (abatacept) approved for use in 
Rheumatoid Arthritis (Sakthivel, 2009). 
 
1.5.3.1.4 Ageing 
Whether CTLA-4 may play a role in T cell ageing has not been comprehensively 
explored. Higher CTLA-4 mRNA and protein expression (Shimada et al., 2009) have 
been reported to be expressed in the T cells of old mice but whether this manifests 
itself as increased surface expression is debated, (Wakikawa et al., 1997; 
Channappanavar et al., 2009; Shimada et al., 2009). In humans, there is a report of 
CTLA-4 expression increasing with age on CD4+ T cells (Leng et al., 2002a) and 
umbilical cord blood lymphocytes expressing less CTLA-4 compared with adult 
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cohorts (Miller et al., 2002) although no increase in CD4+ Treg CTLA-4 expression 
with age was observed (Hwang et al., 2009).  
 
1.5.3.2  PD-1 
 
1.5.3.2.1  Structure, expression and ligands 
Programmed death -1 (PD-1, CD279) was originally isolated as a protein upregulated 
in a T cell hybridoma undergoing apoptotic cell death (Ishida et al., 1992) and is a 
monomeric 55kDa glycoprotein belonging to the CD28 immunoglobulin superfamily 
of transmembrane proteins (Folkl and Bienzle, 2010). In contrast to the T cell specific 
expression of CTLA-4, Programmed Death-1 (PD-1) is broadly expressed on 
lymphocytes, NK cells and macrophages (Freeman et al., 2006). Similarly to CTLA-4, 
PD-1 is not expressed on resting cells, but is induced only following cellular 
activation (Freeman et al., 2006), though recent data suggests that PD-1 may be 
constitutively expressed on naïve T cells at very low levels (Riley, 2009).  
 
PD-1 has 2 endogenous ligands: the structurally related B7 family members PD-L1 
(B7-H1; CD274) and PD-L2 (B7-DC; CD273), which consist of an extracellular IgV-
IgC domain with short cytoplasmic tails with no known signalling motif, though 
bidirectional signalling interactions between PD-1 and both PD-L1 and PD-L2  may 
occur (Keir et al., 2007). PD-L1 is considered its primary ligand by virtue of its broad 
expression: constitutively on DCs, B cells, macrophages and T cells and is further 
upregulated upon activation and can also be induced on parenchymal cells in 
lymphoid and non-lymphoid tissues (Freeman et al., 2006), whereas PD-L2 is 
exclusively and inducibly expressed on DCs and monocytes (Freeman et al., 2006). 
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Indeed, IFNs are powerful inducers of PD-L1 expression on APCs, endothelial and 
epithelial cells such that during inflammatory immune responses PD-L1 expression is 
extensive and intense (Freeman et al., 2006). 
 
1.5.3.2.2 Physiological function 
PD-1 is an immune inhibitory molecule that is critically involved in several 
physiological processes, including the central induction and peripheral maintenance of 
tolerance to both self-antigens and in preventing immunopathological responses to 
chronic pathogens, limiting the extent and duration of adaptive responses and in the 
maintenance of tolerance at immuno-privileged sites. Its functional significance is 
highlighted by the phenotype of PD-1 genetically deficient mice which develop a 
spontaneous tissue specific autoimmunity, whose manifestation depends on the 
genetic background of the mouse, and it also exacerbates disease in other mouse 
models of autoimmunity and graft rejection (Folkl and Bienzle, 2010; Okazaki and 
Honjo, 2007). Moreover, human PD-1 polymorphisms have been associated with 
susceptibility to a wide range of autoimmune diseases (Okazaki and Wang, 2005). 
 
The functions of PD-1 fall into two main categories: 
 
1)  Induction and maintenance of tolerance to self-antigens 
Whereas a role in central tolerance is debated,  PD-1/L clearly has a critical role in the 
regulation of peripheral tolerance (Folkl and Bienzle, 2010). Both CTLA-4 and PD-1 
interactions play critical and non-redundant roles in the induction of homeostatic 
peripheral tolerance mediated by DCs (Probst et al., 2005). However, unlike CTLA-4, 
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PD-1 interactions are also critical in their peripheral maintenance, a consequence of 
PD-L1 expression on non-haematopoietic cells regulating effector T cell responses in 
the periphery (Keir et al., 2006). An extreme example of this is observed in immune 
privileged sites, which are able to tolerate introduction of immunogenic antigens 
without eliciting an inflammatory immune response, where PD-1/L1 interactions 
make critical contributions (Usui et al., 2008; Cheng et al., 2009). PD-1/L interactions 
also play a role in materno-fetal tolerance (Wafula et al., 2009).  
 
2)  Limitation of immunopathologic responses directed against chronic pathogens: 
Infections by acute pathogens result in a transient induction of PD-1 expression on T 
cells, which rapidly returns to basal levels following antigen clearance, giving rise to 
highly functional memory cells (Barber et al., 2006). However, following persistent 
pathogen infection, antigen is not cleared and PD-1 expression remains high and 
dysfunctional or exhausted specific memory cells arise (Barber et al., 2006). This may 
have evolved as a host defence mechanism to limit potentially detrimental 
inflammatory consequences of immune responses directed against relatively 
innocuous persistent pathogens. Indeed, PD-L1-/- mice infected with a chronic 
lymphocytic chorio-meningitis virus (LCMV) strain die as a result of immuno-
pathological damage, whereas those infected with an acute self-limiting strain 
behaved as wild type (WT) mice (Barber et al., 2006). Adenovirus infected PD-1-/- 
mice clear the virus but suffer a severe hepato-cellular injury compared with WT mice 
(Okazaki and Honjo, 2006). Indeed, there is an idea that there is a limited period of 
time to eliminate an immunogenic antigen, otherwise it can be assumed to be either 
self or from a persistent pathogen, and the PD-1/L1 axis comes to dominate and 
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suppress an otherwise immunopathic response. The oscillating immune response to 
Hepatitis B Virus (HBV) infection in association with PD-1 may support such a 
scenario (Isogawa et al., 2005). 
 
1.5.3.2.3 Exploitation by chronic pathogens 
Many highly pathogenic persistent pathogens take advantage of the PD-1/L pathway 
to facilitate their persistence in the host. HIV specific CD8+ T cells highly express 
PD-1 with its expression correlating with the extent of HIV specific CD8+ T cell 
dysfunction and markers of disease progression. Moreover, blocking PD-1/L1 
interactions enhanced their proliferative and effector responses (Trautmann et al., 
2006; Kaufmann and Walker, 2009; Day et al., 2006; Petrovas et al., 2006), though 
such findings have been disputed (Sauce et al., 2007a). Similarly, PD-1 is critically 
implicated in CD8+ T cell dysfunction specific for persistent viral infections including 
HBV (Boni et al., 2007), HCV (Golden-Mason et al., 2007; Urbani et al., 2006), 
human T lymphotophic virus-1 (HTLV-1) (Kozako et al., 2009), Simian 
Immunodeficiency Virus (SIV) (Velu et al., 2009) and LCMV (Barber et al., 2006). In 
addition, PD-L1 is also upregulated on APCs during many persistent infections  
(Kaufmann and Walker, 2009), which further enhances PD-1 signalling on virus 
specific T cells and DCs expressing PD-L1 display a ‘paralysed’ phenotype, (as 
described in section 1.4.1.5). Indeed, PD-L1 expression is a surrogate marker of HIV 
disease progression (Trabattoni et al., 2003). Moreover, PD-1 blockade in vivo, using 
a Rhesus macaque model of SIV infection, revealed significant reductions in plasma 
viral load and improved survival, alongside enhancement of cellular and humoural 
immunity, both in the blood and tissues, with no observable toxicity (Velu et al., 
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2009). Therefore, manipulation of the PD-1/L pathway may show promise in the 
treatment of HIV/AIDS and other chronic pathogenic infections. 
 
1.5.3.2.4 Cellular functions 
The major effect of PD-1 signalling was initially thought to be on proliferation 
(Freeman et al., 2006) but more recent data emphasise its role in promoting cell death 
(Petrovas et al., 2006; Muhlbauer et al., 2006). Nevertheless, the precise outcome of 
PD-1 signalling may depend upon the type of APC and micro-environment (Carter et 
al., 2002; Yamazaki et al., 2005). 
 
1.5.3.2.5 Ageing 
There are reports of uninfected old, but not young, mice highly expressing PD-1 
(mRNA and protein) on their T cells (Shimatani et al., 2009; Channappanavar et al., 
2009; Shimada et al., 2009) and PD-1/L blockade augmenting the virus specific 
responses of aged mice (Suvas et al., 2007; Mirza et al., 2010). However, others have 
made contrasting observations (Lages et al., 2010), suggesting PD-1 may be 
differentially regulated in different mouse strains. Moreover, several reports suggest 
PD-1 expression does not vary with age on human T cells (Fann et al., 2005; 
Czesnikiewicz-Guzik et al., 2008; Henson et al., 2009). Nevertheless, PD-1 may play 
a role in driving immunosenescence by virtue of its expression on CMV specific 
CD8+ T cells, (Petrovas et al., 2006; Day et al., 2006; Sauce et al., 2007a; Trautmann 
et al., 2006), thereby contributing towards their progressive dysfunction, clonal 
expansion and CMV reactivation with age, which represents a key immuno-
senescence driving force (as discussed earlier).  
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1.5.3.3  KLRG1 
 
1.5.3.3.1 NK cell receptors on T cells 
NK cell receptors (NKRs) can accumulate on late stage differentiated T cells, 
particularly in the CD8+ T cell compartment, where they exhibit a distinct pattern of 
NKR expression from that expressed by NK cells (Robbins et al., 2003; Abedin et al., 
2005; Boucher et al., 1998; Pawelec, 2009; Vivier and Anfossi, 2004). Moreover, 
their expression increases with age such that the CD8+ TCR repertoire in old age 
consists of TCR clonal but NKR diverse cells (Abedin et al., 2005; Boucher et al., 
1998; Uhrberg et al., 2001; Vallejo, 2006). 
 
Ligation of NKRs on T cells only transduces signals if TCR is coligated and functions 
to alter the threshold of T cell activation (Fasth et al., 2010; Vivier and Anfossi, 2004). 
Their functional significance on T cells is highlighted by their dysregulated 
expression being associated with several types of chronic inflammatory diseases 
(Fasth et al., 2010; Chen et al., 2009; Meresse et al., 2006), persistent pathogens (De 
et al., 1997; Berg et al., 2003) and tumours (Vivier and Anfossi, 2004). 
 
The expression of NKRs on T cells has been suggested to have several physiological 
roles. Inhibitory NKR expression may promote peripheral tolerance, being induced 
following repeated stimulation and causing inhibition of autoreactive responses. 
Alternatively,  inhibitory NKRs exert a strong impairment on T cell proliferation and 
a leaky impairment on effector functions (Arlettaz et al., 2004), consistent with a role 
in protecting chronically antigen-exposed T cells from exhaustive expansion. 
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Additionally, activatory NKR can also be expressed on T cells (Fasth et al., 2010; 
Monsivais-Urenda et al., 2010), which may represent a secondary immune 
diversification that compensates for the TCR repertoire and CD28/CD27 expression 
loss with age (Vallejo, 2006).  
 
1.5.3.3.2  Structure, expression and ligands 
Killer cell lectin-like receptor subfamily G member 1 (KLRG1) is a type 1 
transmembrane inhibitory receptor belonging to the C-type lectin like superfamily that 
was first identified in a rat basophilic leukaemia cell line and originally termed 
MAFA (Mast cell function associated antigen) (Voehringer et al., 2001b). KLRG1 is 
expressed on the cell surface as a monomer or a disulphide linked homodimer at 
comparable levels (Rosshart et al., 2008). Additionally, a substantial fraction exists as 
disulphide linked trimeric and tetrameric complexes and can non-covalently associate 
to form even larger multimeric forms (Rosshart et al., 2008). This multimerisation 
increases KLRG1 avidity and helps compensate for the very low affinity for its ligand 
compared with other inhibitory NKRs (Li et al., 2009). 
  
KLRG1 is expressed on 50-80% of NK cells and antigen experienced αβ T cells 
(around 20% of CD4+s and 40% of CD8+s in a young adult) (Voehringer et al., 2002) 
and is also expressed on γδ (Eberl et al., 2005) and regulatory T cells (Banh et al., 
2009). KLRG1 is highly expressed on mouse T and NK cells following infections 
(Banh et al., 2009) and human CD8+ T cells specific for persistent but not acute 
pathogens (Rosshart et al., 2008) and increases with human age and T cell 
differentiation (Voehringer et al., 2002; Thimme et al., 2005; Ouyang et al., 2003a; 
 79 
 
 
Ito et al., 2006). This suggests that repetitive and persistent antigen stimulation is the 
factor driving KLRG1 expression and is consistent with a stochastic model of 
inhibitory NKR induction on T cells after antigenic stimulation proposed by Vivier 
and Anfossi (Vivier and Anfossi, 2004). Nevertheless, other factors must also be 
required as repeated T cell activation in vitro is insufficient to induce KLRG1 
expression (Voehringer et al., 2002), and indeed, no known in vitro stimulation 
upregulates KLRG1 and its expression is downregulated and lost within 72 hours in 
vitro (Voehringer et al., 2002). 
 
KLRG1’s physiological ligands are the classical cadherin family members Epithelial- 
(E-), Neural (N-) and Retinal (R-) cadherins (Ito et al., 2006). These are a family of 
ubiquitously expressed transmembrane glycoproteins linked to the cytoskeleton that 
mediate homophilic adhesion to form tight adherent junctions between adjacent cells 
(Banh et al., 2009).  
 
Aside from KLRG1, E-cadherin can also bind the integrin αEβ7 (Cepek et al., 1994). 
Integrins are heterodimeric transmembrane proteins that function as cell adhesion and 
accessory molecules during T cell stimulation (Banh et al., 2009). αEβ7 is highly 
expressed on intra-epithelial lymphocytes, particularly CD8+ T cells, where it 
mediates adhesion to epithelial cells and enhances T cell function (Agace et al., 2000), 
providing immuno-surveillance against damaged, infected or transformed epithelial 
cells. 
 
1.5.3.3.3 Cellular effects 
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KLRG1 expression identifies CD8+ T cells that can perform immediate effector 
functions but exhibit severely impaired proliferative capacity (with KLRG1 
expression being a better marker of CD8+ T cell proliferative inability than CD28 loss 
(Voehringer et al., 2002)) and may thus represent a highly differentiated replicatively 
senescent population (Voehringer et al., 2001a; Voehringer et al., 2002). This 
proliferative defect is observed even in the presence of exogenous IL-2 (Heffner and 
Fearon, 2007), distinguishing T cells expressing KLRG1 from the exhausted 
phenotype mediated by PD-1 signalling (Carter et al., 2002). Moreover, rather than 
just being a marker, a direct role for KLRG1 as an inhibitory receptor has been 
demonstrated in murine and human NK and T cells (Rosshart et al., 2008; 
Schwartzkopff et al., 2007).  
 
1.5.3.3.4 Physiological function 
Aside from roles in preventing persistently stimulated T cells from exhaustive 
expansion (as discussed in section 1.5.3.3.1), KLRG1’s physiological function may 
lie in the maintenance of peripheral tolerance, preventing NK and T cell mediated 
destruction of self tissues expressing E, N or R cadherins. Conversely a role for 
KLRG1 in tumour immunosurveillance can be suggested, analogous to missing self-
recognition by inhibitory NKRs that bind MHC class I (Schwartzkopff et al., 2007; 
Colonna, 2006). Indeed, the mutation or downregulation of E–cadherin is a common 
feature in tumour development that results in the loss of cell contact inhibition and 
acquisition of cellular motility that facilitates tumour metastases (Makrilia et al., 2009) 
but this also results in loss of inhibitory KLRG1 interactions that render tumour cells 
a target for NK and CD8+ T cell mediated killing.  
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Nevertheless, E-cadherin exists as strand exchanged homodimeric complexes that 
constitute adherent junctions on the basolateral membrane of adjacent epithelial cells 
and thus is not easily accessible to NK or T cells (Nakamura et al., 2009). Moreover, 
KLRG1 can only recognise the monomeric form of E-cadherin, which is thought to be 
expressed solely on abnormal epithelial tissues (Nakamura et al., 2009). However, E-
cadherin can also bind the integrin αEβ7, which is highly expressed on intraepithelial 
T cells and whose ligation promotes T cell activation (see 1.5.3.3.2). Therefore, when 
epithelial cells are subject to transformation, viral infection or mechanical injury, the 
tight junctions between cells become disrupted resulting in the expression of 
monomeric E-cadherin that renders them a target for intraepithelial T cell killing via 
αEβ7 ligation. 
 
Langerhans cells (LCs), a DC subset that reside in the skin, form networks anchored 
to neighbouring keratinocytes through homotypic binding of E-cadherin (Fu and Jiang, 
2010). However, under steady state conditions, LCs migrate into the cutaneous lymph 
nodes, present self antigens and induce tolerance to any autoreactive T cells 
encountered. The generation, regulation and function of such tolerogenic DCs remain 
poorly understood though they have been frequently described or predicted as 
immature. However, immature DCs neither efficiently present antigen nor effectively 
interact with T cells (Fu and Jiang, 2010). Nevertheless, disruption of E-cadherin 
mediated interactions results in the alternative maturation of DCs into cells that 
migrate into secondary lymphoid organs but promote tolerogenic rather than 
immunogenic T cell responses (Jiang et al., 2007). Furthermore, KLRG1 has recently 
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been identified as capable of reverse signalling into E-cadherin expressing DCs and 
exerting immuno-suppressive effects by inhibiting cadherin dependent cellular 
adhesion and inhibiting their ability to release inflammatory cytokines (Banh et al., 
2009). Moreover, E-cadherin expression is not limited to LCs but is expressed on a 
wide variety of APCs (Henson et al., 2009). Therefore, ligation of E-cadherin by 
KLRG1 may mediate the steady state migration of DCs to secondary lymphoid organs 
where they tolerise autoreactive T cells.  
 
1.5.3.3.5 Ageing 
KLRG1 expression broadly correlates with age-associated T cell dysfunction, being 
upregulated with age on CD8+ (Ouyang et al., 2003a; Thimme et al., 2005) and to a 
lesser extent on CD4+ T cells (Koch et al., 2007), showing increased expression on 
CMV+ individuals and being expressed on the vast majority of CMV specific cells 
which further increases with age (Vasto et al., 2007). Moreover, KLRG1 appears to 
act as a marker of end-stage differentiation and has been suggested to play a role in 
driving T cell clonal exhaustion (Voehringer et al., 2002) and thus may contribute 
towards age onset T cell immuno-dysfunction. 
 
1.5.4  Molecular Basis of T cell Activation and Inhibition 
 
1.5.4.1 TCR Signalling 
Cross linking TCRs in vitro can activate T cells, suggesting a similar mechanism of 
activation to B cell receptors (BCRs), whose clustering by a multivalent antigen 
activates B cells in vivo (Tolar et al., 2008). However, as single antigenic peptides-
MHC complexes can trigger cytolytic activity in CD8+ T cells (Sykulev et al., 1996), 
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several hypotheses of T cell activation independent of TCR clustering have arisen. 
These include antigen binding inducing conformational changes in the TCR or its 
signalling complex (Ma and Finkel, 2010) that either generates an activatory signal 
itself or produces a stop signal that prolongs TCR-APC engagement, allowing the 
formation of an immunological synapse that concentrates, enhances and sustains 
signalling (Dustin, 2009). Other TCR activation proposals do involve clustering, for 
example the pseudo-dimeric (Krogsgaard et al., 2005) and permissive geometry 
models (Minguet and Schamel, 2008).  
 
TCR heterodimers are associated with a signalling complex consisting of 4 CD3 
chains (2 CD3ε, 1 CD3δ and 1 CD3γ) and a ζ homodimer that together give the TCR 
complex a total of 10 immuno-tyrosine based activation motifs (ITAMs). Upon TCR 
engagement, the ITAM tyrosine residues become phosphorylated by the kinases Lck 
and Fyn, associated with the CD4/CD8 and CD3 chains respectively. These are 
normally kept inactive by inhibitory phosphorylation mediated by Csk, which is 
anchored to lipid rafts by the transmembrane adaptor PAG. Following TCR ligation, 
PAG is dephosphorylated and releases Csk which relieves the inhibition of Lck and 
Fyn.  
 
Phosphorylated ITAM tyrosine residues serve as a binding site for the two SH2 
domains of ZAP-70, a tyrosine kinase which, once recruited, become phosphorylated 
and activated by Lck, and goes on to phosphorylate the scaffold proteins: the 
transmembrane LAT and the cytosolic SLP-76. Together in a complex with Gads, 
these recruit and activate Phospholipase C-γ (PLC-γ), a key signalling molecule that 
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catalyses breakdown of the membrane lipid PIP2 into cytosolic IP3 and the membrane 
lipid DAG. Hereafter, the TCR signalling pathway splits into the following three 
branches, each of which results in the activation of a different transcription factor. 
 
i) IP3 binds receptors on the endoplasmic reticulum where it induces cytosolic Ca2+ 
release that binds calmodulin enabling it to activate calcineurin that dephosphorylates 
and activates the transcription factor NFAT. 
 
ii) DAG diffuses in the plasmamembrane activating several proteins including PKC 
and RasGRP, which is a GTP exchange factor that activates the small G protein Ras. 
This in turn triggers the MAP kinase cascade that promotes the formation of the 
transcriptional regulator AP-1. 
 
iii) The membrane recruitment and activation of PKC results in it forming a 
membrane associated complex that recruits and activates the IκK kinase complex 
which phosphorylates and targets IκB for degradation. NF-κB is normally held in an 
inactive state bound to IκB, and once released, NF-κB enters the nucleus and 
functions as a transcription factor. 
 
1.5.4.2 CD28 
TCR engagement activates the transcription factors AP-1, NF-κB and NFAT that 
induces a genetic program that can result in either a tolerogenic T cell response or an 
immunogenic one (Riley et al., 2002). The choice between these T cell fates is largely 
determined by costimulatory signals. CD28 is considered the quintessential 
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costimulatory molecule that can rescue naïve T cells receiving a TCR stimulus alone 
from anergy/apoptosis and initiate an immune response. Indeed, its functional 
significance is highlighted by the severe immuno-deficiencies of CD28-/- mice 
(Shahinian et al., 1993).  
 
Ligation-dependent tyrosine phosphorylation of CD28 results in the recruitment and 
activation of PI3K. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate  (PIP2) 
to phosphatidylinositol 3,4,5-trisphosphate (PIP3), which binds PH domain containing  
proteins to the membrane, including the serine/threonine kinase Akt (Frauwirth et al., 
2002). Akt is thought to play an important role in diverse cellular processes including 
telomerase activation, survival, cytokine synthesis and glucose metabolism (Parry et 
al., 2005). However, CD28 activity independent of PI3K/Akt has been demonstrated 
(Sanchez-Lockhart et al., 2004) suggesting another distinct pathway is critical for 
CD28 costimulatory activity. Such a pathway may be provided by Grb2 family 
adaptor proteins Grb2 and Gads, which are also recruited by phosphorylated YVKM 
motifs at CD28 and augment TCR induced PLC-γ and Vav activation (Watanabe et al., 
2006). Alternatively, further downstream of the YVKM motif, CD28 has two proline 
rich regions that have been reported to bind Src and Tek kinases (Rudd et al., 2009), 
which could further enhance T cell activation. 
 
CD28 does not stimulate identical signalling effectors as TCR ligation, but primarily 
provides a potent synergistic induction of NFAT, NF-κB and AP-1 (Acuto and Michel, 
2003). TCR ligation induces the expression of over 3000 genes and the genes 
modified by CD28 expression appear virtually identical (Diehn et al., 2002; Riley et 
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al., 2002). This suggests that CD28 functions mainly as an amplifying mechanism to 
overcome signalling thresholds that TCR signalling alone cannot reach in a 
physiological setting. However, CD28 also has a major impact on chromatin 
remodelling and can downregulate a significant proportion of these TCR induced 
genes (Diehn et al., 2002; Riley et al., 2002), indicating that CD28 mediated 
signalling is not merely repetitive of TCR but also alters the balance of signalling 
events and feedback circuits. Indeed, it may be that modulation of large sets of 
identical TCR-induced genes represent a common mechanism of costimulatory and 
coinhibitory molecules; ICOS induces and CTLA-4 counter-regulates virtually the 
same genes that were induced or repressed by CD28 (Riley et al., 2002). CD28 can 
also affect gene regulation independently of TCR ligation, which may have 
contributed towards the disastrous auto-immune complications in the trial of 
TGN1412 (Farzaneh et al., 2007).  
 
1.5.4.3 Inhibitory receptors 
Inhibitory receptors only modulate T cell functions when co-engaged with the TCR 
(Greenwald et al., 2005; Rosshart et al., 2008), which results in the phosphorylation of 
ITIM (for KLRG1 and PD-1) or YVKM (in the case of CTLA-4) motifs by Src family 
kinases, and the recruitment of Sh2 domain-containing phosphatases. These 
phosphatases antagonise the signal transduction processes of T cell and costimulatory 
receptors, which are initiated and sustained by the actions of protein kinases (as 
described earlier). Four such phosphatases have been identified: the two tyrosine 
phosphatases SHP-1 and SHP-2, and the lipid phosphatases SHIP-1 and -2 (Daeron et 
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al., 2008) and their specificity for different ITIMs is determined by two symmetrical 
hydrophobic residues at positions Y-2 and Y+2 (Daeron et al., 2008). 
 
The inositol phosphatase, SHIP-1, recruited by KLRG1 but not CTLA-4 or PD-1, 
mediates its inhibitory effect through hydolysing PIP3 (Daeron et al., 2008), which is 
responsible for the recruitment of critical T cell activation signalling molecules 
containing the PH domain, such as Akt and PLC-γ. In contrast, the tyrosine 
phosphatases: SHP-1 and SHP-2 could theoretically dephosphorylate any of the 
phosphorylated proteins co-localised in the immune synapse, thereby attenuating both 
proximal and distal events in the T cell activation cascade (Daeron et al., 2008).  
 
CTLA-4, PD-1 and KLRG1 have all been demonstrated to recruit at least one of these 
tyrosine phosphatases (CTLA-4: SHP-2, KLRG1: SHP-2 and PD-1: SHP-1 and SHP-
2 and thereby attenuate TCR/CD28 mediated signalling and increase the activation 
threshold (as described in section 1.5.3). However, KLRG1 also recruits SHIP and 
can thus inhibit Akt activity. Moreover, CTLA-4 can recruit the serine/threonine 
phosphatase PP2A and has been demonstrated to inhibit Akt in a PP2A dependent 
manner (Parry et al., 2005). PD-1 inhibits Akt via the dephosphorylation and 
inactivation of PI3K (Parry et al., 2005). This contrasts with KLRG1 and CTLA-4 
which inhibit Akt in a manner that preserves PI3K activity, thereby allowing 
expression of certain pro-survival genes such as Bcl-xl (Riley, 2009). This selective 
inhibition of Bcl-xl and several other growth factors may at least partially account for 
PD-1 signalling effects on promoting cell death (as discussed in section 1.5.3.2.4). 
Moreover, this may provide a molecular explanation for why IL-2 signalling can 
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override the effects of PD-1, but not KLRG1 or CTLA-4 ligation (Carter et al., 2002), 
as IL-2 signalling triggers Akt activity in a PI3K independent manner (Lockyer et al., 
2007). Nevertheless, the precise signalling pathways of CTLA-4 (see Fig 1.02), PD-1 
(see Fig 1.03) and KLRG1 (see Fig 1.04) remain poorly defined, though a major 
contribution to their distinct functions resides in their differing expression patterns, 
ligands and kinetics. Additionally, inhibitory receptors may also regulate the gene 
expression profile of T cells. Indeed, PD-1 has recently been reported to induce the 
expression of a series of proteins that, in combination with its inhibition of 
TCR/CD28 signalling, may mediate T cell exhaustion (Quigley et al., 2010).   
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Fig 1.02 Mechanism by which CTLA-4 mediates inhibition of TCR and CD28 signalling  
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 Fig 1.03 Intracellular signalling pathways of PD-1 
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Fig 1.04 Molecular mechanisms of KLRG1 mediated T cell inhibition 
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1.6   Models for Studying Human Ageing 
 
One of the major difficulties in the study of human ageing is its duration, developing 
over several decades, thus making in vivo longitudinal studies highly impractical. 
 
1.6.1   Animal Models 
 
One solution is to study model organisms which have much shorter lifespans (2-4 
years for most laboratory rodents). The almost ubiquitous nature of aging across the 
animal kingdom is suggestive of common ageing pathways operating across many 
phyla (Longo and Fabrizio, 2002). Moreover, the ability to control and manipulate 
their environment and genetics as well ease of access to tissue samples, make animal 
models a potentially highly useful tool in the study of human ageing.  
 
1.6.1.1  Impracticalities in the Mouse Model  
The most heavily utilised mammalian model of human ageing is the mouse, due to 
their short life cycles and small size. However, evidence is accumulating that such 
animals are poor models of human ageing. For example, some mice exhibit causes of 
ageing unrelated to those of humans, such as the Australian species Antechinus 
stuartii, whose males become intoxicated with sex hormones during the mating 
season that increases their libido to the point that they do not eat and eventually die of 
‘sexual stress’ (Holleley et al., 2006). Moreover, even amongst mice that age 
gradually in a manner analogous to humans, such as Mus musculus (the most 
commonly used laboratory mouse), they exhibit several critical differences that render 
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mice a poor model for human immune ageing (Akbar et al., 2000; Gordon et al., 
2001). These include: - 
 
1)  Differences in telomere regulation.  
Telomere attrition has been suggested as a major player in driving the human ageing 
process (as discussed in section 1.2.3.2.3). However, human telomere lengths are 
much shorter (12-16kB) than those in mice (90-100kB) (Akbar et al., 2000), 
especially considering the much greater lifespan of humans. Moreover, the enzyme 
telomerase, which maintains telomere lengths, is absent in most normal human 
somatic cells, but present in most mice cells (Blasco, 2005). Furthermore, human 
telomerase dysfunction exhibits itself as a premature ageing syndrome (Dyskeratosis 
congenita, DKC), whereas telomerase-deficient mice are normal for up to 6 
generations (Blasco, 2005). In summary, the attrition of telomere lengths is a critical 
determinant of human aging, but plays a comparatively minor role in mouse aging. 
 
2)  Loss of CD28 expression on CD8+ T cells. 
This is considered one of the most consistent biomarkers of human immune system 
ageing and constitutes an important parameter of the Immune Risk Profile (as 
described in section 1.4.2). In contrast, murine CD8+ T cells maintain CD28 
expression with age (Engwerda et al., 1994). 
 
3)  Other contributing factors 
Other factors undermining the use of laboratory mice as a model for human ageing 
include their vastly different immunological history, as antigenic load is considered a 
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critical factor driving age-associated immune changes (as described in section 1.3.2) 
In addition, the comparatively reduced lifespan of mice suggest divergent 
maintenance and repair systems, which play major roles in driving aging. For example, 
loss of telomerase is an important anti-cancer mechanism in human cells whilst its 
maintenance in murine cells may reflect cancer being a less severe mouse mortality 
factor (Wright and Shay, 2000). Finally, mice developed for laboratory research have 
been selected for high fertility and thus have been subject to different evolutionary 
pressures than humans.  
 
1.6.1.2  Longitudinal studies 
A compromise to the impracticality in performing human longitudinal studies is to 
limit the study to the very elderly (octo- or nona-genarians), as there will be sufficient 
mortality to enable meaningful associations within a time frame of several years. This 
was the approach taken by the Swedish OCTO and NONA studies from which the 
Immune Risk Phenotype was defined. Nevertheless, even this approach carries some 
significant limitations, notably that such populations are already successfully aged 
who may possess a confounding genetic or environmental factor that limits their 
applicability.  
 
1.6.1.3  Cross sectional studies 
As longitudinal studies are challenging in humans, most population studies examining 
human ageing have utilised a cross-sectional approach comparing young and old 
individuals. However, the conditions applied during the life course of the current 
elderly differ to the younger generations. Such conditions, including nutrition, 
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pathogen load, environment and population genetics (Caruso et al., 2009), may act as 
confounding variables that account for some of the published differences between the 
old and young, rather than the process of ageing per se. Despite these limitations, we 
utilised cross sectional studies in our investigations, as this was the only practical way 
to perform our studies in humans and believe our results to represent this topic as 
accurately as possible. 
 
1.7 Aims 
 
Ageing impinges upon the immune system, particularly the T cell compartment, and 
lifelong antigenic burden is increasingly implicated in this decline. Various persistent 
antigenic challenges are associated with dysfunctional T cells and upregulation of 
inhibitory receptors. Blockade of such receptors has been shown to reinvigorate 
cellular responses. This thesis investigates the hypothesis that inhibitory receptor 
expression increases with age and/or CMV status, which may contribute towards the 
characteristic dysfunctions of aged T cells and define a reversible defect.  
 
The specific aims of this study were to: - 
 
1) Investigate whether inhibitory receptor blockade can functionally reinvigorate 
aged T cells. 
2) Assess whether different inhibitory receptors are preferentially utilised by T 
cells at distinct differentiation stages. 
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3) Define the role of these inhibitory receptors in mediating the dysregulated 
immune response directed against CMV. 
4) Determine how the age related lymphocyte telomere attrition and impaired 
telomerase induction are influenced by CMV infection and inhibitory receptor 
expression. 
5) Characterise the factors driving the variations of inhibitory receptor expression 
with donor CMV status and age. 
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2 Materials and Methods 
 
2.1  Peripheral blood cell source, culture, sorting and storage 
 
2.1.1 Volunteer Recruitment 
 
Donor samples were obtained in accordance with the ethical committee of Royal Free 
and University College Medical School and voluntary informed consent was obtained 
in accordance with the Declaration of Helsinki. Heparinised peripheral blood samples 
were taken from healthy volunteers. Old donors did not have any co-morbidity, were 
not on any immunosuppressive drugs and retained physical mobility and lifestyle 
independence. Where the data is stratified by age, young is defined as individuals 
between 20-35 years (median age 30) and old subjects over 65 years (median age 78). 
 
2.1.2 Separation of peripheral blood mononuclear cells from whole blood 
 
Heparinised venous blood was mixed in a 1:1 ratio with Hanks Balanced Salt Solution 
(HBSS) (Invitrogen, Paisley, UK) and layered onto Ficoll-Hypaque (Amersham 
Biosciences, Buckinghamshire, UK) in 50ml Falcon tubes before centrifugation at 
800×g for 20 minutes with no brake. The buffy coat at the interphase layer was 
harvested and washed twice for 10 minutes in excess HBSS by centrifugation firstly 
at 650×g and then at 350×g.  
 
2.1.3  Viable cell counts 
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Cell suspensions were diluted 1:1 with 0.4% trypan blue (Sigma-Aldrich, Dorset, UK) 
and incubated for 1 minute at room temperature before 8µl were inserted beneath the 
coverslip on an improved Neubauer chamber (Weber Scientific International, Sussex, 
UK) and the cells were counted. Dead cells were stained blue and were therefore 
excluded from the count. The number of cells in the central grid that excluded dye 
were enumerated and this number was multiplied by the (dilution factor x 10,000) to 
give the number of cells per ml. 
 
2.1.4 Cell culture 
 
Cell preparation was carried out using RPMI 1640 medium (GIBCO, Invitrogen, 
Paisley, UK) supplemented with GPS (100U/ml penicillin, 100µg/ml streptomycin, 
2mM L-glutamine), which will be referred to as RPMI hereafter. This medium was 
supplemented with 10% heat-inactivated Foetal Calf Serum (FCS) or pooled human 
AB serum (all from Sigma-Aldrich, Dorset, UK) for cell culture. Non-sterile solutions 
were filtered through 0.22µm filters and all tissue culture plastics, tubes and filters 
were purchased from BD Biosciences, (Oxford, UK)  
 
2.1.5 Cell storage 
 
PBMCs were pelleted (650×g, 5 mins) and supernatant decanted. Working quickly, 
cells were resuspended in FCS + 10% DMSO and aliquoted into cryovials at 5 x 
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106cells / vial and placed in a Mr. Frosty freezing chamber (Fisher scientific, 
Leicestershire, UK) and put into a –80°C freezer.  
 
2.1.6 Frozen cell retrieval 
 
Working quickly, PBMCs were thawed using pre-warmed complete media +10% FCS 
then pelleted (650×g, 5 minutes) and resuspended in RPMI +10% FCS and counted. 
 
2.1.7 Cell Sorting 
 
Magnetic Cell Sorting (MACS, Miltenyi Biotec, Surrey, UK) allows the purification 
of cell subsets from complex cell mixtures. Cells can be specifically labelled using 
MACS microbeads, which are extremely small biodegradable super-paramagnetic 
beads that do not affect cell function or viability. After magnetic labelling, the cells 
are passed through a separation column which serves to create a high-gradient 
magnetic field. The magnetically labelled cells are retained in the column, while non-
labelled cells pass through. After removal of the column from the magnetic field, the 
magnetically retained cells can be eluted. There are two general approaches to 
magnetic cell sorting: depletion (negative selection) and positive selection. CD4+ and 
CD8+ T cells were isolated using positive MACS separation according to protocol 
provided by manufacturer and the magnetically retained cells were eluted and 
subjected to 40Gy irradiation to form a population of irradiated autologous APCs 
(used as a source of multiple costimulatory signals). When separated CD8+ subsets 
were required, MACS separated CD8+ T cells were labelled with anti-CD27 and 
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either anti-CD28 or anti-CD45RA and were fractioned on a FACSAria high speed cell 
sorter (BD Biosciences, Oxford, UK) 
  
2.2  Flow Cytometry 
 
2.2.1 Flow cytometry 
 
Flow cytometry is a technique that allows for the rapid measurement of individual 
cells as they flow in a fluid stream one by one through a laser beam. Cells are 
analysed on the basis of their size and granularity and the use of antibodies conjugated 
to different fluorochromes enabled the identification of specific cell subsets and 
analysis of inhibitory receptor expression.  
 
Four parameter flow cytometry was performed on a FACS Calibur flow cytometer 
(BD Biosciences, Oxford, UK). This machine has two lasers (488nm and 600-650nm) 
enabling the simultaneous measurement of 4 different coloured fluorochromes 
(channels FL1 – FL4).  Five colour flow cytometry was conducted using a FACS LSR 
(BD Biosciences, Oxford, UK), which is equipped with 4 lasers (488nm, 325nm, 
633nm and 594nm) enabling the concurrent quantification of 6 different 
fluorochromes.  
 
2.2.2 Surface staining by direct immuno-fluorescence 
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For cell surface staining, cells were labelled at a density of 0.5-5 x 106 cells per tube 
in FACS tubes (BD Biosciences, Oxford, UK) at room temperature of 15 minutes. 
The expression of cell surface markers was determined using monoclonal antibodies 
directly conjugated to a specific fluorochrome. Utilising a combination of different 
fluorochromes FITC, PE, PerCP, APC and PE-Cy7, allowed for the detection of up to 
5 different antigens simultaneously. After labelling, cell suspensions were washed in 
5ml FACS test tubes (Falcon, BD Biosciences, Oxford, UK) with excess PBSA (1% 
w/v bovine serum albumin and 0.02% sodium azide, (both Sigma-Aldrich, Dorset, 
UK) in phosphate buffered saline (PBS) by centrifugation at 650×g for 5 minutes. The 
supernatant was carefully decanted and the cells resuspended in the residual fluid by 
vortexing and optimal concentrations of fluorochrome conjugated antibodies added. 
The tubes were vortexed and incubated in the dark at room temperature for 15 
minutes. The cells were again washed in excess PBSA and the supernatant was 
decanted and the cells were then fixed, as detailed in section 2.2.5.  
 
2.2.3 Intracellular staining 
 
The detection of intracellular proteins, including cytokines, requires cells to be fixed 
and permeabilised to facilitate the access of antibody to intracellular structures whilst 
preserving the cells’ morphological scatter characteristics. A modified protocol of the 
Caltag Fix and Perm cell permeabilisation kit (Caltag Laboratories, Paisley, UK) was 
used. If a combination of cell surface and intracellular antigen staining was required, 
cells were first incubated with cell surface antibodies as per the protocol above, 
washed with PBSA and centrifuged at 650 g for 5 minutes. After decanting the 
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supernatant, the cell pellet resuspended by the addition of 100µl reagent A (a fixation 
medium containing formaldehyde) whilst simultaneously vortexing and left to 
incubate in the dark at room temperature for 15 minutes. The cells were washed with 
excess PBSA and centrifuged at 650×g for 5 minutes. The supernatant was decanted 
and the cell pellet was resuspended with the addition of 100µl of reagent B 
(Permeabilisation medium) together with optimal concentrations of directly 
conjugated antibodies to intracellular antigens whilst simultaneously vortexing and 
left to incubate in the dark for 15 minutes at room temperature. The cells were then 
washed and fixed (as described in section 2.2.5). 
 
2.2.4  Intranuclear staining 
 
Ki67 antigen is the prototypic cell cycle related nuclear protein, expressed during all 
active phases of the cell cycle (G1, S, G2 and M phase) but is absent from resting (G0) 
cells. Ki67 is thus considered an excellent marker to determine the growth fraction of 
a given cell population (Scholzen and Gerdes, 2000). Ki67 staining was achieved by 
performing a modified protocol using the intranuclear Miltenyi FoxP3 Buffer Staining 
kit (Miltenyi Biotec, Surrey, UK). Cells were surface stained, as described in section 
2.2.2, and washed by adding 2ml cold PBS and 650×g centrifugation for 5 minutes at 
4°C. The supernatant was decanted and cells were resuspended in 0.5 ml cold freshly 
prepared Fixation/Permeabilisation solution and incubated on ice for 30 minutes. 
Cells washed in 0.5 ml cold permeabilisation buffer and centrifuged at 650×g for 5 
minutes at 4°C. Supernatants were then decanted and 18µl anti-Ki67 antibody added 
before incubating on ice for 30 minutes. Cells were then washed in 0.5ml cold 
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permeabilisation buffer by centrifuging at 650×g for 5 minutes. Supernatants were 
then decanted and cells fixed, as described in section 2.2.5. 
 
2.2.5 Flow Cytometric Analysis 
 
After staining all samples were fixed with 100µl of 2% Paraformaldehyde (Sigma-
Aldrich, Dorset, UK) in PBS and stored for at least 1 hour in the dark at 4°C prior to 
analysis. Acquisition and analysis of all data was undertaken using CellQuest 
software (BD Biosciences, Oxford, UK). Analysis was performed by gating on the 
live lymphocyte population based on the forward and side scatter profile that 
represents size and granularity, respectively to exclude dead cells and debris. Single 
colour fluorochrome controls were used prior to the start of sample acquisition in 
order to compensate between different channels to correct for overlapping emission 
spectra that can occur between different fluorochromes. Negative and isotype controls 
were used to delineate positive populations where positive and negative populations 
were not clearly distinguishable. The optimum concentration of each antibody was 
determined by preliminary titration. This was defined as the concentration that 
allowed the clearest distinction to be made between cells that stained positively and 
negatively for the marker under investigation. The antibodies used in flow cytometry 
are shown in Table 2.1 
 
2.2.6 Determination of donor CMV status 
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106 PBMCs resuspended in RPMI containing 10% heat inactivated human AB serum 
were added to sterile FACS polypropylene tubes (Kendall, Tyco Healthcare group, 
Massachusetts, USA). The cells were stimulated with CMV-infected cell lysate (used 
at 1/10 dilution), which was prepared by infecting human embryonic lung fibroblasts 
with the Towne strain of CMV (European Collection of Animal Cell Cultures) at a 
multiplicity of infection of 2. After 5 days, the infected cells were lysed by repeated 
freeze-thaw cycles. PBMC were left unstimulated or stimulated with CMV lysate for 
15 hrs at 37°C in a humidified CO2 atmosphere, with 5 µg/ml Brefeldin A (Sigma-
Aldrich, Dorset, UK) added after 2 hrs. Brefeldin A is a fungal metabolite that 
enhances the staining of intracellular cytokines by interfering with the vesicular 
transport of cytokines from the rough ER to the golgi complex, thereby preventing 
their secretion in antigen activated T cells.  The cells were surface stained with anti-
CD4, and then intracellularly stained with anti-IFNγ, as described in section 2.2.3. 
Uninfected cell lysates did not induce any IFNγ secretion. There was concordance 
between seropositivity and a positive IFNγ response in the blood for CMV (Fletcher 
et al., 2005). Furthermore, as a positive control, the superantigen Staphylococcal 
Exotoxin B (SEB; Sigma-Aldrich, Dorset, UK) was added to PBMCs at a final 
concentration of 1µg/ml and unstimulated cells were used as a negative control, as a 
guide for delineating positive and negative populations.  
 
2.3  Flow Cytometric Analysis of Inhibitory Receptor Expression 
 
2.3.1 Anti-CD3 Stimulating cells 
 
 105 
 
 
100µl OKT3 diluted in PBS to 0.5µg/ml was added to each required well of a flat 
bottomed 96 well plate. PBS was added to unstimulated wells as a control. The plate 
was then incubated at 37°C for 2 hours before being washed 3 times with PBS. 
Required cells were then added to the relevant wells. 
 
2.3.2 Analysis of Inhibitory Receptor Expression 
 
PBMCs were stained directly ex vivo to examine KLRG1 expression and were 
stimulated with plate coated anti-CD3 (OKT3) at 37°C to enable CTLA-4 and PD-1 
expression for 24hrs and 48hrs, respectively. PD-1 and KLRG1 expression was 
analysed using cell surface staining techniques as described in section 2.2.2, whereas 
CTLA-4 was determined intracellularly as detailed in section 2.2.3.  
 
2.3.3 Determination of cytokine effects on inhibitory receptor expression 
 
PBMC were stimulated in duplicate with plate coated anti-CD3 for 24 hours, as 
detailed in section 2.3.1, in the presence of cytokines (IL-6 10ng/ml, IL-7 10ng/ml, 
IL-10 50ng/ml, IL-15 10ng/ml, IL-17 1µg/ml, IL-21 0.2µg/ml, IFNα 500U/ml, TNFα 
10ng/ml; all from PeproTech EC, London, UK) prior to inhibitory receptor staining as 
detailed in section 2.3.2 
 
2.3.4 Effects of cytokine receptor blockade on inhibitory receptor 
expression 
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PBMC samples were stimulated in duplicate wells in 96-well flat bottomed plates 
which were anti-CD3 coated for 24 hours in the presence of 1µg/ml IFNαR block 
(Calbiochem, Nottingham, UK) or 50µg/ml IL-15R (R&D Systems, Oxford, UK 
block prior to inhibitory receptor staining as described in section 2.3.2. 
 
2.4  Inhibitory receptor blockade 
 
2.4.1 Inhibitory receptor blocking antibodies 
 
Samples were blocked using 10µg/ml of each of E-cadherin (67A4, Chemicon 
International, Hampshire, UK), CTLA-4 (BN13, (BD Biosciences, Oxford, UK), PD-
L1 (29F.2A3, kind gift from G Freeman), PD-L2 (24F, kind gift from Dr. G. Freeman, 
Dana-Farber Cancer Institute, Boston, MA) or the relevant isotype controls: IgG1 
(MOPC31c, Sigma-Aldrich, Dorset, UK), IgG2a (Mg2a-53, Abcam, Cambridge, UK) 
or IgG2b (MPC-11, Abcam, Cambridge, UK), respectively. All blocking antibodies 
were azide free. 
 
2.4.2 3H-Thymidine Incorporation assay with inhibitory receptor blockade 
 
100µl of MACS purified CD8+ T-cells (5 × 105 cells per well) were stimulated in 
triplicate with plate coated anti-CD3 and irradiated autologous APCs (5 × 105 per well) 
in 96-well flat-bottomed plates (Nunc, Roskilde, Denmark).  Cells were cultured for 
3 days at 37°C in a humidified 5% CO2 atmosphere in the presence of either 
inhibitory receptor blockade or isotype controls, as described in section 2.4.1. During 
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the last 18hrs of culture 10µl of 0.0025MBq [3H]-thymidine (Amersham Biosciences, 
Buckinghamshire, UK) was added to each well. Cells were harvested onto glass 
microfibre filter strips using a cell harvester (Cambridge Technology, Massachusetts, 
USA) and counts per minute (cpm) from incorporated [3H]-thymidine were 
determined by liquid scintillation counting. Proliferation was expressed either as the 
mean [3H]-thymidine incorporation (cpm) of triplicate wells ±SD (standard deviation) 
or a proliferation index was calculated. Proliferation index was determined by 
calculating the ratio of cpm in cells proliferating in response to anti-CD3 stimulation 
alone versus the cpm in cells proliferating in response to anti-CD3 in combination 
with the inhibitory receptor blockade or isotype control. 
 
2.4.3 Detection of Virus Specific CD8+ T cell 
 
PBMCs were incubated for 15mins at 37°C with the following PE- and APC-labelled 
HLA-A2 and HLA-B7 restricted pentamers to identify CMV specific CD8+ T cells: 
A2-CMV (NLVPVMTV) and B7-CMV (TPRVTGGGAM) (ProImmune, Oxford, 
UK). Samples were then stained with anti-CD8 and any other required staining 
antibodies as described in section 2.2. 
 
2.4.4 Effects of inhibitory receptor blockade on the proliferative responses 
of CD8+ NLV/TPR specific T cells 
 
Freshly isolated PBMCs from TPR+ or NLV+ donors were resuspended in RPMI 
containing 10% heat inactivated human AB serum and subjected to 0.2µg/ml 
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TPRVTGGGA or NLVPMVATV peptide stimulation (ProImmune, Oxford, UK) for 
3 days in the presence of inhibitory receptor blockade or relevant isotype control 
before Ki67 staining, as described in section 2.2.4 on NLV/TPR+ cells to determine 
virus specific proliferation. 
 
2.4.5 Effects of inhibitory receptor block on the proliferation of CMV-pp65 
specific CD8+ T cells 
 
Freshly isolated PBMCs from CMV+ donors were resuspended in RPMI containing 
10% heat inactivated human AB serum and subjected to 3 day 0.2µg/ml pp65 CMV 
peptide pool (JPT peptide technologies, Berlin, Germany) stimulus in the presence of 
inhibitory receptor blockade or relevant isotype control before Ki67 staining, as 
described in section 2.2.4, on CD8+ T cells to determine virus specific proliferation.  
 
2.4.6 Effects of inhibitory receptor blockade on the proliferative response 
of CMV specific cells from purified CD8+ T cell subsets 
 
MACS purified CD8+ T cells from fresh blood were separated into its CD27/CD45RA 
subsets as described in section 2.1.7. 200,000 of these separated CD8+ T cells were 
mixed with autologous irradiated APCs in a 1:1 ratio in RPMI supplemented with 
heat inactivated 10% human AB serum. These cells were stimulated in 96U round 
bottomed wells with 0.2µg/ml NLV or TPR peptide for 3 days, before the size and 
Ki67 expression of pentamer positive cells was determined. 
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2.4.7 Effects of inhibitory receptor blockade on CD4+ CMV specific cell T 
proliferation 
 
Freshly isolated PBMCs were resuspended in RPMI supplemented with 10% heat 
inactivated human AB serum. The cells were stimulated for 3 days with or without 
CMV lysate (used at a 1 in 10 dilution) in the presence of inhibitory receptor blocking 
antibody or the relevant isotype control. On day 2 the cells were restimulated with 
CMV lysate overnight in the presence of Brefeldin A. Cells were then surface stained 
with anti-CD4 and intranuclearly stained with anti-IFNγ and anti-Ki67 as described in 
section 2.2.4. CD4+IFNγ+ cells were identified as CMV specific and their expression 
of Ki67 represented the proliferative response of these cells. 
 
2.5  Telomere and Telomerase 
 
2.5.1 Measurement of telomere lengths 
 
Telomere lengths measured by a 3 colour flow cytometric detection of fluorescence in 
situ hybridization (flow-FISH.) PBMCs were stained using anti-CD8-FITC and anti-
CD4-biotin (Immunotech, Birmingham, UK) and streptavidin-Cy3 (Cedarlane 
Laboratories Ltd), then fixed and permeabilised (Fix and Perm Cell Permeabilisation 
Kit, Caltag Laboratories, Paisley, UK). Cells were washed once in hybridization 
buffer (70% formamide, 20 mM Tris, 150 mM NaCl, and 1% BSA) and then 
incubated at 82°C for 10 min with 0.75 µg/ml Cy5-conjugated telomeric (CCCTAA) 
peptide nucleic acid probe (Applied Biosystems, Warrington, UK). After rapid 
cooling on ice, the samples were hybridized for 1 hr at room temperature in the dark, 
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washed twice in post-hybridization buffer (70% formamide, 10 mMTris, 150 mM 
NaCl, 0.1% BSA, and 0.1% Tween 20) and then PBSA, and analysed immediately by 
flow cytometry. To ensure consistency of the results between experiments, two 
cryopreserved PBMC samples with known telomere fluorescence were used as 
standards. Results were obtained as median fluorescence intensity values, which could 
then be converted to telomere length in kilobases using a standard curve. The standard 
curve was constructed using 30 samples of varying telomere length analysed both by 
flow-FISH and telomeric restriction fragment analysis. 
 
2.5.2 Measurement of Telomerase Activity 
 
Purified CD8+ T cell subset populations (2 x 105 cells), separated as described in 
section 2.1.7, were snap frozen after 3 day stimulation with either plate coated anti-
CD3 or 0.2 µg/ml pp65 CMV peptide pool in the presence of autologous irradiated 
APCs and inhibitory receptor blocking antibodies. Using trypan blue exclusion 
counting (as described in section 2.1.3) and Ki67 staining the samples were adjusted 
to 500 Ki67+ cells per reaction. The TeloTAGGG telomerase ELISA kit (Roche, 
Lewes, UK) was used to measure the telomerase activity according to the protocol 
provided by the manufacturer.  
 
2.6  Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism version 4.05 for Windows 
(GraphPad Software, California, USA). For correlations between groups, the 
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D’Agostino and Pearson Omnibus Normality test was used to evaluate whether data 
sets were normally distributed. Statistical significance was evaluated using the 
Student’s t test, if data followed a Gaussian distribution, and if data was also paired it 
was assessed using a Student’s paired t test. Unpaired non-parametric data was 
evaluated using a Mann-Whitney U test, with a Wilcoxon matched paired test was 
used if data points also represented paired observations. Two tailed tests were used 
unless otherwise specified. For correlations, Pearson product-moment correlation 
coefficient was used to calculate r2 and P values, and lines of best fit were generated 
using linear regression. Differences were considered significant when P < 0.05. 
 
Antigen Source Clone Isotype Dilution 
CD27-FITC BD M-T271 mIgG1 1/10 
Ki67-FITC BD B56 mIgG1 1/10 
CD8-FITC BD SK1 mIgG1 1/10 
HLA-B7-FITC AbD Serotec BB7.1 mIgG1 1/10 
CD27-PE BD M-T271 mIgG1 1/10 
KLRG1-PE H Pircher 13F12 mIgG1 1/10 
PD-1-PE G Freeman EH12 mIgG2 1/10 
CTLA-4-PE BD BN13 mIgG2a 1/10 
HLA-A2-PE AbD Serotec BB7.2 mIgG1 1/10 
CD8-PerCP BD SK1 mIgG1 1/10 
CD4-PerCP BD SK3 mIgG1 1/10 
CD27-APC eBiosciences O323 mIgG1 1/10 
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IFNγ-APC BD B27 mIgG2b 1/10 
CD45RA-APC Invitrogen MEM-56 mIgG2b 1/10 
CD4-PE-Cy7 BD SK3 mIgG1 1/10 
CD45RA-PE-Cy7 BD L48 mIgG1 1/10 
CD4-Biotin Immunotech 13B8.2 mIgG1  
 
Table 2.01  List of antibodies used for flow cytometry 
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3  Characterisation of Inhibitory Receptor Expression Variations 
with Age & CMV Status 
 
3.1  Introduction and Aims 
 
An emerging field in age-associated immune decline is the role of immune inhibitory 
receptors. Augmented inhibitory receptor expression has been reported in aged mice 
and humans (as described in section 1.5.3) and following infection with various 
chronic pathogens, which may constitute a mechanism by which antigenic burden 
drives immune system ageing (as described in section 1.3.2). Moreover, cellular 
senescence has been demonstrated to be maintained by active signalling and be 
reversible in fibroblasts (d'Adda di et al., 2003). The critical signalling defect amongst 
highly differentiated CD8+ T cells, that accumulate with ageing, is suggested as 
defective Akt activation (as described in section 1.2.3.2.3.2), which PD-1, CTLA-4 
and KLRG1 can all mediate (as described in section 1.5.4). In summary, inhibitory 
receptor expression may increase with age and/or antigen load, which may define a 
reversible defect in T cell functionality of the aged.  
 
In this chapter the role of the inhibitory receptors CTLA-4, PD-1 and KLRG1 in age-
associated immune decline are initially assessed by characterising their expression 
with respect to age on CD8+ and CD4+ T cells. These studies are extended by further 
stratifying their expression based on donor CMV status and T cell differentiation 
stage. Finally, the functional relevance of these inhibitory receptor expression 
variations are elucidated using inhibitory receptor blocking antibodies.  
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3.2 Characterisation of functionally distinct T cell subpopulations at 
different differentiation stages 
 
3.2.1 CD8+ T cells 
Forward scatter (FSC) versus side scatter (SSC) flow cytometry plots enable the 
evaluation of cells based upon size (FSC) and granularity (SSC). Lymphocytes form a 
tight population distinct from the larger monocytes, the smaller red blood cells and 
any highly granular apoptotic cells and cellular debris (Fig 3.01A). CD8 staining on 
gated live lymphocytes revealed 3 distinct populations: a CD8hi population 
representing CD8+ T cells, a CD8int subset that defined NK cells and a CD8lo group 
that includes CD4+ T cells and B cells (Fig 3.01B).  
 
3.2.2  Utilisation of CD27/CD45RA markers to identify distinct T cell 
subsets 
Both the CD8+ and CD4+ T cell pool are heterogeneous and include distinct subsets 
characterised by functional and phenotypic differences that can be defined on the 
basis of their heterogeneity in antigen expression. The phenotypic markers CD27 and 
CD45RA have been suggested as the most useful antigen combination to identify the 
four main T cell subsets: CD27+CD45RA+ (naïve, TN), CD27+CD45RA- (central 
memory, TCM) CD27-CD45RA- (effector memory, TEM) and CD27-CD45RA+ 
(revertant memory, TREV) (as described in section 1.2.3.1.7 and illustrated in Fig 
3.01C,D). 
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3.2.3 CD27/CD28 markers distinguish T cells at distinct differentiation 
stages 
For functional analyses, utilisation of the differentiation markers CD27 and CD28 
were advantageous in that they allowed the enumeration of greater numbers of cells.  
CD28+CD27+CD8+T cells were defined as early differentiated, with CD27-CD28+ as 
intermediate and CD28-CD27- as late (described in section 1.2.3.1.7 and illustrated in 
Fig 3.01E,F). The rare CD28+CD27-CD8+ T cell population is seldom found in 
sufficient numbers for isolation from most donors, though it has been characterised as 
having short telomeres, of comparable length with CD28-CD27-CD8+ T cells, 
suggesting they too are a highly differentiated population (Plunkett et al., 2005). 
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Figure 3.01. Identification of live lymphocytes and CD8+ T cell subpopulations by
fluorescence cytometry
Purified PBMCs were stained with anti- CD8 PerCP, CD27 FITC and either CD45RA APC or
CD28 APC. (A) Live lymphocytes were identified and gated on the basis of FSC/SSC profile
in order to exclude cell debris. (B) A representative dot plot of the CD8+ staining on live
lymphocytes with CD8intermediate cells representing NK cells and CD8hi gated on and indicating
CD8+ T cells. (C) A scatter plot showing CD27/CD45RA staining gated on CD8+ T cells. This
enables the identification of different CD8+ subpopulations including naive (CD27+CD45RA+),
central memory (CD27+CD45RA-), effector memory (CD27-CD45RA-) and revertant memory
cells (CD27-CD45RA+) as depicted in (D). (E) An example of the CD27/CD28 profile of CD8+
T cells. The different populations identified are labelled early differentiated (CD27+CD28+),
intermediate differentiated (CD27+CD28-), late differentiated (CD27-CD28-) and CD27-CD28+,
as illustrated in (F)
A
C
D
B
E
F
CD8+
 117 
 
 
3.2.4  CD4+ T cells 
CD4 staining on gated live lymphocytes reveal a CD4- population and a CD4+ 
population that represents CD4+ T cells (Fig 3.02A,B). CD27/CD45RA expression 
patterns define naïve, central memory, effector memory and CD45RA-revertant 
memory CD4+ T cell populations in a manner analogous to CD8+ T cells (Fierro et al., 
2008) (Fig 3.02C,D). Additionally, the sequential loss of CD27 and CD28 can define 
different stages of CD4+ T cell differentiation. However, in contrast to CD8+ T cells, 
CD4+ T cells lose CD27 expression before CD28, giving rise to the differentiation 
pathway CD27+CD28+→CD27-CD28+→CD27-CD28- (as described in section 
1.2.3.1.7 and illustrated in Fig 3.02E,F). 
 
 118 
 
 
CD4+
Figure 3.02. Using fluorescence cytometry for the identification of live CD4+ T cells at
different differentiation stages as defined by CD27/CD45RA and CD27/CD28
phenotypic markers.
PBMCs were purified and stained with anti- CD4 PerCP, CD27 FITC and either CD45RA
APC or CD28 APC. (A) A typical FSC/SSC profile upon which a live lymphocyte gate is
drawn. (B) A representative FACS plot gated on live lymphocytes of the CD4 staining with
CD4+ gate depicted. (C) CD27/CD45RA staining on CD4+ T cells enabling identification of
naive (CD27+CD45RA+), central memory (CD27+CD45RA-), effector memory (CD27-
CD45RA-) and revertant memory (CD27-CD45RA+) CD4+ T cell subpopulations as depicted
in (D). (E) CD27 and CD28 staining gated on CD4+ T cells permitting the distinguishment of
early differentiated (CD27+CD28+), intermediate differentiated (CD27+CD28-), late
differentiated (CD27-CD28-) and CD27-CD28+ CD4+ T cells, as illustrated in (F)
A
C
D
B
E
F
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3.3 CD4+ T cells are more resistant to age and CMV associated 
phenotypic changes than CD8+ T cells 
 
3.3.1  Changes in CD8+ T cell phenotype with age and CMV status, 
characterised using the phenotypic markers CD27/CD45RA 
The percentage of naïve CD8+ T cells diminished in a strong, highly significant 
manner with donor age and amongst CMV+ donors compared with CMV- in both 
young (<35yrs) and old (>65yrs) cohorts (Fig 3.03A representative example; Fig 
3.03B cumulative data). However, the proportions of central and effector memory 
CD8+ T cells do not significantly differ between these different cohorts (Fig 3.03C,D). 
Nevertheless, these reductions in naïve CD8+ T cells are accompanied by significant 
increases in the percentages of CD45RA-revertant memory T cells with age (Fig 
3.03E) and CMV status amongst young but not old donors (Fig 3.03E, P < 0.05 young, 
P = 0.11 old).  
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Figure 3.03. Change in phenotypic markers CD45RA and CD27 on CD8+ T cells with age
and CMV.
Purified PBMCs were stained and analysed as described in Fig 3.01. (A) Representative
examples of CD27/CD45RA staining on the on CD8+ T cells of a young CMV- (n=13), young
CMV+ (n=9), old CMV- (n=10) and old CMV+ (n=20) donors. (B) Cumulative data showing the
proportion of CD8+ T cells that are naive, (C) central memory, (D) effector memory and (E)
revertant memory cells stratified on the basis of age and CMV status. Filled symbols indicate
CMV negative individuals and open symbols CMV positive individuals. Young donors are <35
years and old donors >65. Horizontal lines illustrate mean values. The P values were
calculated using a Mann-Whitney U test. Significant differences are shown.
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3.3.2  Age and CMV associated alterations in the differentiation status of 
the CD8+ T cell pool as defined by CD27/CD28 expression 
Utilising the alternative differentiation markers CD27 and CD28, a similar age and 
CMV associated remodelling of the CD8+ T cell compartment can be observed (Fig 
3.04A, representative example). Indeed, the proportion of early differentiated CD8+ T 
cells undergo a significant diminution with age and CMV status (Fig 3.04B), which is 
accompanied by a significant accumulation of late differentiated CD8+ T cells among 
old donors and also among CMV+ young compared with their CMV- counterparts (Fig 
3.04D). The proportions of CD8+ T cells belonging to the intermediately 
differentiated CD27-CD28+ subset and the rare CD27+CD28- population did not 
significantly vary between the different cohorts (Fig 3.04 C,E). 
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Figure 3.04. Alterations to CD8+ T cell phenotype, as defined by CD28 and CD27,
stratified by donor age and CMV status.
CD8/CD27/CD28 PBMC staining performed in accordance with Fig 3.01. (A) Illustrative
examples of the CD27/CD28 profile of CD8+ T cells from a young CMV-, (n=12) young CMV+
(n=13), old CMV- (n=8) and old CMV+ (n=13) donors (B) Pooled data illustrating how the
proportion of early, (C) intermediate, (D) late differentiated and (E) CD27-CD28+ CD8+ T
cells changes with ageing and CMV status. Filled symbols indicate CMV negative individuals
and open symbols CMV positive individuals. Young donors are <35 years and old donors
>65. Horizontal lines indicate mean values. A Mann-Whitney U test was used to calculate P
values and only significant differences are shown.
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3.3.3  Phenotypic variation of CD4+ T cells with donor age and CMV status, 
stratified using the markers CD27/CD45RA 
Although reductions in naïve T cells that approached significance could be observed 
amongst the CD4+ T cell compartment, both with age (Fig 3.05A, representative 
example; Fig 3.05B, P = 0.10 amongst CMV+ donors, P = 0.30 within CMV- cohort) 
and CMV seropositivity (Fig 3.05B, P = 0.16 old, P = 0.07 young), these differences 
were much smaller both in magnitude and significance, when compared with those 
among CD8+ T cells. Moreover, this was accompanied primarily by accumulation of 
central memory CD4+ cells, in young CMV+ (Fig 3.05C, P < 0.05 compared with 
young CMV-) and old CMV- donors (Fig 3.05C, P = 0.07 compared with young 
CMV-), rather than CD45RA-revertant memory cells, as observed amongst the CD8+ 
T cell compartment.  
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Figure 3.05. CMV and age related changes in differentiation status of CD4+ cells
defined by their CD27/CD45RA expression .
PBMCs subjected to flow cytometric experiments as in Fig 3.02. (A) Dot plots showing
expression of the phenotypic markers CD27 and CD45RA on a typical young CMV-, (n=6)
young CMV+ (n=8), old CMV- (n=8) and an old CMV+ (n=7) donors’ CD4+ T cells. (B)
Percentages of CD4+ T cells that are naive, (C) central memory, (D) effector memory and (E)
revertants in young and old, CMV negative and positive donors. Filled symbols indicate CMV
negative subjects and open symbols CMV positive individuals. Young donors are <35 years
and old donors >65. Mean values are depicted by horizontal bars. Only significant
differences are shown, calculated using a Mann-Whitney U test
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3.3.4   Alterations in the differentiation state of CD4+ T cells, as defined by 
CD27/CD28 expression, with increasing age and CMV status 
Once again, in contrast to the dramatic reduction observed in early differentiated 
CD8+ T cells, the CD28+CD27+ subset of the CD4+ T cell compartment in CMV+ and 
aged donors undergoes little variation, with significant reductions only being 
observed amongst CMV+ old subjects (Fig 3.06A, representative example; Fig 3.06B, 
P < 0.05 compared with CMV- old, P = 0.07 compared with CMV+ young). The 
proportion of intermediate differentiated or CD27-CD28+ CD4+ T cells did not vary 
with age or CMV status (Fig 3.06C,E) and late differentiated CD4+ T cells were only 
observed in significant numbers in CMV+ old donors (Fig 3.06D, P < 0.05 compared 
with CMV- young and P = 0.07 relative to CMV+ young subjects). 
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Figure 3.06. CMV and age related variations in CD4+ subset distribution according to
CD28 and CD27 expression
PBMCs stained with anti- CD27, CD28 and CD4 before being analysed as stated in Fig 3.02.
(A) Demonstrative dot plots of a young (<35) CMV- (n=10) and CMV+ (n=10), and an old
(>65) CMV- (n=7) and CMV+ (n=12) subjects’ CD27/CD28 profiles gated on CD4+ T cells (B)
Pooled data showing how the proportion of early, (C) intermediate (D) late differentiated and
(E) CD27+CD28- CD4+ T cells changes with age and CMV status Filled symbols indicate
CMV negative individuals and open symbols CMV positive individuals. Horizontal lines depict
mean values. The P values were calculated using Mann-Whiney U test and only differences
that are significant are shown.
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3.4 Age and CMV Associated Upregulation of Different T cell Inhibitory 
Receptors on CD4+ and CD8+ T cells 
 
3.4.1 CTLA-4 expression can be stratified on the basis of donor age only 
on CD8+ T cells 
The role of inhibitory receptors in age onset immune decline was initially assessed by 
characterising expression of these receptors on T cells with respect to age. The 
majority of CTLA-4 molecules are localised in intracellular stores and CTLA-4 is 
only transiently expressed at low levels on the cell surface following T cell activation 
(Linsley et al., 1996) and cannot be demonstrated in unstimulated PBMCs using flow 
cytometry (Steiner et al., 1999). Additionally, the kinetics of CTLA-4 intracellular T 
cell expression after stimulation parallels those of surface expression (Alegre et al., 
1996; Leng et al., 2002b; Miller et al., 2002). Therefore, CTLA-4 expression was 
examined using intracellular staining techniques on PBMCs, stimulated with anti-
CD3 for 24hrs to enable peak expression. CTLA-4 expression increased with age in a 
strong and significant manner on CD8+ T cells, independent of CMV status (Fig 
3.07A, representative example; Fig 3.07B pooled data). In contrast, no age-associated 
CTLA-4 expression variations were observed on the CD4+ pool in either CMV- or 
CMV+ subjects (Fig 3.07C, representative example; Fig 3.07D cumulative data). 
Grouping donors based on their CMV status revealed that CTLA-4 expression on 
CD8+ and CD4+ T cells is significantly higher on CMV+ individuals compared with 
their CMV- counterparts (data not shown, CD8+ P< 0.0001; CD4+ P < 0.005).   
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Figure 3.07. CTLA-4 expression is positively correlated with CMV status in CD8+ and
CD4+ T cells but with age only in CD8+ T cells
CTLA-4 expression was measured by intracellular flow cytometry on PBMCs stimulated for
24hr with OKT3 and then stained with anti-CTLA-4 PE and either anti-CD4 or CD8 PerCP.
(A) Representative examples of CTLA-4 staining in CMV- and CMV+ young and old donors’
CD8+ and (B) CD4+ T cells. Filled plots indicate CTLA-4 and unfilled plots represent
isotype control staining (C) Cumulative data, correlated by age and CMV status, depicting
CTLA-4 expression on CD4+ and (D) CD8 T cells. Filled symbols indicate CMV negative
individuals and open symbols CMV positive individuals. Line of best fit generated using
linear regression. P and r2 values calculated using Pearson’s correlation.
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3.4.2 PD-1 expression displays no age-associated variation on either CD4+ 
or CD8+ T cells 
Similar to CTLA-4, PD-1 is poorly expressed on resting lymphocytes (Parry et al., 
2005) but, in contrast to CTLA-4, it undergoes a strong and sustained surface 
upregulation after cellular activation. Therefore, PD-1 expression was examined using 
surface staining techniques following 48hrs anti-CD3 stimulation of PBMCs to enable 
maximal expression. Unlike CTLA-4, PD-1 expression on CD8+ T cells is not age 
dependent (Fig 3.08A, representative example; Fig 3.08B, grouped data). Similarly no 
age dependent variation in PD-1 expression is observed amongst CD4+ T cells (Fig 
3.08C, representative example; Fig 3.08D cumulative data). However, CMV infection 
upregulates PD-1 expression in both CD8+ and CD4+ T cells (data not shown, CD8+ P 
< 0.0001; CD4+ P < 0.0005).   
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Figure 3.08. PD-1 expression on CD8+ and CD4+ T cells is significantly elevated in
CMV+ individuals but is independent of age
PBMCs were stimulated for 48hrs with anti-CD3 and then surface stained with anti-PD-1 PE
and either anti-CD8 or CD4 PerCP. (A) Representative histograms of PD-1 staining on CD8+
and (B) CD4+ T cells from a young and old, CMV- and CMV+ donors with the filled bars
depicting PD-1 expression and the isotype control staining being represented by an unfilled
plot. (C) Pooled data, demonstrating how PD-1 expression changes with age and CMV
status on CD8+ and (D) CD4+ T cells. Filled symbols indicate CMV negative individuals and
open symbols, CMV positive individuals. Linear regression used to generate line of best fit
and Pearson’s correlation used to calculate P and r2 values
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3.4.3 KLRG1 expression increases with age more dramatically on CD8+ 
than CD4+ T cells 
KLRG1 is constitutively expressed on the T cell surface and its expression was 
examined directly ex vivo, without stimulus. Unlike the expression patterns of CTLA-
4, and PD-1, clearly identifiable KLRG1+ and KLRG1- populations could be observed 
and thus the percentage of cells that express KLRG1 was measured. As observed for 
CTLA-4, KLRG1 expression on CD8+ T cells significantly increased with age (Fig 
3.09A, representative example; Fig 3.09B, pooled data). However, the age-associated 
increases in KLRG1 expression on CD4+ T cells were much more modest and only 
reached significance amongst CMV+ donors (Fig 3.09C, representative example; Fig 
3.09D, grouped data). KLRG1 is also expressed at augmented levels on the CD8+ and 
CD4+ T cells of CMV+ compared with CMV- donors (data not shown, CD8+ P < 
0.0001; CD4+ P <  0.0005).   
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Figure 3.09. Expression of KLRG1 on CD4+ and CD8+ T cells with age and CMV
status.
KLRG1 expression was determined using surface flow cytometry on unstimulated PBMCs
following staining with anti-KLRG1-PE and either CD8 or CD4 PerCP. (A) FACS plots of
KLRG1 expression gated on CD8+ or (B) CD4+ T cells from representative young, old,
CMV- and CMV+ donors. Unfilled plots represent isotype control and filled plots indicate
KLRG1 staining. (C) Pooled data illustrating KLRG1 expression on CD8+ and (D) CD4+ T
cells, stratified by age and CMV status. Filled symbols indicate CMV negative and open
symbols CMV positive individuals. Line of best fit generated using linear regression. P and
r2 values calculated using Pearson’s correlation.
KLRG1
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3.5 Defining Inhibitory Receptor Expression on Different T cell Subsets 
According to Donor Age 
 
3.5.1  Determination of inhibitory receptor expression on distinct T cell 
subsets 
To better characterise the nature of these age- and CMV-associated expression 
changes, inhibitory receptor expression was further characterised upon different T cell 
phenotypic and differentiation stages, amongst both young and old individuals. In the 
case of CTLA-4 and KLRG1, this was achieved by staining cells with 
CD27/CD45RA or CD27/CD28 markers, following 24 hour stimulation (in the case 
of CTLA-4) or directly ex vivo (for KLRG1), as described in Figs 3.01 and 3.02. 
However, in order to measure PD-1 expression, PBMCs were stimulated for 48 hours, 
which was sufficient time to induce T cell differentiation resulting in dramatic 
changes in T cell phenotype (Fig 3.10A). Therefore to measure PD-1 expression at 
different CD8+ T cell differentiation stages, purified CD8+ T cell subsets were 
stimulated with autologous irradiated APCs, as a source of multiple costimulatory 
molecules, for 48 hours before staining. However, this method is significantly more 
labour intensive, therefore when performing the analysis on CD4+ T cells, it was 
found that stimulating PBMCs with anti-CD3 for 24 hours (Fig 3.10B) could generate 
a comparable pattern of PD-1 expression to that generated using FACS sorted CD4+ T 
cell subsets stimulated for 48 hours (Fig 3.10C). Therefore this method was used to 
determine PD-1 expression at different CD4+ T cell phenotypic stages. 
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Figure 3.10. Similar PD-1 expression profiles generated on CD4+ T cell subsets after
stimulating PBMCs or FACS Aria purified subsets with anti-CD3.
(A) Purified PBMCs stimulated with anti-CD3 and stained with anti-CD4 PerCP, CD45RA
APC and CD27 FITC. CD27/CD45RA plots gated on CD4+ T cells are displayed (left panel)
0 hours, (middle panel) 24 hours and (right panel) 48 hours after stimulation. (B) PBMCs
were either stimulated with OKT3 for 24hrs or (C) Purified CD4+ subsets, defined using
CD27 and CD45RA, were stimulated with OKT3 and autologous irradiated APCs for 48hrs.
The cells were then stained with anti-CD27 FITC, CD4 PerCP, CD45RA APC and analysed
by flow cytometry. The mean fluorescent intensity of PD-1 expression on each subset is
indicated.
B
C
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3.5.2 CTLA-4, PD-1 and KLRG1 expression varies with CD8+ T cell 
differentiation states on young and old individuals 
CTLA-4 expression on CD8+ T cells is upregulated on each differentiation stage as 
defined by CD27/CD45RA, except CD45RA-revertant memory cells, in old subjects 
compared to young (Fig 3.11A) with expression concentrated primarily on central and 
effector memory subsets among young individuals, whereas in old individuals naïve 
and central memory subsets express the highest levels. The pattern of PD-1 
expression on different CD8+ T cell differentiation stages does not significantly differ 
between old and young donors, with both age groups expressing peak PD-1 levels on 
central and effector memory T cells (Fig 3.11B). KLRG1 expression dramatically 
increases as CD8+ T cells differentiate with no differences in expression between 
young and old donors (Fig 3.11C).  
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Figure 3.11 Differences in CTLA-4, PD-1 and KLRG1 expression on CD8+ T cells
stratified by the phenotypic markers CD27 and CD45RA in old and young donors
CTLA-4, PD-1 and KLRG1 expression was quantified as described in Fig 3.07, 3.08 and
3.09, respectively, on CD8+ T cells at different phenotypic stages using the makers CD27
and CD45RA. (A, left panel) Histograms from a representative young and old donor
illustrating CTLA-4, (B, left panel) PD-1 and (C, left panel) KLRG1 staining at different
CD8+ T cell phenotypic stages based on CD27/CD45RA staining. (A, right panel) Pooled
data displaying CTLA-4 (B, right panel) PD-1 and (C, right panel) KLRG1 expression of
CD8+ T cells stratified by CD27 and CD45RA expression in young as compared with old
donors. Filled symbols represent young donors, Y, and open symbols signify old individuals,
O. Horizontal lines represent mean values. The P values were calculated using Student’s t-
test. Significant differences between young and old donors are shown.
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3.5.3  Inhibitory receptor expression stratified by CD27/CD45RA 
expression on CD4+ T cells on young and old donor cohorts 
Unlike the results observed for CD8+ T cells, CTLA-4 expression on CD4+ T cell 
subsets does not significantly differ between young and old donors, but displays a 
similar pattern to that of CD8+ T cell subsets of young individuals, with expression 
peaking in the central memory subset (Fig 3.12A). PD-1 expression on CD4+ T cells 
forms a completely different pattern to that of CD8+ cells with expression being 
greatest on TEM and TREV cells (Fig 3.12B). PD-1 expression was also augmented on 
the naïve CD4+ cells of old individuals compared with their young counterparts (Fig 
3.12B). KLRG1 expression on CD4+ T cells increases with differentiation in a similar 
manner to CD8+ T cells but the increases are much less pronounced (Fig 3.12C), with 
significantly elevated expression observed in effector memory and CD45RA-revertant 
memory  subsets of old donors compared to young. 
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Figure 3.12. The expression of CTLA-4, PD-1 and KLRG1 on CD4+ T cells based on
CD27 and CD45RA phenotypic markers amongst the old and young.
PBMCs from young (<35 years) and old (>65) were stimulated stained and analysed by flow
cytometry for CTLA-4, PD-1 and KLRG1 expression defined by CD27/CD45RA, as
described in the previous figure but using ani-CD4 PerCP rather than anti-CD8 PerCP. (A,
left panel) Representative FACS plots of CTLA-4, (B, left panel) PD-1 and (C, left panel)
KLRG1 expression in a young and an old donor on the basis of the phenotypic markers:
CD27 and CD45RA. (A, right panel) Cumulative data is plotted as CTLA-4, (B, right panel)
PD-1 and (C, right panel) KLRG1 expression on different CD4+ T cell subsets defined by
CD27 and CD45RA expression un young and old individuals. Filled symbols represent
young donors, Y, and open symbols signify old individuals, O. Horizontal lines depict mean
values. P values were calculated using Student’s t-test. Significant differences between
young and old donors are shown.
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3.6 Stratifying inhibitory receptor expression on different T cell 
subpopulations on the basis of donor age and CMV status 
 
3.6.1  CTLA-4 
Inhibitory receptor expression was characterised with respect to CMV status in young 
and old donors at different phenotypic stages. CMV positive individuals display 
similar CTLA-4 expression patterns, with respect to T cell differentiation, compared 
with their age matched CMV negative counterparts. Nevertheless, augmented CTLA-
4 expression levels are observed amongst young CMV+ versus CMV- donors which 
reached significance among several subsets (Fig 3.13A,B left panels). Amongst old 
donors, the magnitude of CTLA-4 expression appears greater amongst CMV+ donors, 
but this increase only reaches significance in CD8+ TCM cells (Fig 3.13A,B right 
panels). 
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Figure 3.13 Differences in CTLA-4 expression stratified by the phenotypic markers
CD27 and CD45RA in CMV+ and CMV-, old and young donors
CTLA-4 expression on CD4+ and CD8+ T cells, as defined by CD27/CD45RA expression,
determined as described in Fig 3.11 and 3.12, was compared between CMV- and CMV+, old
and young cohorts. (A) Pooled data comparing the expression of CTLA-4 staining in CMV-
and CMV+ donors on T cell subsets as defined by CD27 and CD45RA on CD8+ or (B) CD4+ T
cells from (left panels) young and (right panels) old individuals. Young donors are defined
as <35 years and old donors, >65. Filled symbols represent CMV negative individuals and
open symbols signify CMV positive donors. Horizontal lines depict mean values. The P values
were calculated using Mann-Whitney U-test. Significant differences in CTLA-4 subset
expression between CMV- and CMV+ donors are shown.
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3.6.2  PD-1 
PD-1 is expressed primarily on central and effector memory CD8+ T cells both on 
CMV+ and CMV- donors independently of age. However, donors seropositive for 
CMV expressed higher levels of PD-1, which were significant amongst young 
individuals’ effector and CD45RA-revertant memory subsets (Fig 3.14A left panel), 
but did not reach significance on CD8+ T cells of old individuals at any differentiation 
stage (Fig 3.14A right panel). Similarly, the differing PD-1 expression pattern on 
CD4+ T cells is observed independent of CMV status, amongst both young and old 
donors, and although CMV+ donors express higher levels of PD-1, this does not reach 
significance at any phenotypic stage of young or old subjects (Fig 3.14B).  
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Figure 3.14. PD-1 expression correlated by CMV status in young and old donors on
different CD8+ T cell differentiation stages in young and old donors
PD-1 expression on CD8+ and CD4+ T cell subsets, defined by CD27/CD45RA expression,
was compared between CMV- and CMV+ age matched donors, as described in Fig 3.11 and
3.12. (A) Cumulative data showing the expression of PD-1 with respect to CD45RA and
CD27 staining in CMV- versus CMV+ individuals amongst (left panels) young and (right
panels) old donors on CD8+ and (B) CD4+ T cells. Filled symbols represent CMV negative
individuals and open symbols signify CMV positive donors. Young donors are defined as <35
years and old donors, >65. Horizontal lines depict mean values. The P values were
calculated using a Mann-Whitney U test. Significant differences in PD-1 between CMV- and
CMV+ donors within a given subset are shown.
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3.6.3  KLRG1 
KLRG1 expression increases with differentiation on CD8+ T cells both in CMV+ and 
CMV- donors from young and old cohorts (Fig 3.15). However, CMV+ individuals 
exhibit significantly augmented KLRG1 expression, compared with their CMV- 
counterparts, among the naïve CD8+ T cells of young donors (Fig 3.15A left panel) 
and the central and effector memory CD8+ subpopulations of old donors (Fig 3.15A 
right panel). In contrast, dependent on their CMV status, individuals exhibit a distinct 
pattern of KLRG1 expression on different CD4+ T cell subpopulations. KLRG1 
expression was greatest on CMV- donors’ effector memory subsets, but amongst 
CMV+ individuals, CD45RA-revertant memory CD4+ T cells expressed the highest 
levels (Fig 3.15B). This effect is most strikingly observed amongst the aged whose 
CMV+ donors exhibit significantly higher levels of KLRG1 expression on their 
effector memory cells, compared with their CMV- counterparts, but exhibit an 
increase of even greater magnitude on their CD45RA-revertant memory cells (Fig 
3.15B right panel).  
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Figure 3.15. KLRG1 expression defined by differentiation status of CD8+ T cells in
young and old donors with and without CMV
KLRG1 expression by different CD4+ and CD8+ T cell subsets, accomplished as described in
Fig 3.11 and 3.12, was stratified by donor age and CMV status. (A) Cumulative data
comparing KLRG1 expression with respect to CD45RA and CD27 in CD8+ and (B) CD4+ T
cells of (left panels) young and (right panels) old donors. Filled symbols represent CMV
negative individuals and open symbols signify CMV positive donors. Young donors are
defined as <35 years and old donors, >65. Horizontal lines depict mean values. The P values
were calculated using a Mann-Whitney U-test and only significant differences in PD-1
between CMV- and CMV+ donors within a given subset are shown.
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3.7 Characterisation of inhibitory receptor expression on CD27/CD28 
defined subsets 
 
3.7.1 CTLA-4 is expressed on early, PD-1 on intermediate and KLRG1 is 
expressed on late differentiated CD8+ T cells 
Utilising the alternative phenotypic markers CD27 and CD28 to distinguish different 
CD8+ T cell stages of differentiation, CTLA-4 expression peaks on early 
differentiated CD8+ T cells and diminishes with differentiation, with both young and 
old displaying similar patterns of expression (Fig 3.16A). PD-1 is similarly expressed 
on young and old individuals, both being maximally expressed on intermediate 
differentiation stages (Fig 3.16B). KLRG1 expression increases with differentiation 
on both the young and old but is significantly higher at each differentiation stage on 
old compared with young subjects (Fig 3.16C) 
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Figure 3.16. Comparison of inhibitory receptor expression on CD8+ T cells stratified
by CD28/CD27 expression
CTLA-4, PD-1 and KLRG1 expression was quantified as described in Fig 3.07, 308 and
3.09, respectively, on CD8+ T cells subsets as defined by CD27 and CD28 staining as
detailed in Fig 3.04. (A, left panel) Histograms depicting CTLA-4, (B, left panel) PD-1 and
(C, left panel) KLRG1 expression on CD8+ T cell subsets from a representative young, Y
<35yrs and old , O >65, donor. Filled plots indicate inhibitory receptor staining whereas
unfilled plots represent isotype controls. (A, right panel) Pooled data comparing CTLA-4,
(B, right panel) PD-1 and (C, right panel) KLRG1 expression at different CD8+ T cell
differentiation stages in young and old individuals. Horizontal lines depict mean values. All
the CTLA-4 and PD-1 data sets passed a D'Agostino & Pearson omnibus normality test
and their P values were calculated using a Student’s t-test. However, not all the KLRG1
data sets followed a Gaussian distribution and thus a Man-Whitney U test was used to
assess P values and only significant differences between young and old donors are shown
CD8+
A
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3.7.2 Alterations in inhibitory receptor expression as defined by the 
phenotypic markers CD27 and CD28 on CD4+ T cells on both young 
and old donors 
Inhibitory receptors display an alternative expression profile on CD4+ T cells with 
CTLA-4 being similar in the young and old and peaking on intermediate 
differentiated rather than early differentiated subsets (Fig 3.17A). PD-1 expression is 
greatest amongst the intermediate and highly differentiated CD4+ T cells (Fig 3.17B). 
KLRG1 increases with differentiation and is higher in old compared to young 
individuals at each differentiation stage (Fig 3.17C), as observed among CD8+ T cells, 
however altogether CD4+ T cells express KLRG1 at comparably lower levels. 
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Figure 3.17. Inhibitory receptor expression on different CD4+ T cell differentiation
stages correlated by age of the donors
Inhibitory receptor levels were quantified on CD4+ CD27/CD28 subsets by flow cytometry as
detailed in Fig 1.10. (A, left panel) Histograms depicting the CTLA-4, PD-1 and KLRG1
expression on the different CD4+ T cell differentiation stages of a representative young and
an old donor (A, right panel) Cumulative data depicting the expression of CTLA-4, (B right
panel) PD-1 and (C, right panel) KLRG1 with respect to CD27 and CD28 staining amongst
young (Y, <35 years) and old (O, >65) donors. Horizontal lines depict mean values. The P
values were calculated using a Mann-Whitney U test. Significant differences between young
and old donors within a given subset are shown.
CD4+
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3.7.3  CD28 expression on CD27/CD45RA defined CD4+ and CD8+ T cell 
subsets 
To account for discrepancies in the inhibitory receptor expression data on different T 
cell subpopulations using CD27/CD45RA versus CD27/CD28 markers, it was 
attempted to define the degree of overlap between the subsets identified using these 
two sets of markers. This was achieved by characterising CD28 expression on CD8+ 
and CD4+ T cell subpopulations, as defined by CD27/CD45RA expression. CD28 is 
expressed on approximately half of all CD8+ T cells with expression being greatest on 
central memory T cells followed by naïve with low levels on effector memory 
CD45RA re-expressing memory T cells, (Fig 3.18A, representative example; Fig 
3.18C, pooled data). In contrast, CD4+ T cells exhibit very high levels of CD28 
expression with near universal expression on naïve and central memory cells. A slight 
reduction was observed in effector memory cells and low levels were only found on 
the CD45RA-revertant memory subset, (Fig 3.18B, representative example; Fig 
3.18D, pooled data). 
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Figure 3.18. The expression of CD28 at different T cell differentiation stages.
PBMCs were stained with anti- CD27-FITC, CD28-PE, CD8-PerCP, CD45RA-APC and
CD4-PE-Cy7. (A) Representative histograms for one donor are shown with the mean
expression of CD28 indicated for each of the CD8+ or (B) CD4+ T cell subsets as defined by
CD27/CD45RA. (B) Scatter graphs showing the expression of CD28 on each CD8+ and (C)
CD4+ T cell subset for all donors (CD8+, n=5; CD4+ n=8). Horizontal bars represent mean
values. P values generated using a Mann-Whitney U test. Significant differences between
subsets displayed.
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3.8 Determination of the Functional Significance of Inhibitory 
Receptors in T cell Ageing 
 
To define whether these observed inhibitory receptor expression changes are 
causative of age onset immune decline, the inhibitory receptor signalling pathway was 
interrupted by antibody blockade to determine whether age-associated immune 
cellular dysfunction could be reversed. PD-1 and KLRG1 were blocked using 
antibodies specific for their major ligands PD-L1 & PD-L2 and E-cadherin, 
respectively, whereas CTLA-4 was blocked directly using CTLA-4 blocking 
antibodies. Functional exhaustion comprises a spectrum of defects with proliferative 
impairment being a key feature, occurring when other functions are intact, and 
becoming increasingly impaired across the exhaustion gradient (Freeman et al., 2006) 
and furthermore, maintenance of high proliferative potential amongst chronic virus 
specific CD8+ T cells is associated with robust protective immunity (Migueles et al., 
2002). Therefore proliferation was used as a functional readout to monitor reversed 
immune dysfunction.  
 
3.8.1  Inhibitory Receptor Blockade Significantly Augments the CD8+ T 
cell Proliferative Responses of Young Donors 
To measure the effects of inhibitory receptor blockade on proliferation, MACS 
purified CD8+ or CD4+ T cells from young and old individuals were stimulated for 3 
days with anti-CD3 in the presence of irradiated autologous APCs, which functioned 
as a source of costimulatory molecules. Either an inhibitory receptor blockade or its 
relevant isotype control antibody was added to the purified cells and [3H]-thymidine 
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incorporation was measured over the last 18hours (Fig 3.19). A representative 
example of the purity of CD8+ T cells obtained from MACS separation is displayed in 
figure 3.20. CTLA-4, PD-1 and KLRG1 blockade induced significant increases in 
proliferation compared to relevant isotype controls in CD8+ T cells of the young (Fig 
3.21A, representative example; Fig 3.21B left panel) and old donors (Fig 3.21B right 
panel). However, although blocking inhibitory receptors could augment the 
proliferative responses of CD4+ T cells this was of diminished significance compared 
with that observed for CD8+ T cells (Fig 3.22A, representative example; Fig 3.22B, 
cumulative data).  
 
These data show that blocking inhibitory receptors significantly increased cellular 
proliferation in response to anti-CD3 stimulus. However, the proliferative increases 
observed for CD8+ T cells were smaller in older individuals (Fig 3.21, CD8+ 0.8-9.7 
fold increase; Fig 3.22, CD4+ 0.7-2.2) compared with the young (Fig 3.21, CD8+ 1.0-
2.9; Fig 3.22, CD4+ 0.7-1.4). This would suggest that the proliferative hypo-
responsiveness of CD8+ T cells from old individuals to antigenic stimuli cannot be 
completely explained by the age related increase in inhibitory receptor expression on 
CD8+ T cells. No additive or synergistic effects were observed following 
simultaneous blockade of multiple inhibitory receptors on either CD4+ or CD8+ T 
cells proliferation. However, what is strikingly apparent from these data is that there 
is a large degree of heterogeneity in the CD8+ T cell proliferative response of different 
individuals to inhibitory receptor blockade, consistent with the heterogeneous 
proliferative responses to cognate antigen observed following blocking of PD-1  and 
CTLA-4 (Kaufmann et al., 2007). 
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Figure 3.19 Schematic illustrating the experimental procedure for detecting the 
effect of inhibitory receptor blockade on anti -CD3 induced CD4+ and CD8+ T cell 
proliferation. 
Blood 
Fresh PBMCs
CD4+ OR CD8+ cells CD4- OR CD8- cells 
PBMC isolation
MACS positive separation 
40Gy irradiation
Irradiated APCs 
Mixed in 1:1 ratio
In plate coated with ?CD3
with inhibitory receptor blocking Ab
or relevant isotype control Ab
[3H]-thymidine added 
56 hr incubation
18hr incubation
[3H-thymidine incorporation measured
using a cell harvester
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Figure 3.20 Purity of cells obtained from MACS positive separation.
CD8+ T cells, separated from PBMCs using MACS positive isolation kit, were stained with
anti-CD8-PerCP. Representative histograms illustrating the proportion of lymphocytes that
are CD8+ (A) before and (B) after MACS positive separation
A BPBMCs After Positive CD8+
MACS separation
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Figure 3.21. Effects of inhibitory receptor blockade on CD8+ T cell proliferation in
young and ld individuals.
CD8+ T cells, isolated from the PBMCs of young (<35yrs, n = 9) and (>65 years, n = 9) old
donors using MACS sorting, were stimulated for 72 hours with anti-CD3 and autologous
irradiated APCs in the presence of anti-CTLA-4, PD-L1/2 and E-cadherin blocking antibody or
the relevant isotype control. Cellular proliferation was measured by thymidine incorporation
over the last 18hours. (A) Representative example changes in thymidine incorporation values
following inhibitory receptor blockade versus the relevant isotype control of the CD8+ T cells of
a (left panel) young and (right panel) old person. (B) Pooled data comparing proliferation of
CD8+ T cells from (left panel) young and (right panel) old individuals following inhibitory
receptor antibody blockade. Proliferation index was calculated by determining the ratio
between cells proliferating in the presence of anti-CD3 stimulation versus inhibitory receptor
blockade. The P values were calculated using a Mann-Whitney U test. Significant differences
between inhibitory receptor blocks and their isotype controls are displayed.
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Figure 3.22. Effects of inhibitory receptor blockade on CD4+ T cell proliferation in
young and old individuals
MACS separated CD4+ T cells were stimulated with anti-CD3 and autologous irradiated
APCs for 72 hours in the presence of inhibitory receptor blocking antibodies or the relevant
isotype control and the amount of thymidine incorporated over the final 18 hours was taken
as a measure of CD4+ T cell proliferation. (A) Bar chart illustrating changes in thymidine
incorporation following inhibitory receptor blockades versus the isotype controls in a
representative (left panel) young and (right panel) old donor. (B) Cumulative data
comparing the effects of blocking inhibitory receptors compared with their relevant isotype
controls on the proliferation of CD4+ T cells from (left panel) young and (right panel) old
donors. Horizontal bars depict mean values. Proliferation index was calculated by
determining he ratio between cells proliferating to anti-CD3 stimulation with inhibitor
receptor blockade in comparison with the addition of their relevant isotype control. The P
values were calculated using a Mann-Whitney U test. Significant differences between
inhibitory receptor blocks and their isotype controls are displayed.
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3.8.2  The proliferative deficit of highly differentiated CD8+ T cells can be 
significantly reversed upon blocking KLRG1 interactions with its 
ligand 
The functional relevance of inhibitory receptor expression at different T cell 
differentiation stages was then investigated by performing inhibitory receptor 
blocking experiments as described above but using purified CD8+ T cell subsets rather 
than whole CD8+ T cells. Blocking PD-L, CTLA-4 and E-cadherin significantly 
augmented the proliferative responses of early and intermediate differentiated CD8+ T 
cell subsets (Fig 3.23 B-D). However, only E-cadherin blockade was able to 
significantly increase the proliferation of highly differentiated CD8+ T cells (Fig 
3.23A, representative example; Fig 3.23D, pooled data).  
 
 158 
 
 
α  IgG2a α  CTLA-4 α  IgG2a α  CTLA-4 α  IgG2a α CTLA-4
0
1
2
3
4
CD28+CD27+      CD28-CD27+   CD28-CD27-
P < 0.05P < 0.01
Pr
o
lif
e
ra
tio
n
 
In
de
x
CTLA-4
α IgG1 α  E-cad α IgG1 α  E-cad α IgG1 α  E-cad
0
1
2
3
4
CD28+CD27+      CD28-CD27+   CD28-CD27-
P < 0.05 P < 0.05P < 0.01
KLRG1
Pr
o
lif
e
ra
tio
n
 
In
de
x
Figure 3.23. Effects of inhibitory receptor blockade on proliferative responses of
CD8+ T cells at different stages of their differentiation.
MACS separated CD8+ T cells subsets, identified on the basis of their CD27/CD28
expression (detailed in figure 3.02), from 5 young donors were stimulated with anti-CD3
for 72 hours in the presence of autologous irradiated APCs and either inhibitory receptor
blocking antibody or their relevant isotype control. Thymidine incorporation over the last
18 hours was taken as a measure of CD8+ T cell subset proliferation. (A) Representative
bar chart illustrating proliferative responses of CD8+ CD27/CD28 subsets in response to
E-cadherin blockade as compared to isotype control or stimulation alone. (B) Pooled data
comparing the effects of anti-PD-L (C) anti-CTLA-4 and (D) anti- E-cadherin blocking
antibodies on different CD8+ T cell subsets, as defined by CD27/CD28 expression.
Horizontal bas represent mean values. Proliferation index was calculated by determining
the ratio between cells proliferating to anti-CD3 stimulation with inhibitor receptor blockade
in comparison with the addition of their relevant isotype control. The P values were
calculated using a Mann-Whitney U test. Significant differences between inhibitory
receptor blocks and their isotype controls are displayed.
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The finding that KLRG1 mediated signalling contributes to the attenuated 
proliferative responses of highly differentiated CD8+ T cells was further extended by 
other members of the Akbar group who elucidated the precise role of this molecule in 
mediating other dysfunctions of this CD8+ T cell population (Table 3.01). As well as 
reduced proliferative capacity, these cells have several characteristic defects including 
defective Akt phosphorylation at Ser473 (Plunkett et al., 2007), which could be 
augmented upon blocking KLRG1/E-cadherin interactions (Henson et al., 2009). 
However, their characteristic impaired telomerase induction (see Chapter 5) and IL-2 
synthesis capacity were not reversible upon E-cadherin blockade (Henson et al., 2009). 
Extending these studies to aged donors revealed that although blocking E-cadherin 
could still significantly reverse the defective Akt phosphorylation of their highly 
differentiated CD8+ T cells, this was accompanied by a proliferative increase of much 
reduced magnitude compared to that observed in the young. This suggests that other 
age related defects contribute towards the characteristic dysfunctional proliferative 
responses of highly differentiated CD8+ T cells in old subjects.   
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Table 3.01 Functional roles for KLRG1 in highly differentiated human CD8+ T cells.
Summary of data generated by the Akbar group, illustrating key features of highly
differentiated CD8+ T cells and which of these can be at least partially reversed upon
blocking interactions of KLRG1 with its ligand E-cadherin
KLRG1 signaling induces defective Akt (Ser473) phosphorylation and proliferative dysfunction of
highly differentiated CD8+ T cells. Henson,S.M.; Franzese,O.; Macaulay,R.; Libri,V.;
Azevedo,R.I.; Kiani-Alikhan,S.; Plunkett,F.J.; Masters,J.E.; Jackson,S.; Griffiths,S.; Pircher,H.P.;
Soares,M.V.; Akbar,A.N. Blood. 2009 Apr 30.
Features of highly 
differentiated CD8+ T cells
Reversible upon E-
cadherin blockade?
Reduced proliferative 
capacity
Poor capacity for IL-2 
synthesis
Defective Akt synthesis after 
activation
Reduced telomerase activity
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3.9  Discussion 
 
This chapter addresses the potential role of immune inhibitory receptors in age onset 
immune decline. Data presented here demonstrate that the immune inhibitory 
receptors CTLA-4, PD-1 and KLRG1 can be upregulated by both CMV and age in 
total CD4+ and CD8+ T cells and also at different stages of their differentiation. 
Antibody blocking studies reveal that although none of these receptors directly 
mediates the general CD8+ T cell hypo-responsiveness seen during ageing, KLRG1 
signalling contributes towards the characteristic dysfunctional proliferative responses 
and Akt phosphorylation of highly differentiated CD8+ T cells in younger subjects.  
 
These results confirm previous reports that CMV infection can be associated with 
global changes to the hosts peripheral T lymphoid pool, where CMV is said to leave a 
fingerprint of infection (van de Berg et al., 2008), being associated with lymphocyte 
phenotype alterations very similar to those published as age-associated (Weinberger et 
al., 2007). Similarly, rapid alterations are observed following primary infection of 
renal transplant recipients with CMV, which is suggestive of CMV playing a 
causative role in these changes (van de Berg et al., 2008; van de Berg et al., 2010), 
that have been estimated to accelerate the physiological decline by 35 to 40 years 
(Chidrawar et al., 2009; Northfield et al., 2005). An inverted CD4:CD8 ratio is an 
important component of the IRP, which results from the increased prevalence of 
CD27-CD28-CD8+ T cells, whose numbers are augmented in those infected with 
CMV (Pawelec and Derhovanessian, 2010). Indeed, CMV infection has been 
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suggested to influence all parameters of the IRP with the possible exception of low B 
cell numbers (Derhovanessian et al., 2010). 
 
The striking features of this data, in how ageing affects CD4+ and CD8+ T cell 
compartments differently, is reflected in CD4+ T cells being more resistant to CMV 
and age-associated phenotypic changes than CD8+ T cells, concurrent with studies in 
aged humans (Weinberger et al., 2007; Czesnikiewicz-Guzik et al., 2008; Kovaiou et 
al., 2005; Koch et al., 2007) and CMV infected humans (Weinberger et al., 2007; 
Northfield et al., 2005; Pourgheysari et al., 2007; Almanzar et al., 2005; Looney et al., 
1999; Gratama et al., 1987). This may reflect the more clonal nature of CD8+ T cell 
responses (Maini et al., 1999), in that following antigenic challenges, CD8+ T cells 
exhibit more rapid expansion kinetics, producing larger numbers of responding 
effector cells and memory cells (Beverley, 2008). Additionally, this difference may 
also be accounted for by their different lifespans (Aw et al., 2007), apoptotic 
sensitivities (Pawelec et al., 2002), gene expression instabilities (Czesnikiewicz-
Guzik et al., 2008) or thymic selection biases (Czesnikiewicz-Guzik et al., 2008).  
 
T cell inhibitory receptor expression characterisation with respect to age revealed that 
only CTLA-4 and KLRG1 on CD8+ T cells underwent significant expression 
increases with age, consistent with previous reports (Thimme et al., 2005; 
Czesnikiewicz-Guzik et al., 2008; Fann et al., 2005; Ouyang et al., 2003a). The 
observation that CTLA-4 shows no age related upregulation on CD4+ T cells contrasts 
with a previous report by Leng et al. (Leng et al., 2002a). However, this group did not 
stratify their data on the basis of CMV status, whereas data presented here shows 
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CTLA-4 upregulation on CMV positive donors. Therefore, the increased CTLA-4 
expression observed by Leng et al may be a consequence of age-associated increases 
in CMV prevalence (Stowe et al., 2007; McVoy and Adler, 1989; Looney et al., 1999; 
Dowd et al., 2009).  
 
This lack of any large age-associated inhibitory receptor changes amongst CD4+ T 
cell subsets, correlates with the lack of functional impairment observed in CD4+ T cell 
subsets of old versus young donors (Kovaiou et al., 2005), suggesting that age-
associated changes in the function of the CD4+ T cell compartment may primarily be 
a consequence of quantitative alterations in CD4+ subsets to more differentiated cells.  
 
Data presented here reveal that CMV+ individuals express significantly higher levels 
of PD-1, CTLA-4 and KLRG1 on their CD4+ and CD8+ T cells, consistent with the 
well documented role of CMV infection in inducing dramatic phenotypic changes to 
the total T cell pool, in otherwise healthy individuals (as described earlier). These 
changes may reflect a combination of CMV associated immune activation, T cell 
differentiation and alterations to the host cytokine profile. 
 
Amongst CD8+ T cells, CTLA-4 expression peaks in naïve and central memory stages 
of differentiation, PD-1 is maximal amongst central and effector memory and KLRG1 
peaks in the CD45RA-revertant memory differentiation stages. An alternate profile 
emerges within the CD4+ T cell compartment, with PD-1 and KLRG1 expression 
peaking on highly differentiated and CTLA-4 maximal at intermediate differentiation 
stages. These data are consistent with intracellular CTLA-4 stores being present in 
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memory T cells, enabling a greater and more rapid induction of expression compared 
with naïve cells, who have no such stores and synthesise CTLA-4 de novo (Jago et al., 
2004). Moreover, PD-1 and KLRG1 expression have previously been demonstrated to 
peak on intermediate (Sauce et al., 2007a; Petrovas et al., 2006) and highly 
differentiated (Voehringer et al., 2002; Thimme et al., 2005; Henson et al., 2009) 
CD8+ T cells, respectively. This gives rise to the novel idea that as CD4+ and CD8+ T 
cells differentiate they utilise different inhibitory receptors, which may make distinct 
contributions to the function of different T cell subsets. Furthermore, T cells specific 
for different chronic viruses occupy distinct differentiation stages (van Leeuwen et al., 
2006a; Kuijpers et al., 2003), and may thus induce unique sets of inhibitory receptors 
that differentially impair antiviral immunity. This idea may have particular relevance 
in the exploration of inhibitory receptor blocking therapies as immuno-therapeutic 
regimens to augment chronic viral treatments and vaccination strategies. Indeed, 
blocking CTLA-4 and PD-1 have been explored as a strategy to augment vaccine 
responses against tumours and chronic pathogens (Yuan et al., 2011; Curran and 
Allison, 2009; Song et al., 2011; Ha et al., 2008). Moreover, increasing the efficacy of 
vaccinations, particularly influenza, for aged individuals would have an enormous 
impact on their health and well-being.  
 
The age related upregulation of CTLA-4 on CD8+ T cells was shown not to be a 
consequence of differentiation but reflects CTLA-4 upregulation, particularly on 
naïve cells, with age. In contrast, KLRG1 expression experiences a large and dramatic 
increase with differentiation on CD8+ T cells and although age-associated 
upregulation on some subsets are observed, these are comparatively small in 
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magnitude, suggesting that KLRG1 expression upregulation with age on CD8+ T cells 
is primarily a consequence of the increased prevalence of increasingly differentiated 
cells.  
 
Following simultaneous TCR engagement, CTLA-4, PD-1 and KLRG1 all oppose 
TCR/CD28 mediated signalling and may thus contribute to setting a threshold for 
stimulation. Indeed, PD-1 and CTLA-4 appear to be most effective at inhibiting 
responses to suboptimal stimuli, such as self-antigens, whereas potent responses 
against microbial antigens are relatively unaffected (Abbas and Sharpe, 2005). 
Therefore, their increased expression may contribute towards the characteristic T cell 
hypo-responsiveness of aged individuals. The functional significance of inhibitory 
receptor upregulation is highlighted by the pathogenesis of HIV which, rather than 
being a consequence of direct viral cytopathic effects, has been suggested to reflect 
chronic immune activation (Appay et al., 2005), mediated in part through inhibitory 
receptor upregulation (Leng et al., 2002b).  
 
However, inhibitory receptor blockade on CD8+ T cells from old donors failed to 
augment their proliferative responses to a polyclonal T cell stimulus, to a level 
equivalent to those observed in young, which concurs with a recent report in mice 
(Lages et al., 2010). Moreover, highly differentiated CD27-CD28-CD8+ T cells 
display defective proliferative responses and telomerase induction, possess short 
telomeres and are said to be close to replicative senescence (Plunkett et al., 2007). 
They also express high levels of KLRG1 and blocking interactions with its ligand 
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reversed these characteristic dysfunctions in proliferation and Akt phosphorylation, 
representing the first demonstration of a functional role of KLRG1 in primary human 
CD8+ T cells (Henson et al., 2009). However, KLRG1 blockade in aged individuals 
resulted in a proliferative enhancement of these highly differentiated CD8+ T cells of 
reduced magnitude compared with young individuals. These data suggest the 
proliferative hypo-responsiveness of aged CD8+ T cells involve additional 
mechanisms independent of CTLA-4, PD-1 and KLRG1 signalling. 
 
The inability of inhibitory receptor blockade to reinvigorate the general CD8+ T cell 
hypo-responsiveness of aged individuals combined with the findings that expression 
of CTLA-4, PD-1 and KLRG1 on CD8+ and CD4+ T cells is more consistently 
correlated with CMV status than ageing. This leads to the idea that inhibitory 
receptors may play a role in immunosenescence by contributing to the dysregulation 
of CMV specific immune responses, which constitute a major force driving T cell 
immunosenescence (as discussed in section 1.3.2.2). This hypothesis is investigated in 
the next chapter. 
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4  Role of inhibitory receptors in mediating the dysregulated T cell 
response to CMV 
 
4.1  Introduction 
 
Replicative senescence is not just associated with old age but can be observed in 
relatively young individuals who have been subjected to a high antigenic load (as 
described in section 1.3.2). In particular, the ubiquitous and relatively innocuous 
herpesvirus CMV appears to act as the dominant chronic stressor (as described in 
section 1.4). Indeed, the magnitude of the immune response directed against CMV 
undergoes a progressive age related expansion and the increasing amount of immune 
resources dedicated to controlling CMV with advancing age may be a major 
contributor to age onset immuno-decline (as described in section 1.4.3.3.2). This so-
called ‘memory inflation’ is especially prominent in the CD8+ T cell compartment, 
which accumulates large dysfunctional CMV epitope-specific T cell expansions, often 
comprised of a small number of clones that have undergone extensive antigen driven 
proliferation (Shin et al., 2007). Indeed, it has been suggested that lifelong persistent 
CMV reactivation may drive clonal exhaustion of the most efficient and specific T 
cells so that an increased number of suboptimal cells are required to control virus 
infection (Akbar and Fletcher, 2005). Therefore, reinvigorating CMV specific CD8+ T 
cell functions could allow better control of CMV infection and thus impair memory 
inflation and the development of immunosenescence. Indeed, mathematical models 
have demonstrated that decreasing antigenic burden leads to a considerable increase 
in the resistance to immunosenescence (Romanyukha and Yashin, 2003). This has 
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been supported by two studies illustrating that the treatment of an Ethiopian 
population for intestinal parasites (Kassu et al., 2003) and migration of Ethiopians to 
Israel (Kalinkovich et al., 1998), an environment with a comparatively low antigenic 
burden, is associated with a reversal of immune parameters to that of much younger 
individuals. In this chapter the role of inhibitory receptors in mediating these CMV 
specific CD8+ T cell dysfunctions is investigated. 
 
4.2  Characterisation of CMV specific CD8+ T cells 
 
4.2.1 Determination of donor CMV status 
Purified PBMCs were either left unstimulated, as a negative control (Fig 4.01A), 
stimulated with superantigen SEB, as a positive control, (Fig 4.01B) or stimulated 
with CMV lysate. The CD4+ T cells of donors who were identified as CMV 
seropositive significantly induced IFNγ production (Fig 4.01C), whereas CMV 
seronegative donors failed to secrete IFNγ (Fig 4.01D). 
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Figure 4.01 Characterisation of donors CMV status.
Purified PBMCs from donors were (A) left unstimulated, as a negative control, (B) stimulated with
the superantigen SEB as a positive control, or (C,D) stimulated with CMV lysate for 18hours.
Following a 6 hour Brefaldin A incubation, they were then stained with CD4 PerCP and
intracellularly with IFNγ-APC. (C) Donors whose CD4+ T cells upregulated significant amounts of
intracellular IFNγ were deemed CMV positive (D) and those who did not were labelled CMV
negative
IFNγ
U/S SEB
IFNγ
CMV lysate
IFNγ
Negative control Positive control
CMV positive donor CMV negative donor
CMV lysate
IFNγ
A B
C D
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4.2.2 Elucidation of CMV specific CD8+ T cells 
HLA-A2 and HLA-B7 antibodies and their isotype controls were used to stain 
PBMCs and determine a donor’s A2/B7 status (Fig 4.02A, isotype control; Fig 4.02B, 
representative example of HLA-B7+A2- donor). The CD8+ T cell response is highly 
focussed on a small number of epitopes, most frequently against peptides derived 
from the pp65 protein (Wills et al., 1996). Therefore, we used HLA-A2 and HLA-B7 
restricted pp65 specific pentamers to identify CMV specific CD8+ T cells. HLA-A2+ 
or -B7+ donors were then stained with NLV or TPR pentamers, respectively, plus an 
irrelevant control pentamer, to determine if a suitable CMV specific CD8+ T cell 
population was present (Fig 4.02C, irrelevant pentamer; Fig 4.02D, representative 
TPR staining of a TPR+ donor).  
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HLA-B7 FITCFITC
HLA-A2/B7 ScreenIsotype control
Figure 4.02 Identification of donors with pentamer positive cell populations.
Purified PBMCs were stained with HLA-A2-PE, HLA-B7-FITC or the relevant isotypes and CD8-
PerCP. (A) Gated on CD8+ T cells, isotype control staining and (B) HLA- A2 and -B7 staining of a
HLA-A2-B7+ donor is displayed. HLA-B7+ or HLA-A2+B7- donors were then stained with TPR or NLV
pentamer, respectively to identify CMV specific CD8+ T cells. (C) Gated on live lymphocytes, a HLA-
B7+TPR+ donor PBMCs stained with an irrelevant peptide-pentamer (NLV) or (D) TPR peptide-
pentamer.
TPR pentamerIrrelevant pentamer
NLV TPR
A B
C D
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4.2.3 Phenotypic definition of pp65CMV specific CD8+ T cells 
Utilising the CD27/CD45RA phenotypic markers (as described in Fig 3.01) it was 
determined that CMV specific CD8+ T cells are significantly more differentiated than 
the pentamer negative CD8+ pool from the same young donors containing 
significantly fewer naïve cells alongside a concomitant increase in effector memory 
cells (Fig 4.03A, representative example; Fig 4.03B, grouped data) and also from a 
single representative old donor (Fig 4.03C). Moreover, the frequency of these pp65 
epitope specific CD8+ T cells increased with ageing (data not shown; r2 = 0.55, P < 
0.01). 
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Figure 4.03 Characterisation of CMV specific CD8+ T cell phenotype.
(A). A representative example of a young donor whose PBMCs had been stained with anti-
CD8-PerCP, anti-CD27-FITC, anti-CD45RA-APC and the relevant HLA-A2 or HLA-B7
restricted CMV specific pentamer. The CD8+ cells were gated on (left panel) pentamer- or
(right panel) pentamer+ (for CMV specific) cells and their phenotype assessed using CD27
and CD45RA markers with the percentage of cells present in each quadrant displayed. (B)
Pooled data showing CD45RA and CD27 expression on the pentamer negative CD8+ pool
and on virus specific CD8+ T cells on 7 young donors. Horizontal lines depict mean values.
P values calculated using a Wilcoxon signed rank test, only significant differences between
CMV specific CD8s and their pentamer negative counterparts indicated. (C)
Representative dot plots showing CD45RA and CD27 expression on the CMV specific and
pentamer negative CD8+ T cells from an old individual (aged 91).
A
B
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4.2.4 Inhibitory receptor expression on CMV specific CD8+ T cells 
Inhibitory receptor expression was characterised on CMV specific CD8+ T cells, 
identified as described above. CTLA-4 expression was observed at low levels on 
CMV specific cells in both young and old individuals; approximately half of all CMV 
specific cells expressed PD-1; KLRG1 expression was observed at high levels on 
CMV specific cells and was further upregulated on CMV specific cells of old versus 
young donors (Fig 4.04).  
Figure 4.04. Comparison of CTLA-4, PD-1 and KLRG1 levels on CMV specific CD8+ T cells in the old
and young.
Peripheral blood from young and old donors was stained with APC labelled HLA-A2 and HLA-B7
restricted pentamers plus anti- CD8-PerCP and either PD-1-PE, CTLA-4-PE or KLRG1-PE antibodies.
Graph illustrates the percentage of CMV specific cells from young, Y, <35 years, and old, O, >65,
donors, that express CTLA-4, PD-1 and KLRG1. Horizontal bars depict mean vales. Statistical
differences calculated using a Man-Whitney U test and only significant differences between young
and old donors for a given inhibitor receptor are displayed.
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4.3  Determining the contribution of inhibitory receptor signalling to 
CMV specific CD8+ T cell proliferative dysfunction  
 
The contribution of inhibitory receptor expression towards the dysfunction of CMV 
specific CD8+ T cells was investigated using antibody blocking studies. This first 
required the identification of CMV+ donors who possessed the HLA alleles B7 or A2 
together with a sufficiently large population of CMV specific CD8+ T cells (Fig 4.05). 
The proliferative responses of CMV specific CD8+ T cells were determined using the 
proliferative marker Ki67, a nuclear antigen strictly associated with cellular 
proliferation (Scholzen and Gerdes, 2000). Ki67 was expressed at low levels directly 
ex vivo by bulk CD8+& CD4+ T cells (Fig 4.06) and CMV specific CD8+ T cells (Fig 
4.07). Moreover, Ki67 was expressed at low levels throughout all CD8+ and CD4+ T 
cell differentiation stages, being most highly expressed on central and effector 
memory populations of CD8+ T cells and reaching maximal levels on effector 
memory CD4+ T cells (Fig 4.08) 
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Figure 4.05 Schematic for identification of suitable donors for the experiment to
investigate the effects of inhibitory receptor blockade on CMV specific CD8+ T cells.
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Figure 4.06. Ex vivo Ki67 expression on CD8+ and CD4+ T cells.
Purified fresh PBMCs were stained with anti- CD8-PerCP or CD4-PerCP and intranuclearly with
KI67-FITC. (A) Representative density dot plots gated on live lymphocyte populations illustrating
CD8+ T cells and (B) CD4+ T cells from the same donor and their expression of (right panels) Ki67 or
(left panels) its isotype control antibody. (C) Pooled data from 4 donors illustrating the proportion
of CD8+ and CD4+ T cells that stained positively for Ki67 expression. Horizontal bars indicate mean
values. A Mann-Whitney U test was used to generate P values but no significant difference was
generated.
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Figure 4.07. Ex vivo Ki67 expression on CMV specific CD8+ T cells.
Purified fresh peripheral blood cells were stained with anti- CD8-PerCP and NLV or TPR specific PE
labelled pentamers plus anti-Ki67-FITC intranuclearly (A) Representative FACS plots gated on live
lymphocytes illustrating the identification of CMV specific CD8+ T cells and (B) their expression of
(right panels) Ki67 or (left panels) its isotype control with the proportion of CMV specific and
pentamer negative cells expressing Ki67 indicated. (C) Pooled data illustrating the proportion of
CMV specific and pentamer negative CD8+ T cells that stained positively for Ki67 expression. The
black dots represent TPR+ donors and the red dots indicate NLV+ donors. Horizontal bars indicate
mean values. P values generated using a Mann-Whitney U test. Only significant differences are
displayed.
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Figure 4.08. Ki67 expression on CD8+ and CD4+ T cells ex vivo vary with stage of differentiation. 
Freshly isolated PBMCs were stained with anti- CD8-PerCP or CD4-PerCP, CD27-PE, CD45RA and
intranuclearly with anti-Ki67-FITC and analysed by flow cytometry. (A) Representative dot plots
illustrating the proportion of CD8+ and (B) CD4+ T cell subsets, identified using CD27 and CD45RA
markers, as described earlier, that express Ki67. (C) Pooled data of 4 donors illustrating the
proportion of CD8+ and (D) CD4+ T cells and their subsets that stained positively for Ki67
expression. Horizontal bars illustrate mean values. P values calculated using a Mann Whitney U
test. Significant differences in Ki67 expression between different subsets are indicated.
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4.3.1 PD-1/L blockade reverses the proliferative defect of CMV specific 
CD8+ T cells 
Fresh PBMCs, from donors with a suitable population of CMV specific CD8+ T cells, 
were stimulated for 3 days with CMV peptide, and the effect of inhibitory receptor 
blockade on the size of the CMV response and their proliferative capacity was 
determined, as measured by the expression of Ki67 (Fig 4.09). The pp65CMV peptide 
was titrated to find the concentration that would be sufficiently high to induce an 
adequate proliferative response, as measured by Ki67 expression of pentamer+ CD8+ 
T cells, (Fig 4.10C), but not be so high that it would be toxic to the pentamer+ CD8+ T 
cells, as determined by the size of the pentamer response (Fig 4.10B). Thus, 0.2µg/ml 
was determined appropriate. Of the inhibitory blocks tested, only PD-L1/2 blockade 
produced significant increases in the proliferative responses of CMV specific CD8+ T 
cells, compared to its relevant isotype control (Fig 4.11), which was similarly 
observed in young and old donors (Fig 4.12A,B). This increased proliferative 
response was accompanied by a significant increase in the size of the CMV specific 
CD8+ T cell response (Fig 4.13). The simultaneous blockade of PD-L, CTLA-4 and 
E-cadherin failed to show any synergistic or additional effects on either the 
proliferation (Fig 4.14) or the magnitude (data not shown) of CMV specific CD8+ T 
cell response of a young and an old donor. Moreover, in the absence of any 
pp65CMV peptide stimulus, blocking PD-L for 3 days did not upregulate the size (Fig 
4.15, left panels) or proliferation (Fig 4.15, right panels) of the CMV specific CD8+ T 
cell response. 
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Fresh PBMCs
PBMC isolation
Inhibitory receptor blocking antibody 
or relevant isotype control  added 
Incubated 30mins at 37oC
Relevant CMV peptide  added
3 day incubation
Flow cytometry
NLV/TPR+ cells = CMV specific CD8+ cell
Ki67+ cells = Proliferating cells
Figure 4.09 Schematic for the experiment to determine the effects of inhibitory receptor
blockade on CMV specific CD8+ T cell size and function
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Figure 4.10 pp65 CMV peptide titration for optimal CMV specific CD8+ T cell proliferation.
Freshly isolated PBMCs were stimulated for 3 days with different concentrations of NLV peptide
and then stained with anti- CD8-PerCP, NLV-PE and intranuclearly with anti- Ki67-FITC and then
analysed using flow cytometry. (A) FACS plots of the frequency of (upper panels, red dots) CMV
specific CD8+ T cells and (lower panels, blue dots) their Ki67 expression after 3 day incubation with
different concentrations of CMV peptide. (B) Cumulative data illustrating the effects of stimulating
PBMCs with different concentration of NLV peptide on the proportion of CD8+ T cells that are NLV+
and (C) on the percentage of these NLV+ cells that express Ki67.
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Figure 4.11 Blocking PD-1/PD-L interactions significantly enhanced CMV specific CD8+ T cell
proliferative responses, whereas no such effect was observed by blocking CTLA-4 or KLRG1
interactions with their ligands
0.2μg/ml NLV or TPR CMV peptide was added to freshly purified PBMCs for 3 days in the presence
of αCTLA-4, αPD-L1/2 or αE-cadherin blocking antibody or their relevant isotype controls, as
described in Fig 4.10. The cells were then stained with CD8-PerCP, NLV or TPR-PE pentamer and
intranuclearly with Ki67-FITC. (A) Representative FACS plots, gated on TPR+ or NLV+ CD8+ T cells, of
the proportion of peptide stimulated CMV specific CD8+ T cells that are Ki67+ following blockade of
different inhibitory receptors. (B) Pooled data of the effects of inhibitory receptor blockade,
compared with their relevant isotype control antibody, on the proliferation of NLV or TPR specific
cells. The red dots indicate NLV+ donors and the black dots represent TPR+ donors. Horizontal lines
depict mean values. The P values were calculated using a paired Student’s t-test. Significant
differences between the inhibitory receptor block and their relevant isotype controls are shown.
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Figure 4.12 Comparing the effects of blocking inhibitory receptors on the proliferative responses
of CMV specific CD8+ T cells in the old and young.
PBMCs from young/middle (<55 years, n =8) or old (>65 years, n= 3) individuals were incubated
with 0.2μg/ml NLV or TPR peptide for 3 days in the presence of CTLA-4, PD-L or E-cadherin blocking
antibody or their relevant isotype control. The cells were then stained with NLV or TPR-PE, CD8-
PerCP and intranuclearly with Ki67-FITC. (A) Pooled data displaying the proportion of NLV and TPR
specific cells expressing Ki67 from young/middle and (B) old donors following CMV peptide
stimulation in the presence of different inhibitory receptor blockades The red dots indicate NLV+
donors and the black dots represent TPR+ donors. Horizontal lines depict mean values. The P values
were calculated using Student’s paired t-test and only significant differences between the
inhibitory receptor block and their relevant isotype controls are shown.
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Figure 4.13 The effects of blocking inhibitory receptors on the size of the CMV specific CD8+ T cell
response
PBMCs were stimulated and stained as described in the previous figure. (A) Representative FACS
plots gated on live lymphocytes of changes in the proportion of CD8+ T cells that are NLV+ or TPR+
following 3 day CMV peptide stimulation in the presence of CTLA-4, PD-L or E-cadherin blockade
and their relevant isotype controls. The percentage of CD8+ T cells that are TPR+ are indicated. (B)
Cumulative data illustrating effects of inhibitory receptor blockade on the proportion of CD8+ T
cells that are CMV specific. The red dots indicate NLV+ donors and the black dots represent TPR+
donors. Horizontal lines depict mean values. The P values were calculated using a Wilcoxon signed
rank test. Significant differences between the inhibitory receptor block and their relevant isotype
controls are shown.
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Young Old
Figure 4.14 Effects of concurrently blocking PD-L, CTLA-4 and E-cadherin on CMV specific CD8+ T
cells proliferative responses
Freshly isolated PBMCs were subjected to a 3 day TPR peptide stimulation in the presence of
either PD-L, E-cadherin and CTLA-4 blocking antibodies together, PD-L blockade alone or the
relevant isotype controls. The cells were then stained with TPR-PE pentamer, anti- CD8-PerCP and
intranuclearly with anti-Ki67-FITC and analysed by flow cytometry. (A) Representative dot plots
gated on TPR+ CD8+ T cells showing alterations in the percentage of CMV specific CD8+ T cells
expressing Ki67 following a 3 day CMV peptide stimulus in the presence of PD-L, CTLA-4 and E-
cadherin together, PD-L blockade alone or the relevant isotype control, in a young and (B) an old
individual.
A B
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Figure 4.15 The effects of blocking PD-L on CMV specific CD8+ T cells in the absence of any 
stimulus 
Fresh purified PBMCs were incubated with or without PD-L blockade for 3 days. The cells were
then stained with anti-CD8-PerCP, TPR-PE and intra-nuclearly with either anti-Ki67-FITC or its
isotype control-FITC and analysed by flow cytometry. (Left panels) Dot plots of changes in the
proportion of CD8+ T cells specific for CMV and (right panels) the expression of Ki67 by these CMV
specific cells either (A) following 3 days PD-L blockade and isotype control staining, or (B) Ki67
staining in the absence or (C) presence of PD-L blockade.
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4.3.2 CMV specific CD45RA-revertant memory CD8+ T cells exhibit 
diminished proliferative responses compared with their central and 
effector memory counterparts, which are largely reversed following 
PD-L blockade 
The effects of PD-L blockade on the proliferative responses of CMV specific CD8+ T 
cells were further explored by stratifying the results using T cell phenotypic markers. 
CMV specific CD45RA-revertant memory CD8+ T cells were found to elicit a lesser 
proliferative response to pp65CMV peptide, compared with their central and effector 
memory counterparts (Fig 4.16). However, following PD-L blockade, the proliferative 
responses of CD45RA-revertant memory CMV specific CD8+ T cells were 
augmented by a significantly greater magnitude than that of its central or effector 
memory counterparts (Fig 4.17). This largely compensated for the deficit observed in 
Fig 4.16. However, Fig.3.10 revealed that 48hrs of TCR stimulation was sufficient to 
induce T cell differentiation. Similarly, phenotype analysis of CMV specific CD8+ T 
cells, following 3 day pp65 stimulation with PD-L blockade, revealed that significant 
phenotypic changes occurred compared to its isotype control. Indeed, reductions in 
the proportion of CMV specific CD8+ T cells that are TN and TCM were observed, 
accompanied by increases in their TEM and TREV counterparts (data not shown). 
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Figure 4.16 CMV specific revertant CD8+ cells elicit a defective proliferative response to CMV
peptide compared to central and effector memory cells.
Freshly isolated PBMCs were subjected to a 3 day NLV or TPR stimulus after which they were
stained with anti- CD8-PerCP, NLV or TPR-PE, CD27 APC, CD45RA-PE-Cy7 and intranuclearly with
anti-Ki67-FITC. CD27/CD45RA phenotypic markers used to identify CD8+ T cell subsets as previously
described. (A) Representative dot plots, gated on NLV+ CD8+ T cells, illustrating Ki67 expression on
peptide stimulated CMV specific CD8+ T cells at different T cell differentiation stages. (B) Pooled
data illustrating the effects of a 3 day CMV peptide stimulus on the Ki67 expression of whole CD8+
T cells and CD8+ T cell subsets. Horizontal bars depict mean values. Red dots represent NLV+ donors
and black dots indicate TPR+ donors. P values assessed using a one tailed Wilcoxon signed rank test.
Significant differences between revertant cells and other subsets are displayed.
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Figure 4.17. Blocking PD-1/PD-L interactions augments the proliferative responses of revertant
CMV specific CD8+ T cell’s by a greater magnitude than that of central or effector memory subsets.
PBMCs were stimulated with 0.2μg/ml TPR or NLV peptide for 3 days in the presence of PD-L block
or IgG2b isotype control. Cells were then stained with anti- CD8-PerCP, TPR or NLV-PE, CD27 APC,
CD45RA-PE-Cy7 and intranuclearly with Ki67-FITC. CD27 and CD45RA phenotypic markers used to
define CD8 subsets as previously described. (A) Representative FACS plots gated on NLV+ CD8+ T cells
of Ki67 staining on peptide stimulated CMV specific CD8+ T cell subsets in the presence of PD-L
blockade compared to IgG2b isotype control. (B) Cumulative data illustrating effects of PD-L
receptor blockade on the fold increase of the proportion of CMV specific CD8+ T cells subsets
expressing Ki67. Red dots indicate NLV+ donors and black dots represent TPR+ donors. Horizontal
bars depict mean values. A Mann-Whitney U test was used to calculate P values. Significant
differences between revertant, central and effector memory subsets are indicated.
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To confirm that the increased proliferative responses of CMV specific CD8+ 
CD45RA-revertant memory T cells following PD-L blockade reflects a true reversal 
of their proliferative deficit, rather than central and effector memory CD8+ T cells 
differentiating to CD45RA-revertant memory CD8+ T cells, the effects of PD-L 
blockade on CMV specific CD8+ T cells was repeated using purified CD27/CD45RA 
subsets. This enabled analysis of the effects of PD-L blockade on the proliferative 
responses of CD45RA-revertant memory CD8+ T cells independent of differentiation 
(Fig 4.18). The purity of CD8+ T cells at different stages of differentiation, obtained 
using FACS Aria cell separation, is depicted in Fig 4.19. This experiment revealed 
that, independent of differentiation, the proliferative responses of CD45RA-revertant 
memory CD8+ CMV specific T cells undergo the strongest upregulation following 
PD-L blockade, compared with its isotype control (Fig 4.20), accompanied by the 
greatest increase in the CMV response size (Fig 4.21). 
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Figure 4.18 Schematic for measuring the effects of PD-L blockade on purified CD27/CD45RA 
subsets in response to a CMV specific stimulus 
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Figure 4.19 Purity of cells obtained from FACS Aria CD8+ T cell subset separation using
CD27/CD45RA markers.
CD8+ cells were isolated from peripheral blood cells using MACS separation. CD8+ cells were
stained with anti-CD27-PE and CD45RA-APC and then purified into 4 subsets using FACS Aria. (A)
Representative FACS plot of CD27 and CD45RA staining on CD8+ T cells before sort. (B)
Representative FACS plots showing the purity of CD27-CD45RA+, (C) CD27+CD45RA+, (D) CD27-
CD45RA- and (E) CD27+CD45RA+ CD8+ T cell subsets obtained after sort with the percentage of cells
occupying each quadrant indicated.
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Figure 4.20 CMV specific proliferative responses in purified revertant cells undergo the strongest
upregulation after blocking PD-1/PD-L interactions
CD8+ T cells subsets from a single donor, were purified, as described in the previous figure, and
stimulated with 0.2μg/ml NLV plus irradiated APCs for 3 days in the presence of PD-L blockade or
its isotype control. Cells were then stained with anti- CD8-PerCP, NLV-PE and intranuclearly with
Ki67-FITC. (A) FACS plots of Ki67 staining on peptide stimulated CMV specific CD8+ T cell from
purified naive, (B) central memory, (C) effector memory and (D) revertant subsets in the presence
of PD-L blockade or their relevant isotype control. The proportion of NLV+ CD8+ T cells that express
Ki67 is indicated on each plot.
A
B
C
D
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Figure 4.21 The effects of blocking PD-L on the size of the CMV specific response, from purified
CD8+ T cell subsets
Fresh PBMCs were stimulated and stained as described in the previous figure (A) FACS plots of NLV
staining on peptide stimulated CMV specific CD8+ T cell from purified naive, (B) central memory,
(C) effector memory and (D) revertant subsets in the presence of PD-L blockade or its relevant
isotype control. The percentage of CD8+ T cells that are NLV+ is indicated on each plot.
A
B
C
D
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4.4 Inhibitory receptor blockade is insufficient to augment the 
proliferative responses of CMV specific CD4+ T cells 
 
CMV specific CD4+ T cells have been documented as having a restricted replicative 
capacity, which becomes increasingly severe with age (Fletcher et al., 2005). We 
therefore examined whether inhibitory receptor blockade could reinvigorate the CD4+ 
CMV specific T cell proliferative response. PBMCs were stimulated with CMV lysate 
for 3 days, which were restimulated after 48 hrs with Brefeldin added over the last 4 
hrs (Fig 4.22), after which time the CMV+ CD4+ T cells were identified as those CD4+ 
T cells being IFNγ+, and their proliferative responses measured using Ki67 staining 
(Fig 4.23). The effect of inhibitory receptor blockade compared with their relevant 
isotype controls on the size and proliferative capacity of the CD4+ CMV specific T 
cell response was determined. None of the inhibitory receptor blockades were able to 
significantly alter either the size (Fig 4.24) or proliferation (Fig 4.25) of the CMV 
specific CD4+ T cell response. 
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Figure 4.22 Schematic for the effects of inhibitory receptor blockade on CMV specific CD4+ T cell
number and proliferation experiment
Blood
Fresh PBMCs
PBMC isolation
Inhibitory receptor blocking antibody 
or relevant isotype control added 
Incubated 30mins at 37oC
CMV lysate added
48hr incubation
Samples restimulated with CMV lysate
24hr incubation
Brefaldin A added
4hr incubation
Flow cytometry
IFNγ+ cells = CMV specific  CD4+ T cells
Ki67+ cells = Proliferating cells
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Figure 4.23. Identification of CMV specific CD4+ T cells and their proliferative responses.
Fresh PBMCs were incubated with CMV lysate for 3 days and re-stimulated on day 2. Cells were
then stained with anti- CD4-PerCP and intranuclearly with anti- IFNγ-APC and Ki67-FITC. (Left
panels) Representative FACS plots gated on live lymphocytes showing the proportion of CD4+ T
cells that produce IFNγ (and were identified as CMV specific) and (right panels) the proportion of
these IFNy cells that express Ki67 (A) without and (B) with stimulation both following isotype
staining and (C) following Ki67+ staining
A
B
C
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A
Figure 4.24. The effects of inhibitory receptor blockade on the size of CMV specific CD4+ T cell
response.
PBMCs were stimulated with CMV lysate for 3 days and restimulated on day 2 in the presence of
inhibitory receptor blockade antibody or relevant isotype control. Cells were then stained using
anti- CD4-PerCP and intranuclearly with anti-IFNγ-APC and Ki67-FITC. CMV specific cells were
identified as those that synthesize IFNγ. (A) Representative FACS plots of changes in the proportion
of CD4+ T cells that are specific for CMV following stimulation in the presence of αCTLA-4, PD-L or E-
cadherin blockade and their relevant isotype controls. (B) Cumulative data illustrating the effects of
inhibitory receptor blockade on the proportion of CD4+ T cells that respond to a CMV stimulus.
Horizontal lines depict mean values. The P values were assessed using a Mann-Whitney U test. Only
significant differences between blocking antibody and its isotype control are shown.
B
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A
B
Figure 4.25. The effects of inhibitory receptor blockade on the proliferative response of CMV
specific CD4+ T cells
PBMS were stimulated and stained as detailed in the previous figure. CMV specific CD4+ cellular
proliferation was measured using Ki67 staining on specific cells that produce IFNγ. (A)
Representative density dot plots, gated on CD4+ T cells, indicating the percentage of responding
CMV specific CD4+ cells that express Ki67 in the presence of anti-CTLA-4, PD-L1/2 or E-cadherin
blocking antibody and their relevant isotype controls. (B) Pooled data illustrating the effects of
inhibitory receptor blockade on the proliferative response of CMV specific CD4+ T cells. Horizontal
lines depict mean values. The P values were calculated using a Mann-Whitney U test. Only
significant differences between blocking antibody and its isotype control are shown.
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4.5  Discussion 
 
Inhibitory receptor characterisation on CMV specific CD8+ T cells confirmed 
previous reports of low CTLA-4 expression (Day et al., 2006; Kaufmann et al., 2007; 
Trautmann et al., 2006), mid-levels of PD-1 (Day et al., 2006; Trautmann et al., 2006; 
Sauce et al., 2007a; Kaufmann et al., 2007) and very high levels of KLRG1 
expression on virus specific cells, which further increased with age (Ouyang et al., 
2003a; Thimme et al., 2005).  
 
Phenotypic characterisation of pp65CMV specific CD8+ T cells confirmed previous 
findings, that expression is predominantly observed in the CD45RA-revertant 
memory T cell population, particularly amongst aged donors (van Leeuwen et al., 
2006a). These increasingly differentiated CMV-pp65 specific CD8+ T cells also 
increased in number with ageing, consistent with previous findings (Khan et al., 2002; 
Ouyang et al., 2003a; Hadrup et al., 2006). These CMV specific CD8+ T cells, which 
we report can occupy 38% of the total CD8+ T cell pool, reflect a single epitope of a 
single CMV protein. However, as many other CMV proteins can encode 
immunogenic epitopes (Sylwester et al., 2005) this figure represents an 
underestimation of the proportion of total CD8+ T cells that are CMV specific. These 
large oligoclonal CD8+ T cell expansions may outcompete naïve and pre-existing 
memory T cells for finite survival factors such as homeostatic cytokines and 
significantly contribute towards age onset immunodecline (Welsh and Selin, 2009).  
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The long standing idea, however, that the immunological space is inflexible in size 
(Goldrath, 2002; Freitas and Rocha, 2000) is being increasingly challenged. Recent 
data suggest that the T cell compartment can grow in response to antigenic challenge, 
such as CMV infection, and pre-existing memory cells specific for other infections 
are largely preserved, predicting immunity to be maintained (Vezys et al., 2009; 
Chidrawar et al., 2009; van Leeuwen et al., 2006b). However, a further study revealed 
that the functionality of this pre-existing protective immunity is nevertheless 
compromised (Huster et al., 2009). 
 
Quantification of CD4+ and CD8+ T cell by ex vivo Ki67 expression also confirmed 
previous findings, that under steady state conditions naïve T cells turnover at a 
relatively poor rate. Memory T cells, on the other hand proliferate rapidly, with TREVs 
demonstrating the lowest turnover of the memory cell subsets (Geginat et al., 2003). 
CMV specific CD8+ T cells also exhibited low ex vivo proliferation that did not 
significantly differ from the total CD8+ T cell pool, consistent with previous reports 
(Doisne et al., 2004; Miles et al., 2007; Champagne et al., 2001), indicating that these 
are resting quiescent cells.  
 
Inhibitory receptor blocking studies revealed that PD-L blockade, but not E-cadherin 
or CTLA-4, enhanced the proliferative responses of CMV specific CD8+ T cells. 
Indeed, PD-1 is also upregulated on dysfunctional HIV, HBV and HCV chronic virus 
specific cells and ex vivo PD-1/L blockade improves the functionality of these cells 
(Penna et al., 2007; Petrovas et al., 2006; Fisicaro et al., 2010). Thus, PD-1 
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upregulation may reflect a common immune evasion strategy that facilitates the 
establishment and maintenance of chronic infections.  
 
Significantly, unlike CD8+ T cell responses to inhibitory receptor blockade, seen in 
the previous chapter, the effects of PD-L blockade on CMV specific CD8+ T cells 
were maintained amongst aged donors. However, PD-L1 has also been show to bind 
B7.1 at an interface that overlaps with the CD28 and CTLA-4 binding site and with an 
affinity higher than it binds CD28 (Butte et al., 2008). Therefore, it is possible that 
some functions attributed to PD-L1 blockade may reflect PD-L1 competing with 
CD28 for B7.1 binding. Nevertheless, the failure of anti-CTLA-4, blocking antibody, 
to augment CMV specific CD8+ T cell responses, either individually or in 
combination with PD-L blockade, suggests the effects of PD-1 inhibition to be 
primarily mediated through interactions with PD-1. 
 
The increased proliferative response of CMV specific CD8+ T cells following PD-L 
blockade (IgG2b mean, 28.0%; PD-L mean, 61.8%) was not accompanied by a 
proportional increase in the response size (IgG2b mean, 2.75%; PD-L mean, 3.27%). 
This, nevertheless, concurs with PD-1 blocking studies performed in a murine LCMV 
model (Barber et al., 2006), suggesting that proliferation is accompanied by 
considerable cell death. This death may be analogous to the contraction phase of 
effector cell responses. Alternatively, PD-L blockade may drive the selective 
expansion of less exhausted cells over their more exhausted counterparts, which are 
driven further along the exhaustion spectrum to death (Blattman and Greenberg, 
2006). Indeed, two subpopulations of virus specific CD8+ T cells have been identified 
 204 
 
 
in both mouse LCMV and human HCV infections: a more terminally differentiated 
PD-1hisubset, that responds poorly to PD-1 blockade and a less exhausted more 
functional PD-1int population that responds well to blockade (Blackburn et al., 2008; 
Nakamoto et al., 2008).  
 
The inability of PD-1hi virus specific CD8+ T cells to respond to PD-L1 blockade may 
reflect the expression of additional inhibitory receptors on these highly exhausted 
cells (Blackburn et al., 2009). Indeed, PD-1hi intrahepatic HCV specific CD8+ T cells 
expressed CTLA-4 (unlike circulating HCV specific CD8+ T cells) and responded to a 
combination of CTLA-4 and PD-L1 blockade, but not to the blocks individually 
(Nakamoto et al., 2008). Nevertheless, CTLA-4 was not expressed on LCMV or HIV 
specific CD8+ T cells nor did CTLA-4 blockade augment their responses (Trautmann 
et al., 2006; Kaufmann et al., 2007; Barber et al., 2006). However, in addition to PD-1; 
HIV, HCV, LCMV and tumour specific CD8+ T cells upregulate the inhibitory 
receptor: T-cell immunoglobulin domain and mucin domain 3, (Tim-3) (Jones et al., 
2008; Jin et al., 2010; Fourcade et al., 2010; Sakuishi et al., 2010; Golden-Mason et 
al., 2009; Vali et al., 2010) and LCMV and tumour specific CD8+ T cells co-express 
the CD4 homoloue, Lymphocyte-activation gene 3 (LAG-3) (Blackburn et al., 2009; 
Matsuzaki et al., 2010) and their blockade can induce functional restoration. 
Therefore, PD-1 may play a universal role in T cell exhaustion to persistent antigenic 
challenges whereas other inhibitory receptors may be may be differentially induced 
by different viruses, T cell subsets or anatomical locations.  
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The behaviour of PD-1inter and PD-1hi populations of CD8+ T cells specific for poorly 
controlled persistent viral infections such as LCMV, HCV and HIV may nevertheless, 
not be applicable to the well controlled latent CMV infection. Indeed, an HBV study,  
reported that the more exhausted intrahepatic specific CD8+ T cells, expressing higher 
PD-1 levels, responded more effectively than their less exhausted, lower PD-1 
expressing, circulating counterparts (Fisicaro et al., 2010). In contrast, Nakamoto et al, 
(2008) documented opposing results; however in this case, the disease status of the 
subjects was much more advanced. 
 
CD45RA re-expressing revertant CD8+ T cells were originally named a terminally 
differentiated, near senescent population, as they were thought to have lost the ability 
to self renew and expand (Champagne et al., 2001). However, subsequently they were 
shown to proliferate upon challenge with specific peptide (van Leeuwen et al., 2002; 
Wills et al., 2002; Waller et al., 2007). HIV specific CD8+ T cells from elite 
controllers, which are highly functional, share this typically revertant phenotype 
(Lichterfeld et al., 2008), in contrast to specific cells from typical HIV progressors, 
which are profoundly exhausted but exhibit a more intermediate differentiated 
phenotype (Addo et al., 2007). Nevertheless, data presented here indicate that the 
proliferative responses of CD45RA-revertant memory CD8+ T cells are still 
suboptimal compared with central and effector memory populations.  
 
Following PD-L blockade, this reduced proliferative capacity of CMV specific CD8+ 
TREVS is largely reversed. Nevertheless, we also show that PD-L blockade results in 
extensive phenotypic changes amongst CMV specific CD8+ T cells, such that the 
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increased proliferative response of CD45RA-revertant memory cells may reflect 
differentiation changes of other subsets. Nonetheless, repeating this experiment using 
purified CD8+ T cell subsets revealed that the revertant subset of CMV specific CD8+ 
T cells show the strongest augmentation of proliferative responses following PD-L 
blockade. In contrast to results from bulk PBMCs, the proliferative response of 
CD45RA-revertant memory CD8+ T cells, following PD-L blockade, was greater than, 
rather than equal to, that of their central and effector memory counterparts. This may 
reflect stimulated CD45RA-revertant memory CD8+ T cells losing CD45RA and 
regaining CD45RO expression (van Leeuwen et al., 2002; Geginat et al., 2003; Wills 
et al., 2002).  
 
The greatest functional effect of PD-L inhibition was found in the CD45RA-revertant 
memory CD8+ T cell subset; this may appear at odds with expression data, showing 
PD-1 to be expressed at maximal levels on TCM and TEM populations. This dilemma 
may be resolved by a closer examination of the function of disrupting PD-1 signalling 
on different CD8+ T cell populations. The blockade of PD-L on exhausted PD-1int 
LCMV and HCV specific exhausted CD8+ T cells, but not their PD-1hi counterparts, 
restored effector functions (Nakamoto et al., 2008; Blackburn et al., 2008), while the 
engagement of PD-1 on resting naïve T cells, which express barely detectable levels 
of PD-1, effectively inhibits T cell activation (Riley, 2009). This suggests that rather 
than increased PD-1 expression correlating with greater signalling, differing PD-1 
expression levels may engage distinct pathways (Riley, 2009). For example, PD-1 
binds SHP-1 and SHP-2 in naïve T cells but in exhausted cells, the very high levels of 
PD-1 expression could provide more targets than SHP-1 or -2 can bind allowing the 
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engagement of other signalling molecules that engage distinct signalling pathways. 
Additionally, PD-1 may mediate distinct effects on different cell types. Indeed, 
modest variations in SHP-1 expression levels have been shown to switch a cell from 
an antigen responsive to an unresponsive state (Feinerman et al., 2008). SHP-1 levels 
could vary with T cell differentiation and the altered relative ratio between SHP-1 and 
SHP-2 may account for the distinct effects of PD-1 ligation on different T cell subsets. 
Furthermore, the PD-1 signalling domain contains an ITSM, which can recruit distinct 
signalling molecules dependent on the presence or absence of an adaptor protein 
(Shlapatska et al., 2001). Thus, differential expression of an as yet uncharacterised 
PD-1 adaptor may also play critical roles in mediating distinct effects of PD-1 
signalling in different T cell subsets. 
 
The question remains that if PD-L blockade has the greatest effects on revertant 
CD27-CD45RA+ CD8+ T cells, why did it not significantly augment the response of 
highly differentiated CD27-CD28- CD8+ T cells to an anti-CD3 stimulus? Conversely, 
E-cadherin blockade was shown to augment the proliferative responses of highly 
differentiated CD8+ T cells but, contrary to what might have been expected, did not 
have a similar effect on CMV specific CD8+ T cells. This may be a consequence of 
the different stimuli being used with the anti-CD3 stimuli reflecting an acute model of 
activation and, indeed, PD-L1-/- mice make responses analogous to WT towards an 
acute LCMV strain but succumb to a chronic strain (Barber et al., 2006) and also 
KLRG1 is upregulated during acute but not chronic LCMV infections (Wherry et al., 
2007). Alternatively, the revertant CD27-CD45RA+ CMV specific CD8+ T cell 
population may not be analogous to the highly differentiated CD27-CD28- CD8+ T 
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cell subset. Nevertheless, in both these models, the simultaneous blockade of PD-1, 
CTLA-4 and KLRG1 did not result in any additional or synergistic effects, reflecting 
that these inhibitory receptors feed into a common PI3K/Akt signalling pathway 
(Parry et al., 2005; Tessmer et al., 2007; Henson et al., 2009). 
 
Unlike CD8+ T cells, PD-1/L blockade does not augment CMV specific CD4+ T cell 
proliferative responses, which is consistent with previous findings (Kaufmann et al., 
2007; Sester et al., 2008; Kassu et al., 2010) and may reflect CMV specific CD4+ T 
cells being exhausted to a much more modest extent than CD8+ T cells or, 
alternatively, CMV specific CD4+ and CD8+ T cells may be subject to distinct 
mechanisms of immune regulation, as observed in HIV infection (Kaufmann et al., 
2007).  
  
In summary, PD-1/L blockade can augment the proliferative response of CMV 
specific CD8+ T cells, however, it is unclear as to whether this reflects true reversal of 
exhaustion and cellular ageing processes or whether it simply increases turnover that 
may further exhaust cells already close to replicative senescence. This idea is 
investigated in chapter 5 by examining whether PD-1/L blockade upregulates 
telomerase expression in CMV specific CD8+ T cells. 
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5 Determination of the Role of CMV Infection and Immune 
Inhibitory Receptors in Age-associated Telomere Attrition 
 
5.1  Introduction 
 
The impairment of telomerase upregulation and resultant lymphocyte telomere 
attrition are critically implicated in age onset immune decline (see chapter 1.2.3.2.3). 
However, the effects of CMV infection on T cell telomere length have yet to be fully 
explored and will be investigated in this chapter. Moreover, CD28 is required for the 
induction of telomerase activity through Akt, which phosphorylates and activates the 
catalytic component of telomerase, hTERT (Akbar and Vukmanovic-Stejic, 2007) and 
CTLA-4, PD-1 and KLRG1 all inhibit CD28 signalling (see section 1.5.4.3). 
Therefore, their increased expression on T cells with age and/or CMV status may be 
responsible for driving age-associated telomere attrition and associated 
immunosenescence and this hypothesis is explored in the current chapter. 
 
5.2  Measuring telomere lengths using the Flow-FISH assay 
 
Lymphocyte telomere lengths were determined using a 3 colour flow-FISH assay. A 
representative dot plot depicting a FSC/SSC profile following flow-FISH, with a live 
lymphocyte gate depicted (Fig 5.01A). A representative CD4 and telomere probe stain, 
gated on live lymphocytes (Fig 5.01B), with the small proportion of cells not uptaking 
the probe indicated. To counteract the effect of these outliers, the median value of the 
telomere probe intensity was recorded on the relevant population (representative 
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example gated on CD4+ T cells Fig 5.01C). This telomere median fluorescence 
intensity was converted into telomere length using a standard curve generated in the 
laboratory (Fig 5.01D). Two cryopreserved PBMC samples of known telomere length 
and fluorescence were also used as instrument controls to ensure consistency of 
results.  
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Figure 5.01. Measurement of telomere lengths by flow-FISH
The telomere length of total lymphocytes, as well as CD8+, CD4+ and CD4-CD8-
lymphocyte subpopulations was measured using a 3 colour flow-FISH (flow cytometry
in combination with fluorescence in situ hybridization) assay with anti-CD8-FITC,
CD4-biotin and a telomere Cy5 probe which was then subjected to flow cytometric
analysis. (A) Representative dot plot of FSC/SSC profile with gate for live
lymphocytes displayed. (B) FACS plot gated on live lymphocytes demonstrating
telomere probe staining against CD4 expression. Indicated are a minority of cells hat
have not uptaken the telomere probe. (C) Histogram of telomere probe staining on
CD4+ T cells and the median value is measured rather than the mean to prevent these
outliers skewing measurement of the distribution. (D) Telomere MFI could be
converted into telomere length in kilobases using a standard curve. Two
cryopreserved PBMC samples of known telomere fluorescence used as standards to
ensure consistency of results
Cells that have 
not uptaken 
telomere probe
A B
C D
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5.3 CMV accelerates age-associated telomere attrition in T cell 
populations 
 
5.3.1 Live lymphocytes 
The telomere lengths of total live lymphocyte populations strongly negatively 
correlated with age, both in CMV- and CMV+ cohorts (Fig 5.02A). However, this 
diminution was exacerbated amongst CMV+ donors, losing an average of 61 base 
pairs per year (bpy) compared to 45 bpy amongst CMV-s, such that CMV+ old 
individuals have significantly shorter telomeres than aged CMV- donors, whereas no 
such difference is observed in the young (Fig 5.02B). 
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Figure 5.02 CMV accelerates telomere attrition in total lymphocytes from healthy
individuals.
The telomere length was measured as described in the previous figure. (A) Correlation
between telomere length and age in total lymphocytes (CMV negative: n=56, r2=0.41,
P<0.0001; CMV positive: n=58, r2=0.58, P<0.0001), from CMV positive and negative
healthy individuals. The rate of telomere attrition, represented as loss of base pairs per
year (bpy) was calculated from the gradient is indicated. Open circles and an unbroken line
represent CMV negative individuals, filled circles and a dashed line represent CMV positive
individuals. Line of best fit generated using linear regression. r2 and P values generated
using Pearson’s correlation. (B) Telomere lengths of these individuals is represented by
grouping via age (young < 40 years, old > 70) and CMV status. Horizontal bars depict
mean values and Students t test was used to calculate P values, only significant
differences between age matched CMV- and CMV+ individuals are shown.
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5.3.2  CD8+ T cells 
The rate of age-associated telomere attrition was greatest amongst CD8+ T cells and 
was further accelerated by CMV infection (Fig 5.03A, CMV+: -94bpy, CMV-: -
72bpy). Old CMV+ donors exhibited significantly shorter telomeres than their CMV- 
counterparts (Fig 5.03B). 
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Figure 5.03. CD8+ T cell telomere loss is accelerated in CMV infected as compared to
CMV free donors
Telomere lengths of CD8+ T cells was determined as described in Fig 5.01. (A) CD8+
telomere lengths of healthy donors correlated by age and CMV status (CMV negative:
n=40, r2=0.63, P<0.0001; CMV positive: n=29, r2=0.79, P<0.0001). The gradient was used
to calculate the rate of telomere attrition as expressed in base pairs per year. Open
symbols represent CMV- donors and filled symbols depict CMV+ subjects. Line of best fit
generated using linear regression. r2 and P values generated using Pearson’s correlation.
(B) CD8+ T cell telomere lengths of CMV- and CMV+ individuals compared by grouping
them into either young (<40) or old (>60 years) and performing Student’s test with only
significant differences between CMV+ and CMV- age matched donors indicated.
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5.3.3  CD4+ T cells 
Similarly, CMV infection accelerated donor telomere loss in CD4+ T cells (Fig 5.04, 
CMV+: -65bpy; CMV-: -47bpy) with CMV+ old possessing significantly reduced 
telomeres than observed for CMV- old donors (Fig 5.04B). 
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Figure 5.04. Age associated telomere shortening of CD4+ T cells is accelerated in
CMV+ donors
CD4+ T cell telomere lengths were determined in accordance with the protocol described in
Fig 5.01. (A) Scatter plots illustrating telomere lengths of CD4+ T cells from donors,
stratified by age and CMV status (CMV negative: n=52, r2=0.41, P<0.0001; CMV positive:
n=64, r2=0.58, P<0.0001) with the average rate of telomere attrition in both CMV- and
CMV+ cohorts indicated. Linear regression was used to generate line of best fit and
Pearson’s correlation generated r2 and P values. (B) Column graphs depicting the CD4+ T
cell telomere lengths amongst CMV- and CMV+ individuals within young and old cohorts.
Open symbols represent CMV- and closed symbols depict CMV+ donors. Mean values are
depicted by horizontal bars and P values calculated using Student’s t test. Only significant
differences between CMV infected and CMV free donors of the same age cohort are
depicted.
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5.3.4  CD4-CD8- Lymphocytes 
CMV did not exhibit any acceleration in telomere attrition in CD4-CD8- lymphocytes 
(Fig 5.05A, CMV-: -43bpy, CMV+: -46bpy) and CMV+ and CMV- donors do not 
significantly differ in their telomere lengths amongst young and old donors (Fig 
5.05B) 
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Figure 5.05. CMV does not accelerate telomere attrition in CD4-CD8- T cells
populations from healthy individuals.
Flow-FISH was performed in accordance with Fig 5.01 to determine telomere lengths of
CD4-CD8- lymphocytes. (A) Scatter plots illustrating how the telomere lengths of CD4-CD8-
lymphocytes change with age and CMV status of donors. (CMV negative: n=36, r2=0.26,
P<0.005; CMV positive: n=22, r2=0.50, P<0.0005). Linear regression was used to produce
lines of best fit, from which the rates of telomere loss in CMV- and CMV+ donors, expressed
as base pairs per year (bpy), was calculated. (B) Telomere lengths of CD4-CD8-
lymphocytes comparing in CMV- compared with CMV+ subjects in both young and old
donors are displayed in a column graph with student’s t test used to calculate P values.
Only significant differences are displayed. Filled symbols represent CMV+ and open
symbols depict CMV- donors.
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5.4  Correlating telomere length with inhibitory receptor expression 
 
5.4.1  CTLA-4 
CTLA-4 expression on CD8+ T cell exhibited a strong highly significant negative 
correlation with their telomere lengths (Fig 5.06A) both amongst CMV- and CMV+ 
donors (Fig 5.06B). However, amongst CD4+ T cells, CTLA-4 expression exhibits a 
weak, negative correlation with their telomere lengths that does not reach significance 
irrespective of CMV status (Fig 5.07).  
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Figure 5.06. Telomere lengths of CD8+ T cells varies with their CTLA-4
expression
PBMCs were stimulated for 24hrs with anti-CD3 before staining with anti- CD8-FITC,
CD4-PerCP and intracellularly with CTLA-4-PE to determine CTLA-4 expression on
CD8+ T cells. The telomere length of these donors was assessed using Flow-FISH as
described earlier. (A) Correlation between CTLA-4 expression and length of
telomeres on the CD8+ T cell pool of different individuals. (B) Relationship between
CD8+ T cell telomere lengths and their CTLA-4 expression of CMV negative (unfilled
circles) and CMV positive (filled circles) donors. Line of best fit generated using linear
regression. P and r2 values generated using Pearson’s correlation.
A
B
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Figure 5.07 The relationship between CTLA-4 expression of CD4+ T cells and their
telomere lengths
PBMCs were stained and analysed as described in the previous figure. (A) Scatter plot
depicting variation of telomere lengths of CD4+ T cells with their CTLA-4 expression (B)
CD4+ T cell telomere lengths as stratified by their CTLA-4 expression and donor CMV
status. Line of best fit generated using linear regression. Open circles indicate CMV- donors
and filled symbols depict CMV+. P and r2 values generated using Pearson’s correlation.
A
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5.4.2  PD-1 
Telomere lengths of CD8+ T cells did not exhibit a significant correlation with their 
PD-1 expression on total, CMV- or CMV+ donors (Fig 5.08). The same result was 
observed for CD4+ T cells (Fig 5.09). 
 
 
 
 224 
 
 
0 5 10 15 20 25 30
2500
5000
7500
10000
12500
r 2 =
P = N.S.
0.020
PD-1 MFI on CD8+ T cells
Te
lo
m
e
re
 
Le
n
gt
h 
CD
8+
 
T 
ce
lls
 
(b
p)
0 5 10 15 20 25 30
2500
5000
7500
10000
12500
r 2 =
P =
r 2 =
P =
N.S.
0.0047
N.S.
0.035
CMV-
CMV+
PD-1 MFI on CD8+ T cells
Te
lo
m
e
re
 
Le
n
gt
h 
CD
8+
 
T 
ce
lls
 
(b
p)
Figure 5.08 Correlation between PD-1 expression and telomere lengths of CD8+ T
cells.
PBMCs stimulated for 48hr and then stained with anti- CD8-FITC, CD4-PerCP and PD-1-
PE and analysed by flow cytometry. Telomere lengths using PBMCs from the same donor
was determined, as stated in Fig 5.01. (A) Correlation between PD-1 expression and length
of telomeres in their CD8+ T cell pool. (B) Telomere lengths of CD8+ T cells was stratified
by their PD-1 expression on CMV negative (unfilled circles, dashed line) and positive (filled
circles, solid line) donors. Line of best fit generated using linear regression. Pearson’s
correlation was used to generate r2 and P values
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Figure 5.09 Differences in telomere lengths of CD4+ T cells as stratified by PD-1
expression in CMV- and CMV+ donors.
PBMCs stimulated and stained as described in the previous figure. (A) CD4+ T cell
telomere lengths, as correlated by PD-1 expression and (B) further stratified based on
donor CMV status. Line of best fit generated using linear regression. CMV+ donors
depicted by filled circles and broken line whereas the solid line and open symbols depict
CMV- donors. R2 and P values generated using Pearson’s correlation.
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5.4.3  KLRG1 
The KLRG1 expression of CD8+ T cells could be strongly and negatively correlated 
with their telomere lengths on all donors (Fig 5.10A) and also after stratification for 
CMV status (Fig 5.10B). However, the telomere lengths of CD4+ T cells could only 
be weakly correlated with their KLRG1 expression in a manner that does not reach 
significance (Fig 5.11A). However, whereas CMV+ individuals display a non-
significant weak negative correlation, the CD4+ T cell telomere lengths of CMV- 
donors appears to be independent of their KLRG1 expression (Fig 5.11B). 
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Figure 5.10 KLRG1 expression negatively correlates with telomere lengths in CD8+ T
cells
PBMCs stained with anti- KLRG1-PE and CD8-FITC and their telomere lengths determined
as described in Fig 5.01. (A) Telomere lengths of CD8+ T cells (y-axis) is plotted against
their KLRG1 expression (x axis) and (B) further stratified on the basis of donor CMV status.
Open circles represent CMV- and filled circles CMV+ donors. R2 and P values generated
using Pearson’s correlation and the line of best fit was generated using linear regression.
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Figure 5.11 Telomere lengths of CD4+ T cells correlated by their KLRG1 expression
PBMCs stained and analysed as described in the previous figure. (A) Correlation between
KLRG1 expression and length of telomeres on the CD4+ T cell pool of different individuals.
(B) CD4+ T cell telomere lengths stratified by their KLRG1 expression on CMV negative
(unfilled circles, filled line) and CMV positive (filled circles, dashed line) donors. Line of best
fit generated using linear regression. R2 and P values generated using Pearson’s correlation
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B
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5.5 Functionally defining inhibitory receptor expression in mediating 
telomerase defects of highly differentiated bulk and CMV specific 
CD8+ T cells 
 
5.5.1  Blocking inhibitory receptor interactions with their ligands does not 
augment telomerase expression of CD8+ T cells at any stage of their 
differentiation 
Ex vivo CD8+ T cells at different stages of differentiation, from 3 different donors, 
were purified and stimulated with anti-CD3 and autologous irradiated APCs in the 
presence of inhibitory receptor blockade or their relevant isotype control. Following a 
3 day stimulation the cells were stained with Ki67 and a telomerase ELISA was 
performed using samples adjusted to 500 Ki67+ cells per reaction. However, blocking 
CTLA-4, PD-L or E-cadherin did not increase the CD8+ T cell telomerase activity at 
any differentiation state (data not shown). 
 
5.5.2 CMV specific CD8+ T cell telomerase activity was not upregulated 
following PD-L blockade 
Whether the increased proliferative capacity seen in CMV specific CD8+ T cell 
following PD-L blockade represents true reversal of exhaustion (Chapter 4) was 
determined by investigating if this proliferative increase was accompanied by 
telomerase upregulation. This was accomplished by repeating the above experiment 
but using a pp65 CMV peptide pool instead of an anti-CD3 stimulus. A pp65CMV 
peptide pool was used as NLV or TPR peptides did not induce a sufficiently large 
Ki67 expression to perform the telomerase assay. Blocking PD-1/L interactions 
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significantly increased the proliferative responses of CD8+ T cells stimulated with 
pp65, in a manner analogous to an NLV/TPR peptide stimulus, (data not shown, P < 
0.005). However, despite this increase in proliferation, blocking PD-1 interactions did 
not upregulate the telomerase activity of CD8+ T cells at any differentiation state (data 
not shown). 
 
5.6  Discussion 
 
Data presented here confirm previous reports of age-associated telomere attrition 
among live lymphocytes (Slagboom et al., 1994), CD8+ and CD4+ T cells (Weng et al., 
1995; Rufer et al., 1999) of healthy donors. The CD4-CD8- T cell population also 
displayed age related telomere diminution and likely comprises a mixture 
predominantly of NK and B cells, which have also been shown to shorten their 
telomeres with increasing age (Mariani et al., 2003; Ouyang et al., 2007; Son et al., 
2000).  
 
What are the factors driving age related telomere attrition? Twin studies reveal initial 
telomere length of peripheral blood lymphocytes to be genetically determined 
(Slagboom et al., 1994) and its subsequent diminution with age is primarily a 
consequence of repeated cellular activation, which drives telomerase loss (Akbar and 
Vukmanovic-Stejic, 2007; Akbar et al., 2004), and proliferation, whose main drivers 
include antigen load and inflammation (Aviv et al., 2006; Plunkett et al., 2005; 
Andrews et al., 2009). In addition, the continuous exposure of cells to free radicals is 
also considered an significant influence on the maintenance of telomeres (Starr et al., 
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2008; Epel et al., 2004), which are highly susceptible to oxidative damage (Kawanishi 
and Oikawa, 2004; von, 2002).  
 
Furthermore, the novel observation that CMV accelerates the erosion of telomeres in 
live lymphocytes, CD8+ and CD4+ T cells of healthy donors is also reported. There is 
one previous report of CMV promoting telomere loss but this was limited to CD8+ T 
cells and involved patients with coronary heart disease (Spyridopoulos et al., 2009). 
Shortened telomeres have been observed in peripheral lymphocyte populations of 
individuals infected with other chronic viral infections such as HIV (Bestilny et al., 
2000), HCV and HBV (Satra et al., 2005) and multiple autoimmune diseases 
(Andrews et al., 2009). These data suggest a common mechanism whereby persistent 
antigen stimulation results in increased T cell clonal turnover and inflammation which 
augments the rate of telomere shortening.   
 
The importance of adequate clonal lymphocyte expansion in the optimal function of 
the adaptive immune system and the potential barrier of replicative senescence may 
provide a mechanism whereby short telomeres may contribute towards age and CMV 
associated immune dysfunctions. However, cellular telomere length also serves as a 
biological indicator of both the proliferative history and the replicative capacity of 
somatic cells (Allsopp et al., 1992; Hodes et al., 2002). Therefore, short telomeres 
may either be a cause or simply represent a biomarker of immune system ageing. 
Nevertheless, data supporting the causal hypothesis include a number of genetic 
diseases characterized by deficient telomere maintenance that are associated with 
premature ageing, such as DKC (Armanios, 2009) or ataxia telangiectasia (Akbar et 
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al., 2004) and animal models, as observed in the telomerase deficient mouse (Blasco, 
2002; Akbar et al., 2004). Moreover, mice born with short telomeres, even in the 
presence of normal telomerase, exhibit rapid onset of ageing (Armanios et al., 2009). 
Furthermore, enhancing telomerase activity in HIV specific CD8+ T cells dramatically 
restored their antiviral function (Dagarag et al., 2004; Fauce et al., 2008).  
 
KLRG1 and CTLA-4 expression both display inverse correlations with CD8+ T cell 
telomere length. Nevertheless, they also exhibit significant positive correlations with 
age (chapter 3), which itself is inversely correlated with CD8+ T cell telomere length. 
To better define the functional relevance of the inhibitory receptor expression of a T 
cell on its telomere length, blocking studies were performed. However, neither 
CTLA-4, PD-1 nor KLRG1 blockade augmented telomerase activity of CD8+ T cells 
at any stage of their differentiation. Nevertheless, this may reflect these receptors 
functioning through PI3K/Akt (as described in section 1.5.4.3), whereas the 
Ras/p38MAPK/Erk pathway may be the major route through which telomerase is 
regulated (Fauce et al., 2008; Maida et al., 2002). There is a report of PD-L blockade 
augmenting telomerase activity, as well as mediating proliferative increases, of HIV 
specific CD8+ T cells (Lichterfeld et al., 2008). However, the authors did not take into 
account that T cells upregulate telomerase when induced to proliferate and didn’t 
adjust their experiment accordingly, whereas our experiments were normalised to 500 
Ki67+ cells per reaction. Indeed, we observed significant increases in Ki67 
proliferation following PD-L blockade, suggesting that if we had not standardised the 
number of Ki67+ cells, we would have similarly observed increased telomerase 
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activity. The mechanisms driving these age and CMV associated inhibitory receptor 
variations were further investigated in the next chapter. 
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6 Determination of factors driving CMV and age-associated 
inhibitory receptor changes. 
 
6.1  Introduction 
 
In the previous three chapters we have characterised T cell inhibitory receptor 
expression variances with age and CMV status and defined their role in driving age-
associated immune decline. This raises questions as to what mechanisms are driving 
these expression changes and whether they can be manipulated to modify inhibitory 
receptor expression, which is explored in this chapter. 
 
Extrinsic factors, such as cytokines, in the serum of the aged are heavily implicated in 
age related immune decline (as described in section 1.2.3.2.4). The role of such 
cytokines in driving age and CMV associated inhibitory receptor expression changes 
were investigated in this chapter. In particular, we have chosen to study IL-6, whose 
well documented positive correlation with ageing and multiple age related diseases 
(Maggio et al., 2006; Ershler and Keller, 2000) have led it to be labelled the 
“gerontologists cytokine” (Ershler, 1993), alongside the closely correlated pro-
inflammatory cytokine TNFα (Bruunsgaard et al., 2003). Additionally, naïve CD4+ T 
cells from the aged exhibit impaired differentiation into Th1 and Th2 subsets but 
display retained or even enhanced ability to generate Th17 effectors (Huang et al., 
2008; Tesar et al., 2009), which are broadly implicated in many autoimmune diseases 
(Mesquita et al., 2009) and are characterised by production of the pro-inflammatory 
cytokine IL-17, which will constitute an additional focus of my study (Blaschitz and 
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Raffatellu, 2010; van de Veerdonk et al., 2009). Furthermore, we will examine the 
anti-viral cytokine IFNα, which is secreted at high levels in response to CMV and, by 
virtue of its ability to induce costimulatory receptor loss and inhibit telomerase 
activity, has been suggested to be the factor driving accelerated T cell differentiation 
in CMV infected individuals (Fletcher et al., 2005; Reed et al., 2004). The anti-
inflammatory cytokine IL-10, whose activity is critical for the attenuation of immune 
responses and is exploited by several chronic pathogens to enable their persistence 
after primary infection (Brockman et al., 2009; Slobedman et al., 2009) was also 
studied, as any age related immune dysfunction in its production may contribute 
towards the defective immune responses or pro-inflammatory phenotype of the aged.  
 
The common gamma chain of cytokines were an additional subject of my studies, 
including IL-2, a key component for the optimal activation and proliferation of B and 
T cells, whose decreased production is recognised as one of the most consistent age 
related changes in cytokine production (Pawelec et al., 2001; Gardner and Murasko, 
2002). Moreover, multiple studies have revealed that many of the age-associated 
lymphocyte functional defects can be abrogated following the in vitro addition of 
exogenous IL-2 (as described earlier). Additionally, IL-7 and IL-15 are key regulators 
in the extrathymic homeostatic proliferation of T cells (Surh and Sprent, 2008). These 
cytokines have been implicated in driving the increasingly differentiated T cell pool 
associated with ageing, as IL-15 can induce the loss of CD28 expression on CD8+ T 
cells (Pawelec, 2007) and loss of IL-7 is correlated with accumulation of TEM CD4+ T 
cells (Kang et al., 2004). Finally, IL-21 is another common gamma chain cytokine 
which has been implicated in T cell homeostasis and has been shown to act as an 
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antagonist to the IL-15 induced loss of CD28 expression on CD8+ T cells (Nguyen 
and Weng, 2010). IL-21 also is a potent enhancer of NK cell and CD8+ T cell 
proliferation, IFNγ production and cytotoxicity (Nguyen and Weng, 2010). Thus, age 
related IL-21 loss may contribute towards the increased differentiation of the CD8+ T 
cell pool, and the increased tumourigenesis and defective immune responses observed 
in old age. The effects of these cytokines on CD4+ and CD8+ T cell inhibitor receptor 
expression were studied alongside the influence of donor age and CMV status, to 
elucidate the roles of these cytokines in driving age and CMV associated immune 
alterations. 
 
6.2 Measurement of the effects of cytokines on inhibitory receptor 
expression 
 
The ability of cytokines to modulate inhibitory receptor expression was measured by 
anti-CD3 stimulation of PBMCs over a 24 hour period in the presence or absence of 
the relevant cytokine. The response of CD4+ or CD8+ T cells and the difference in 
MFI, with and without cytokine, was documented (Representative example, Fig 6.01).   
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Figure 6.01 Illustrative example of the quantification of the effects of various
cytokines on T cell inhibitory receptor expression.
PBMCs were stimulated with anti-CD3 for 24hrs in the presence and absence of IL-15.
Cells were then stained with anti- CD8-PerCP, CD4-FITC and intracellularly with CTLA-4-
PE and analysed by flow cytometry. Representative example of CTLA-4 expression, on
CD8+ T cells, that were left unstimulated (black line), stimulated with anti-CD3 alone (blue
line) and stimulated with anti-CD3 in the presence of IL-15 (red line). The difference in
inhibitor receptor expression between αCD3 stimulated PBMC samples in the presence
and absence of the cytokine is what was recorded.
Stimulus MFI
U/S 5.24
αCD3 alone 9.48
αCD3  + IL-15 17.1
CTLA-4
Co
u
n
ts
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6.3  How cytokines modulate the expression of inhibitory receptors 
 
6.3.1 CTLA-4 
Only the common gamma chain cytokines IL-2, IL-7, IL-15, IL-21 significantly 
upregulated CTLA-4 expression on both CD8+ (Fig 6.02A) and CD4+ (Fig 6.02B) T 
cells, whereas IFNα, IL-6, IL-10, IL-17 and TNFα did not significantly affect CTLA-
4 expression. In both CD8+ and CD4+ T cells, IL-15 and IL-2 induced of the greatest 
magnitude changes in CTLA-4 expression followed by IL-21 and then IL-7. 
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Figure 6.02 The effects of various cytokines on T cell CTLA-4 expression.
The effects of cytokines on CTLA-4 expression was accomplished as detailed in the
previous figure. (A) Pooled data comparing effects of addition of different cytokines to anti-
CD3 induced CTLA-4 expression on CD8+ and (B) CD4+ T cells. Horizontal lines represent
mean values and P values represent Wilcoxon signed rank tests indicating if data is
significantly non zero. Only significant differences are shown.
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When comparing the effects of cytokines between young and old donors, it was found 
that IL-15 and IL-21 were able to upregulate CTLA-4 by greater amounts on old 
compared to young donors’ CD8+ T cells (Fig 6.03A). No age dependent effects of 
IL-2, IL-7, IL-15 or IL-21 were observed on CTLA-4 expression of CD4+ T cells (Fig 
6.03B). Stratifying the effects of cytokines by donor CMV status revealed that CMV+ 
donors augmented CTLA-4 production by a greater magnitude than CMV- ones in 
their CD8+ T cell response to IL-15 (Fig 6.04A) and on their CD4+ T cells to IL-7 
(Fig 6.04B). No other cytokines significantly differed in their effects between CMV- 
and CMV+ subjects. 
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Figure 6.03. Contrasting the effects of cytokines on CTLA-4 expression of T cells in
old and young donors.
PBMCs from young and old donors were stained and analysed as described in the figure
6.01. (A) Pooled data comparing CTLA-4 expression changes induced on CD8+ and (B)
CD4+ T cells following coincubation of various cytokines with OKT3 compared with those
stimulated in the absence of cytokines in young and old donors. Horizontal lines depict
mean values. Filled symbols represent young donors (Y, <35 years) and open symbols
represent old donors (O, >65). Statistical significance was assessed using a Mann-
Whitney U-test. Significant differences between old and young donors are shown
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Figure 6.04. Comparison of the effects of cytokines on CTLA-4 expression of CD8+ T
cells in CMV+ and CMV- donors.
PBMCs from CMV- and CMV+ donors were treated and stained as detailed in the Fig 6.02.
Cumulative data comparing CTLA-4 expression changes on CD4+ T cells of CMV- and
CMV+ donors following IFNα, IL-2, IL-7, IL-15, IL-21, IL-10, IL-6, TNFα and IL-17 co-
incubation on (A) CD8+ and (B) CD4+ T cells Filled symbols represent CMV- donors and
open symbols represent CMV+ donors. A Mann-Whitney U-test was used to generate P
values and only significant differences between CMV+ and CMV- donors are shown
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6.3.2  PD-1 
Similar to the findings seen using CTLA-4, PD-1 expression on CD8+ and CD4+ T 
cells was augmented by the common gamma chain cytokines (Fig 6.05). However, 
unlike CTLA-4, IFNα significantly upregulated PD-1 on both CD8+ and CD4+ T cells 
and IL-10 significantly diminished PD-1 expression on CD4+ but not CD8+ T cells 
(Fig 6.05). The magnitude of PD-1 upregulation did not significantly differ between 
these cytokines. Moreover, stratifying the effects of these cytokines based on donor 
age did not reveal any significant differences in their responses among the CD8+ or 
CD4+ T cell compartment (Fig 6.06). Comparing the responses of CMV- and CMV+ 
donors revealed significant differences only in response to IL-7, which induced a 
significantly higher level of PD-1 expression on the CD8+ T cells of CMV+ compared 
with their CMV- counterparts (Fig 6.07).  
 
6.3.3  KLRG1 
No cytokines were able to modulate KLRG1 expression on either CD4+ or CD8+ T 
cells (data not shown), this is consistent with published data that no known in vitro 
stimulus has been found to upregulate KLRG1 (Voehringer et al., 2002).   
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Figure 6.05. PD-1 expression of CD4+ T cells can be altered by various cytokines
PBMCs were stimulated and subject to flow cytomeric analysis as detailed in Fig 6.01 but
using anti-CTLA-4-PE rather than an anti-PD-1-PE staining antibody. (A) Cumulative data
showing PD-1 expression changes on CD8+ T cells following IFNα, IL-2, IL-7, IL-15, IL-21,
IL-10, IL-6, TNFα and IL-17 co-incubation on CD8+ and (B) CD4+ T cells. Horizontal lines
represent mean values and P values represent Wilcoxon signed rank tests indicating if data
is significantly non zero. Only significant non zero differences are shown.
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Figure 6.06. The effects of cytokines on PD-1 expression of CD8+ and CD4+ T cells in
old compared with young donors.
PBMCs from old and young donors were stimulated, stained and analysed as depicted in
the previous figure. (A) Cumulative data showing PD-1 expression changes on OKT3
stimulated CD8+ and (B) CD4+ T cells following cytokine coincubation in old compared to
young donors. Filled symbols represent young donors (<35 years) and open symbols
represent old donors (>65). Horizontal lines depict mean values. Statistical significance was
assessed by a Mann-Whitney U test and only significant differences between old and young
donors are shown
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Figure 6.07. Comparing the effects of cytokines on PD-1 expression of T cells based
on the CMV sero-status of the donors
PBMCs from CMV+ (open symbols) and CMV- (filled symbols) donors were stained and
analysed as described in Fig 6.05. (A) Pooled data comparing differences in PD-1
expression alterations induced by the coincubation of IFNα, IL-2, IL-7, IL-15, IL-21 and IL-10
on αCD3 stimulated CD8+ T cells and (B) CD4+ T cells, in CMV+ and CMV- individuals.
Horizontal lines represent mean values. Filled symbols represent young donors (<35 years)
and open symbols represent old donors (>65). Statistical significance was calculated using a
Mann Whitney U test. Only significant differences between CMV negative and positive
donors are shown
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6.4 Blocking cytokine receptor signalling can manipulate T cell 
inhibitory receptor expression levels 
 
Blocking antibodies were used to quantify the significance that these cytokines play in 
inducing inhibitory receptor expression. PBMCs were stimulated with anti-CD3 in the 
presence of cytokine receptor blockade or their relevant isotype control and the 
expression of CTLA-4 and PD-1 on both CD4+ and CD8+ T cells was monitored. The 
IL-15 cytokine receptor was selected for blocking, as IL-15 induced the greatest 
CTLA-4 expression changes on both CD4+ and CD8+ T cells. However, IL-15R 
blockade was unable to significantly alter PD-1 or CTLA-4 expression levels on 
CD8+ or CD4+ T cells (Fig 6.08). IFNα was also chosen, as it was the only non-
common gamma chain receptor that upregulated PD-1 and CMV induces the 
production of large amounts of IFNα (Fletcher et al., 2005). Blocking IFNα receptors 
significantly reduced the level of PD-1 expression induced by anti-CD3 by 
approximately half among both CD8+ (Fig 6.09A) and CD4+ T cells (Fig 6.09B).     
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Figure 6.08. The effect of IL-15 receptor blockade on inhibitory receptor expression 
of CD8+ T cells.. 
PBMCs were stimulated with anti-CD3 for either 48 hours, to measure the effects on PD-1
expression or 24 hours to examine CTLA-4 in the presence of IL-15R blockade or its
relevant isotype controls. Cells were then stained using CD4-PerCP, CD8-FITC and either
PD-1-PE or intracellularly with CTLA-4-PE. (A) Pooled data showing the effect of IL-15R
block on the expression of PD-1 on CD8+ and (B) CD4+ T cells. (C) Cumulative data
illustrating the effect of blocking IL-15R on the expression of anti-CD3 induced CTLA-4 on
CD8+ and (D) CD4+ T cells. Horizontal bars depict mean values. The P values were
calculated using a Mann Whitney U test. Only differences between inhibitory receptor
blockade and its isotype control are shown.
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Figure 6.09. Consequences of blocking IFNα receptors on the expression PD-1
PBMCs were stimulated and stained as detailed in the previous figure but using IFNαR
blocking antibody rather than an anti-IL-15R block. (A) Cumulative data illustrating the
effects of IFNαR blockade on the PD-1 expression of CD8+ T cells and (B) CD4+ T cells.
Horizontal lines indicate mean values. The P values were calculated using a Mann-
Whitney U test. Significant differences between receptor blockade and isotype control are
shown.
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6.5  Discussion 
 
Ageing is characterised by an upregulation of inflammatory markers, however, no 
pro-inflammatory cytokine tested upregulated CTLA-4, PD-1 or KLRG1 on CD4+ or 
CD8+ T cells. Indeed, no cytokines of any type significantly augmented KLRG1 
expression, consistent with the notion that age and CMV associated KLRG1 
expression changes primarily reflect differentiation of the T cell pool. In contrast, the 
common gamma chain cytokine family members upregulated both CTLA-4 and PD-1 
on CD8+ and CD4+ T cells. This ability of homeostatic cytokines to upregulate PD-1 
expression was recently confirmed by Kinter et al. in vitro and in vivo, where it was 
suggested this may represent a negative feedback mechanism by which homeostatic 
proliferation is regulated to prevent inappropriate expansion and activation of a single 
T cell (Kinter et al., 2008). Nevertheless, they were unable to demonstrate that the 
PD-1 expression induced interfered with homeostatic proliferative expansion and 
understanding of such a pathway is becoming more important as common gamma 
chain cytokines are increasingly being used as a therapeutic modality (Sondergaard 
and Skak, 2009; Leone et al., 2009). Data presented here demonstrate that these 
cytokines also upregulate CTLA-4, which may represent an additional or alternative 
mechanism of regulating homeostatic peripheral expansion. Indeed, the large increase 
in CTLA-4 expression on naïve CD8+ T cells amongst the aged (observed in chapter 3) 
could reflect a compensatory homeostatic response of these cells undergoing high 
levels of lymphopoenia-induced expansion as a consequence of age related extreme 
CD8+ T cell differentiation (Cicin-Sain et al., 2007; Ferrando-Martinez et al., 2010). 
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Whether common gamma chain cytokines could account for the age and CMV related 
changes in CTLA-4 and PD-1 expression is unclear, as data suggests that their serum 
levels either decrease or remain unchanged with increasing age. Nevertheless, 
classification of cytokine receptors is being increasingly recognised as a more 
experimentally and clinically useful measure of cytokine activity (Fry and Mackall, 
2005), reflecting the pleiomorphic and redundant nature of cytokine responses being a 
consequence of their homologous receptors. Indeed, IL-15 upregulated CTLA-4 
expression on CD8+ T cells by a greater degree amongst aged compared with young 
donors. This is in accordance with IL-15 receptor expression and cytokine 
responsiveness increasing as CD8+ T cells differentiate (Geginat et al., 2003). In 
response to IL-15 and IL-21, old donors exhibited increased CTLA-4 induction on 
their CD8+, but not CD4+ T cells, compared with their young counterparts, which may 
account for the association of CTLA-4 expression with age observed only on CD8+ T 
cells. Similarly, in response to IL-7 and IL-15, CMV+ donors upregulate significantly 
more CTLA-4 on their CD4+ and CD8+ T cells, respectively, which may account for 
the augmented CTLA-4 expression among CMV+ donors’ T cells. 
 
Unlike CTLA-4, the cytokine induced upregulation of PD-1 expression does not 
significantly differ with donor CMV status. This may reflect expression changes of 
smaller magnitude being induced compared with CTLA-4, making significant 
differences between cohorts more difficult to elucidate. Additionally, cryopreserved 
samples were utilised to compare the upregulation of inhibitory receptors in response 
to cytokines by donor age and CMV status and recently the cryopreservation process 
has been associated with reductions in PD-1 expression (Campbell et al., 2009), such 
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that a correlation established with fresh PBMCs was not observable using 
cryopreserved samples (Holm et al., 2008). Alternatively, data presented here 
showing IFNα upregulates PD-1, may account for the T cell pool of CMV+ donors 
expressing enhanced levels of PD-1 compared with their CMV- counterparts. Indeed, 
large amounts of IFNα are induced as part of anti-CMV immune responses and 
blocking studies revealed that IFNα alone contributes half the PD-1 expression 
induced by an anti-CD3 stimulus, highlighting its functional significance. Similarly, 
the upregulation of PD-1 on the global CD8+ and CD4+ T cell pool of HIV 
(Trautmann et al., 2006; Day et al., 2006; D'Souza et al., 2007) and the CD8+ T cell 
compartment of acute HCV infected individuals (Nakamoto et al., 2008) may be 
mediated through IFNα. Moreover, the high levels of PD-1 expression and 
comparative absence of CTLA-4 expression on CMV and HIV specific CD8+ T cells 
(Kaufmann et al., 2007) may reflect IFNα inducing PD-1 but not CTLA-4 expression. 
Furthermore, IFNα drives T cell differentiation and may significantly contribute 
towards the CMV and HIV associated global differentiation of the T cell pool (Appay 
et al., 2007; van de Berg et al., 2008). 
 
The observed differences in age and CMV related cytokine induced inhibitory 
receptor upregulation may reflect changes in cytokine signal transduction. Indeed, 
lipid rafts have been suggested to be critical for cytokine signalling as part of the 
‘raft-STAT’ hypothesis (Sehgal et al., 2002). Thus, the compromised function of lipid 
rafts amongst the increasingly rigid cell membrane of the aged, as described in section 
1.2.3.2.5, predicts a generalised defect in cytokine signalling amongst old donors. 
Nevertheless, my data illustrates the ability of common gamma chain receptor 
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cytokines to upregulate CTLA-4 and PD-1 is generally maintained and in a few cases 
actually enhanced amongst the aged. Little data exists on age related signalling 
alterations of common gamma receptor cytokines with age but this finding is 
consistent with old donor T cells exhibiting no age related deficit in IL-7R signalling 
(Nasi et al., 2006; Kang et al., 2004). Enhanced cytokine signal transduction may also 
reflect age related exhaustion of negative regulators that inhibit cytokines responses, 
such as SHP-1 and SHP-2 phosphatases, protein inhibitors of activated stats (PIAS) 
and suppressors of cytokine signalling (SOCS), as suggested by (Fulop et al., 2006).  
 
Nevertheless, other explanations for inhibitory receptor expression variances amongst 
different cohorts, independent of cytokines, exist. For example, CTLA-4 and PD-1 are 
internalised following surface expression (Alegre et al., 1996; Pentcheva-Hoang et al., 
2007; Raimondi et al., 2006) and defective internalisation has been suggested to 
underlie the age related increase in inhibitory receptor expression in mice (Shimada et 
al., 2009).  
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7 Overall discussion 
 
The fate of cellular immune responses is critically dependent on the balance between 
signals delivered by positive and negative costimulatory receptors. Manipulation of T 
cell inhibitory receptor pathways constitutes a novel approach for re-invigorating 
exhausted T cell responses in the context of chronic infections. T cells also exhibit 
profound exhaustion in old age and this thesis investigates the hypothesis that the 
modulation of T cell inhibitory receptors may have the potential to reverse the 
changes seen in age onset immunodecline. 
 
7.1 Reinvigorating CMV specific CD8+ T cell function by 
manipulation of the PD-1/L axis 
 
The PD-1/L pathway is revealed to define a reversible defect among CMV specific 
CD8+ T cell proliferative responses. More specifically, CD45RA-revertant memory 
CMV specific CD8+ T cells exhibit a proliferative deficit compared with central and 
effector memory T cells, which is reversed following PD-L blockade, an effect 
demonstrated to be independent of T cell phenotypic changes. Overall, these data 
demonstrate that PD-1 plays a role in the dysregulation of CD8+ T cell responses to 
CMV, which constitutes a major force driving T cell immunosenescence (see section 
1.3.2.2). Moreover, reducing the chronic antigen burden may impair the development 
of immunosenescence (Kassu et al., 2003; Kalinkovich et al., 1998; Romanyukha and 
Yashin, 2003). Furthermore, despite critical roles of PD-1 in the development and 
maintenance of tolerance (as described in section 1.5.3.2.2), its blockade in vivo is 
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remarkably well tolerated (Velu et al., 2009; Berger et al., 2008). Therefore, 
manipulation of the PD-1/L axis may partially reinvigorate CMV specific CD8+ T cell 
function and contribute to improved control of CMV reactivation, reducing its effects 
in driving extreme T cell differentiation and the accumulation of oligoclonal 
expansions. 
 
The failure, however, of PD-L blockade to augment telomerase expression in virus 
specific CD8+ T cells would suggest that, rather than representing true functional 
reversal of exhaustion, blocking PD-L drives a short term functional increase that will 
further exhaust these already near senescent cells. Moreover, my studies solely 
investigated the peripheral blood compartment, however virus specific and bulk CD8+ 
T cells residing in peripheral sites of viral replication are more differentiated and 
exhausted than those from the circulating pool (van Leeuwen et al., 2006a; Blackburn 
et al., 2010) and may be refractory to PD-1/L blockade (Nakamoto et al., 2008). 
Furthermore, pp65 restricted HLA-A2 or -B7 tetramers were used to study CMV 
specific CD8+ T cell function, as it has been well documented that the CMV specific 
CD8+ T cell responses are extremely focussed on just two epitopes: IE-1 and pp65 
(Kern et al., 1999; Khan et al., 2007; Wills et al., 1996). However, many other viral 
proteins can encode immunogenic epitopes and CD8+ T cell recognition of CMV is 
unusually broad, complex and poorly approximated by responses to any one or two 
open reading frames (ORFs) (Lilleri et al., 2009; Sylwester et al., 2005). Indeed, 
although the majority of studies on CMV specific CD8+ T cells have focussed on IE-1 
and pp65, it can not necessarily be assumed that the largest detectable response 
corresponds as the most critical for the viral control. Thus, the behaviour of pp65 
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specific CD8+ T cells in response to PD-L blockade may not reflect the behaviour of 
those cells specific for the precise antigens crucial for the control of CMV. 
 
In vivo studies, nevertheless, reveal that PD-1/L blockade results in a CD8+ T cell 
response of much higher quality, resulting in better control of LCMV (Barber et al., 
2006), SIV (Velu et al., 2009) and cancer (Berger et al., 2008). This may reflect that 
in vivo PD-1 blockade may not reinvigorate exhausted cells but instead may function 
during the priming phase to prevent CD8+ T cells from becoming exhausted, as 
demonstrated cancer and infections of MCMV and Friend virus (Matsuzaki et al., 
2010; Benedict et al., 2008; Takamura et al., 2010). PD-L blockade may also abrogate 
the PD-L1 mediated induction of iTregs, whose numbers are augmented in chronic 
infections (Belkaid, 2008). 
 
7.2  Other immuno-rejuvenation strategies 
 
Aside from inhibitory receptor blockade to reinvigorate exhausted CMV specific 
CD8+ T cell functions, several alternative immuno-rejuvenation strategies are also 
being explored. Indeed, rather than improving their function, depletion of the 
exhausted CMV specific CD8+ T cell clones could allow a smaller number of less 
differentiated, more functional cells to replace them, (Touvrey et al., 2009; 
Weinberger et al., 2009) freeing up immune space for other naïve and memory T cells 
(Alexander et al., 2009). Alternatively, eradication of CMV has been suggested to be 
a desirable goal and indeed, a partially effective prophylactic vaccine has recently 
been developed (Pass et al., 2009). However, a few beneficial effects of CMV 
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infection have been documented, including possibly being protective against 
infectious disease (Barton et al., 2007), cancer (Pawelec et al., 2010a) and transplant 
rejection (Nickel et al., 2009; Pawelec and Derhovanessian, 2010), so there may be 
consequences resulting from its elimination. Other possible interventions could 
include thymic rejuvenation strategies (reviewed in (Pinti et al., 2010)), long term 
treatment with anti-inflammatory and/or anti-viral agents (Pawelec and 
Derhovanessian, 2010) and stress reducing behavioural therapies (Irwin et al., 2007; 
Epel et al., 2009; Gouin et al., 2008). 
 
7.3  Roles of CTLA-4 in age onset immune decline 
 
Although CTLA-4 expression increased on CD8+ T cells with age, its blockade did 
not reverse the characteristic hypo-responsiveness of neither CMV specific nor aged 
CD8+ T cells, suggesting that CTLA-4 may not play a direct role in age onset immune 
decline. This is at odds with the observed CTLA-4 upregulation with both CMV sero-
positivity and age on CD8+ T cells. Nevertheless, SLE patients exhibit augmented 
CTLA-4 expression on their FOXP3- T cells but this CTLA-4 exhibits an impaired 
ability to regulate T cell signalling, as it is excluded from lipid microdomains (Jury et 
al., 2010). Significant alterations to the lipid content of cell membranes of aged 
humans have also been documented (as described in section 1.2.3.2.5) that could 
compromise CTLA-4 signalling, despite its increased expression. Alternatively, this 
may reflect the fact that the blocking antibodies utilised may not have been physically 
capable of accessing an immune synapse due to their large size, which may be 
particularly relevant to CTLA-4, a predominantly intracellular molecule that is 
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expressed directly into the immune synapse (as described in 1.5.3.1). Indeed, different 
preparations of anti-CTLA-4 antibodies have different effects on cellular functions 
(Sansom and Walker, 2006) and the best blockers in terms of affinity and ligand 
binding perturbation did not have the most potent CTLA-4 modulatory effects 
(Sansom and Walker, 2006; Chandraker et al., 2005). Alternatively, upregulation of 
CTLA-4 amongst old and CMV+ donors also mirrors CMV and age-associated 
downregulation of the co-stimulatory molecule CD28 (Boucher et al., 1998; Looney 
et al., 1999; Czesnikiewicz-Guzik et al., 2008). Indeed, when taken together with a 
report indicating that CTLA-4 may deliver its inhibitory function via promoting the 
internalisation and degradation of CD28 molecules (Berg and Zavazava, 2008), the 
age and CMV associated CD28 expression loss may be consequence of enhanced 
CTLA-4 expression. Alternatively, CTLA-4 can also exert dominant suppression via 
its ligands into APCs (Munn et al., 2002), thus its augmented expression may 
significantly contribute towards the impaired immune responsiveness of old age. 
 
7.4  Functions of KLRG1 in immunosenescence 
 
KLRG1 expression increases with age on T cells and is highly expressed on CMV 
specific CD8+ T cells and perturbation of its signalling significantly increased the 
proliferative activity of highly differentiated CD8+ T cells from young but not old 
donors. In addition, KLRG1 signalling blockade also failed to augment the 
proliferative CD8+ T cell responses of aged donors to levels observed in the young, 
nor enhance CMV specific responses. This suggests that although KLRG1 signalling 
is causative of dysfunction in highly differentiated CD8+ T cells of the young, the 
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functional exhaustion experienced by chronic virus specific and old CD8+ T cells 
involve additional mechanisms, possibly including induction of distinct inhibitory 
receptors and the increasing cholesterol content and rigidity of cell membranes of the 
aged (as described in section 1.2.3.2.5), independent of KLRG1 signalling. However, 
E-cadherin blocking antibodies were used to pertubate KLRG1 signalling but E-
cadherin is expressed on multiple leukocyte subsets, particularly myeloid DCs 
(Henson et al., 2009) and is being increasingly implicated in the mediation of critical 
inhibitory signals (Banh et al., 2009; Fu and Jiang, 2010), thus the increased 
functional responses following E-cadherin blockade may reflect activation of DCs 
rather than suppression of KLRG1 signalling. Nevertheless, it should be noted that the 
potential of KLRG1 blocking antibodies to cross-link and provide a negative signal 
mean that E-cadherin blocking antibodies were the best available reagent. Data 
presented here also illustrate upregulation of KLRG1 on T cells with age, CMV 
infection and differentiation state, higher levels of expression on CD8+ than CD4+ T 
cells and augmented expression on CMV specific CD8+ T cells, which further 
increases with age. These data support the idea that increased cellular replication 
histories; associated with chronic infection, increasing age and differentiation state, 
drive T cell KLRG1 expression (Thimme et al., 2005; Voehringer et al., 2002).  
 
7.5 Other candidate inhibitory receptors involved in CMV specific 
CD8+ T cell dysregulation 
 
Data presented here depict that PD-1 is not universally expressed on CMV specific 
CD8+ T cells and its blockade does not fully reinvigorate their functions. This is 
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consistent with data from other viral infections, both in terms of PD-1 expression 
(Wang et al., 2007; Day et al., 2006) and incomplete functional restoration by PD-
1/L1 blockade (Barber et al., 2006) suggesting the involvement of other molecules. 
However, since I began my PhD an increasingly diverse array of inhibitory molecules 
have been implicated in regulating T cell exhaustion, with gene expression profiles 
revealing exhausted CD8+ T cells co-expressing up to seven inhibitory receptors 
(Wherry et al., 2007; Blackburn et al., 2009). Indeed, one of these inhibitory receptors, 
Tim-3, is expressed on a distinct subpopulation of HIV specific CD8+ T cells to PD-1 
and has been shown to enhance their functional responses when blocked (Jones et al., 
2008). Moreover, CD8+ T cells specific for LCMV, HCV and tumours co-express 
Tim-3 and/or the inhibitory receptor LAG-3, alongside PD-1, and their blockade can 
synergise with blocking PD-L in reinvigorating the functions of these cells (as 
detailed in section 4.1). In summary, the expression of multiple inhibitory receptors 
by exhausted CD8+ T cells may represent a multitude of redundant pathways that 
control immuno-pathology in a variety of different circumstances, determined by their 
different ligand distributions. These receptors may also have non-overlapping 
intracellular targets enabling each to mediate a distinct inhibition of different cellular 
functions that together produce an exhausted phenotype. Nevertheless, the exhaustion 
mediated by inhibitory receptor signalling does not account for all the dysfunctions of 
CMV specific CD8+ T cells, with senescence also making a significant contribution. 
Indeed, inhibition of the key senescence signalling protein p38 augments CMV 
specific CD8+ T cell function and has an additive effect in combination with PD-L 
blockade (Henson et al, in preparation). 
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7.6 Reasons for the putatively unique effects of CMV in age related 
immune decline, compared with other pathogens 
 
Data presented here further illustrate the dominant role of CMV infection in driving 
age-associated T cell changes in causing dramatic phenotypic and inhibitory receptor 
expression changes, dominating the immune response with age and accelerating 
telomere attrition. Reasons for this unique effect of CMV compared with other 
pathogens have not been fully elucidated but it may reflect the unique replication 
pattern of CMV. Indeed, latent infections such as herpes simplex virus (HSV), 
Epstein Barr Virus (EBV) and Varicella zoster virus (VZV) are initially cleared and 
subsequently undergo a well-defined transcriptionally near silent latency with 
periodic reactivations (Brunner et al., 2010), whereas persistent viruses like HCV and 
HIV are never cleared and maintain high viraemia (Wherry and Ahmed, 2004). In 
contrast, CMV is often characterized as a “smouldering” chronic infection lying in 
between the two ends of this spectrum (Wherry and Ahmed, 2004), which may reflect 
three unusual features of CMV: that antigen clearance after primary infection can 
require over a year (Campbell et al., 2008), its very high frequency of reactivations 
(McVoy and Adler, 1989; Wiesel et al., 2009; Kurz and Reddehase, 1999) and having 
a much less well defined latency which may not be transcriptionally silent (Kurz and 
Reddehase, 1999) and may even undergo a continuous low level productive chronic 
infection of salivary gland and kidney epithelial cells (Brunner et al., 2010). 
Alternatively, the unique role of CMV may reflect the cell types it infects: endothelial, 
monocytes/macrophages and DCs, with their roles as critical mediators of immune 
responses, body wide distribution and frequent reactivation associated with 
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inflammation, enabling CMV to exert a strong and persistent systemic immune 
stimulation. Additional factors underlying these effects of CMV infection may 
include its ability to activate DC secretion of the differentiation inducing cytokines: 
IFNα (Fletcher et al., 2005) and TNFα (Geist et al., 1997; Bryl et al., 2005), and it 
may also act to reduce thymic output, possibly by infecting bone marrow progenitor 
cells (Jimenez et al., 2006).  
 
7.7  How CMV drives age related immunological changes 
 
In old people, the effects of extended periods of persistent CMV infection may reach 
a climax with the development of the Immune Risk Phenotype (Pawelec et al., 2009a). 
Indeed, data presented here illustrate that CMV infection accelerates the rate of age-
associated lymphocyte telomere erosion, implicating duration of infection as a critical 
factor underlying CMV associated immune decline. Alternatively, such data may 
reflect exacerbation of the effects of CMV by the thymically insufficient, subclinical 
inflammatory and immuno-depressive environment of the aged, which may increase 
the frequency (Stowe et al., 2007) and exacerbate the consequences of CMV 
reactivation (Sauce et al., 2009; Peggs et al., 2003). Nevertheless, phenotypic 
alterations have been demonstrated to occur very rapidly upon primary CMV 
infection, amongst both healthy and immunocompromised donors (Wills et al., 2002; 
Khan et al., 2007; van de Berg et al., 2008; van de Berg et al., 2010; van Leeuwen et 
al., 2006a; Waller et al., 2008; Elbou Ould et al., 2004). Data presented here illustrate 
that CMV seropositivity results in phenotypic and immune inhibitory receptor 
changes of similar magnitude amongst both old and young populations, suggesting 
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that such differences are not caused by duration of CMV infection. Thus, the role of 
CMV infection in driving age-associated changes may reflect global changes to the 
host T cell profile occurring rapidly upon primary infection and the subsequent effects 
of continuous lifelong immune surveillance driving accelerated T cell senescence.  
 
7.8  CMV infection: a cause or an effect of immunosenescence? 
 
Data presented in this thesis adds to the growing body of literature that implicates 
CMV infection in the acceleration of age-associated immune decline. Nevertheless, 
rather than a contributory factor towards the development of immunosenescence, 
CMV sero-positivity may function as a mere marker of immune competency. Indeed, 
there is a strong independent relationship between both socioeconomic status (SES) 
and race with health outcomes, whereby caucasians and those of greater 
socioeconomic privilege tend to enjoy better health and greater longevity (Farmer and 
Ferraro, 2005). An analysis of The National Health and Nutrition Examination Survey 
(NHANES) IIIs data, involving several thousand American individuals, reveals 
significant racial and socioeconomic disparities in CMV seroprevalence beginning at 
early ages and persisting into middle age, with lowest rates of infection observed 
amongst white racial groups and higher income groups (Dowd et al., 2009). Moreover, 
this study accounted for a wide range of exposures commonly cited as risk factors for 
CMV and found that differences in these potential exposures did not easily explain 
the relationship between race, SES and CMV status. Furthermore, individuals from 
long lived families appear to be more resistant to CMV infection and even after 
infection are less susceptible to CMV associated immune changes (Pawelec et al., 
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2009b; Derhovanessian et al., 2010) and there is also data suggesting that individuals 
experiencing an increased level of stress, which is associated with lower SES, 
undergo more frequent CMV reactivation (Esterling et al., 1993; Glaser and Kiecolt-
Glaser, 1997; Glaser et al., 1999; Mehta et al., 2000; Herbert and Cohen, 1993). 
Possibly most significantly, the Leiden Longevity Study has recently disputed the 
association of CMV with an Immune Risk Phenotype and premature mortality (Maier 
et al, unpublished observations). In summary, rather than CMV driving many of the 
deleterious immune changes commonly cited as age-associated, there is evidence that 
individuals who are more susceptible to these age related immune changes are also 
more likely to become infected with CMV and that such individuals, once infected are 
likely to experience more frequent CMV reactivation.  
 
7.9  Further Work 
 
Extending my studies from independent community dwelling older adults to include 
those institutionalised in hospitals or care homes would help clarify if the correlations 
observed with ageing are contributory towards the ageing process or if they reflect 
adaptations to successful ageing.  
 
The effects of PD-1/L blockade on functions of CMV specific CD8+ T cells other than 
proliferation and telomerase, such as cytokine production, cytotoxicity and apoptosis, 
will be interesting to quantify. Additionally, extending these studies to include 
different non-pp65 CMV epitopes, would allow the investigation of whether the 
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effects on pp65 specific CD8+ T cells are representative of the anti-CMV CD8+ T cell 
response. 
 
Additionally, it will be important to characterise the expression and functional 
relevance of additional inhibitory receptors such as LAG-3, Tim-3, CD160, PTGER4 
and LILRB (Blackburn et al., 2009; Wherry et al., 2007) to determine whether 
additional blocks could act in synergy with PD-1 to fully reverse the exhaustion of 
CD45RA-revertant memory and CMV specific CD4+ and CD8+ T cells.  
 
The utilisation of siRNA techniques to specifically knock out inhibitory receptor 
genes would represent a more accurate quantification of the role of inhibitory 
receptors than using inhibitory receptor blocking antibodies, as it would account for 
the inability of blocking antibodies to access the immune synapse. 
 
Furthermore, the potential use of manipulating inhibitory receptor signalling as a 
therapeutic modality in cancer and chronic infections would be aided by clarifying 
whether PD-1/L blockade functions in vivo through reinvigorating exhausted CD8+ T 
cells, preventing naïve T cells developing an exhausted phenotype or inhibiting the 
PD-1/L mediated induction of iTregs. 
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